CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
Webcasts Slide Library Abstract Library Conference Highlights
 
HBV | Abstract Library
Abstract Library
 
The summaries are free for public use. The Chronic Liver Disease Foundation will continue to add and archive summaries of articles deemed relevant to CLDF by the Board of Trustees and its Advisors.
  1. Feasibility, acceptability and safety of a nurse led hepatitis B clinic based in the community
    Pritchard-Jones J, Stevens C, McCaughan G, Strasser S. Collegian. 2015;22(2):233-40.


  2. Hepatocellular Carcinoma in the Setting of Chronic Hepatitis B Virus Infection: Tumor Recurrence and Survival Rates After Liver Transplantation
    Dugum M1, Hanouneh I2, Lopez R3, Aucejo F4, Eghtesad B4, Zein N2. Transplant Proc. 2015 Jul-Aug;47(6):1939-44. doi: 10.1016/j.transproceed.2015.02.021.


  3. Hepatitis B: Working Towards a Cure
    Chang BW1, Kaung A, Robbins L, Tran TT. Curr Gastroenterol Rep. 2015 Sep;17(9):460. doi: 10.1007/s11894-015-0460-2.


  4. Present and future therapies of hepatitis B: From discovery to cure
    Liang TJ1, Block TM2, McMahon BJ3, Ghany MG1, Urban S4, Guo JT2, Locarnini S5, Zoulim F6, Chang KM7, Lok AS8. Hepatology. 2015 Aug 3. doi: 10.1002/hep.28025. [Epub ahead of print]


  5. Randomized Controlled Trial of Entecavir Versus Placebo in Children with HBeAg-positive Chronic Hepatitis B
    Jonas MM1, Chang MH2, Sokal E3, Schwarz KB4, Kelly D5, Mo Kim K6, Ling SC7, Rosenthal P8, Oraseanu D9, Reynolds L10, Thiry A10, Ackerman P10. Hepatology. 2015 Jul 29. doi: 10.1002/hep.28015. [Epub ahead of print]


  6. Comparison of Accelerated and Standard Hepatitis B Vaccination Schedules in High-Risk Healthy Adults: A Meta-Analysis of Randomized Controlled Trials
    Jin H1, Tan Z2, Zhang X2, Wang B1, Zhao Y1, Liu P1. PLoS One. 2015 Jul 21;10(7):e0133464. doi: 10.1371/journal.pone.0133464. eCollection 2015.


  7. A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: 2015 Update
    Martin P1, Lau DT2, Nguyen MH3, Janssen HL4, Dieterich DT5, Peters MG6, Jacobson IM7. Clin Gastroenterol Hepatol. 2015 Jul 15. pii: S1542-3565(15)00963-5. doi: 10.1016/j.cgh.2015.07.007. [Epub ahead of print]


  8. Effects of long-term entecavir treatment on the incidence of hepatocellular carcinoma in chronic hepatitis B patients
    Watanabe T1, Tokumoto Y, Joko K, Michitaka K, Mashiba T, Hiraoka A, Ochi H, Koizumi Y, Tada F, Hirooka M, Yoshida O, Imai Y, Abe M, Hiasa Y. Hepatol Int. 2015 Jul 22. [Epub ahead of print]


  9. Comparative Meta-Analysis of Tenofovir Disoproxil Fumarate versus Emtricitabine and Tenofovir Disoproxil Fumarate as Treatments for Patients with Chronic Hepatitis B
    Cui G1, Xu X2, Diao H1. Sci Rep. 2015 Jul 13;5:11854. doi: 10.1038/srep11854.


  10. Noninvasive Assessment of Liver Fibrosis
    Castera L1. Dig Dis. 2015;33(4):498-503. doi: 10.1159/000374097. Epub 2015 Jul 6.


  11. The Severity of Liver Fibrosis Influences the Prognostic Value of Inflammation-Based Scores in Hepatitis B-Associated Hepatocellular Carcinoma
    Wang Q1, Blank S, Fiel MI, Kadri H, Luan W, Warren L, Zhu A, Deaderick PA, Sarpel U, Labow DM, Hiotis SP. Ann Surg Oncol. 2015 Jul 10. [Epub ahead of print]


  12. Optimal Management of Hepatitis B Virus Infection - EASL Special Conference
    Lampertico P1, Maini M2, Papatheodoridis G3. J Hepatol. 2015 Jul 3. pii: S0168-8278(15)00453-5. doi: 10.1016/j.jhep.2015.06.026. [Epub ahead of print]


  13. Hepatitis B and C virus infection and risk of lymphoid malignancies: A population-based cohort study (JPHC Study)
    Abe SK1, Inoue M2, Sawada N3, Iwasaki M3, Shimazu T3, Yamaji T3, Sasazuki S3, Tanaka Y4, Mizokami M5, Tsugane S6; JPHC Study Group. Cancer Epidemiol. 2015 Jul 3. pii: S1877-7821(15)00130-7. doi: 10.1016/j.canep.2015.06.002. [Epub ahead of print]


  14. Outcomes of Infants Born to Women Infected With Hepatitis B
    Schillie S1, Walker T2, Veselsky S3, Crowley S4, Dusek C5, Lazaroff J6, Morris SA7, Onye K8, Ko S3, Fenlon N9, Nelson NP3, Murphy TV3. Pediatrics. 2015 Apr 20. pii: peds.2014-3213. [Epub ahead of print]


  15. The Epidemiology of Acute Hepatitis B in the United States from Population-Based Surveillance, 2006-2011
    Iqbal K1, Klevens RM1, Kainer MA2, Baumgartner J3, Gerard K4, Poissant T5, Sweet K6, Vonderwahl C7, Knickerbocker T8, Khudyakov Y1, Xia GL1, Roberts H1, Teshale E1. Clin Infect Dis. 2015 Apr 22. pii: civ332. [Epub ahead of print]


  16. Chronic hepatitis B: a wave of new therapies on the horizon
    Block TM1, Rawat S2, Brosgart CL3. Antiviral Res. 2015 Jun 22. pii: S0166-3542(15)00145-X. doi: 10.1016/j.antiviral.2015.06.014. [Epub ahead of print]


  17. Cluster-Randomized Trial to Increase Hepatitis B Testing among Koreans in Los Angeles
    Bastani R1, Glenn BA2, Maxwell AE2, Jo AM3, Herrmann AK2, Crespi CM2, Wong WK2, Chang LC2, Stewart SL4, Nguyen TT5, Chen MS Jr6, Taylor VM7. Cancer Epidemiol Biomarkers Prev. 2015 Jun 23. pii: cebp.1396.2014. [Epub ahead of print]


  18. Role of T-regulatory cells in the response to hepatitis B vaccine in hemodialysis patients
    Mathew RO1,2, Mason DL1,3, Song R4, Tryniszewski T5, Kennedy JS5. Hemodial Int. 2015 Jun 23. doi: 10.1111/hdi.12326. [Epub ahead of print]


  19. A Comparison of Entecavir and Lamivudine for the Prophylaxis of Hepatitis B Virus Reactivation in Solid Tumor Patients Undergoing Systemic Cytotoxic Chemotherapy
    Chen WC1, Cheng JS2, Chiang PH2, Tsay FW3, Chan HH4, Chang HW5, Yu HC2, Tsai WL4, Lai KH4, Hsu PI4. PLoS One. 2015 Jun 29;10(6):e0131545. doi: 10.1371/journal.pone.0131545. eCollection 2015.


  20. Hepatitis B Reactivation During Successful Treatment of Hepatitis C with Sofosbuvir and Simeprevir
    Collins JM1, Raphael KL2, Terry C2, Cartwright EJ3, Pillai A4, Anania FA5, Farley MM6. Clin Infect Dis. 2015 Jun 16. pii: civ474. [Epub ahead of print]


  21. Chronic hepatitis B: virology, natural history, current management and a glimpse at future opportunities
    Gish RG1, Given BD2, Lai CL3, Locarnini SA4, Lau JY5, Lewis DL2, Schluep T2. Antiviral Res. 2015 Jun 16. pii: S0166-3542(15)00139-4. doi: 10.1016/j.antiviral.2015.06.008. [Epub ahead of print]


  22. Improvement of liver function and non-invasive fibrosis markers in hepatitis B virus-associated cirrhosis: 2 years of entecavir treatment
    Shin SK1, Kim JH2, Park H1, Kwon OS1, Lee HJ3, Yeon JE3, Byun KS3, Suh SJ4, Yim HJ4, Kim YS1, Kim JH1. J Gastroenterol Hepatol. 2015 Jun 11. doi: 10.1111/jgh.13020. [Epub ahead of print]


  23. Hepatitis B screening and prevalence among resettled refugees - United States, 2006-2011
    Scott KC, Taylor EM, Mamo B, Herr ND, Cronkright PJ, Yun K, Altshuler M, Shetty S. MMWR Morb Mortal Wkly Rep. 2015 Jun 5;64(21):570-3.


  24. Medical training fails to prepare providers to care for patients with chronic hepatitis B infection
    Chao SD1, Wang BM1, Chang ET1, Ma L1, So SK1. World J Gastroenterol. 2015 Jun 14;21(22):6914-23. doi: 10.3748/wjg.v21.i22.6914.


  25. Role of antiviral therapy in the natural history of hepatitis B virus-related chronic liver disease
    Russo FP1, Rodríguez-Castro K1, Scribano L1, Gottardo G1, Vanin V1, Farinati F1. World J Hepatol. 2015 May 18;7(8):1097-104. doi: 10.4254/wjh.v7.i8.1097.


  26. Similar efficacy and safety of tenofovir in Asians and non-Asians with chronic hepatitis B
    Pan CQ1, Chan S1, Trinh H1, Yao A1, Bae H1, Lou L1. World J Gastroenterol. 2015 May 14;21(18):5524-31. doi: 10.3748/wjg.v21.i18.5524.


  27. Long-term safety of oral nucleos(t)ide analogues for patients with chronic hepatitis B - a cohort study of 53,500 subjects
    Wong GL1,2,3, Tse YK1,2, Wong VW1,2,3, Fung TY4, Choi KK5, Chan HL1,2,3. Hepatology. 2015 May 14. doi: 10.1002/hep.27894. [Epub ahead of print]


  28. Thyroid function is associated with non-alcoholic fatty liver disease in chronic hepatitis B infected subjects
    Ding WJ1, Wang MM2, Wang GS1, Fen S1, Qin JJ1, Fan JG1. J Gastroenterol Hepatol. 2015 May 14. doi: 10.1111/jgh.12998. [Epub ahead of print]


  29. Tenofovir-based rescue therapy for chronic hepatitis B patients who had failed treatment with lamivudine, adefovir, and entecavir
    Kim BG1, Jung SW1, Kim EH1, Kim JH1, Park JH1, Sung SJ1, Park BR2, Kim MH2, Kim CJ2, Lee BU1, Park JH1, Jeong ID1, Bang SJ1, Shin JW1, Park NH1,2. J Gastroenterol Hepatol. 2015 May 14. doi: 10.1111/jgh.12993. [Epub ahead of print]


  30. Hepatitis B Virus Screening for Patients With Cancer Before Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update
    Hwang JP1, Somerfield MR1, Alston-Johnson DE1, Cryer DR1, Feld JJ1, Kramer BS1, Sabichi AL1, Wong SL1, Artz AS1. J Clin Oncol. 2015 May 11. pii: JCO.2015.61.3745. [Epub ahead of print]


  31. High Risk of Hepatitis B Reactivation among Patients with Acute Myeloid Leukemia
    Chen CY1, Huang SY1, Cheng A2, Chou WC3, Yao M1, Tang JL4, Tsay W1, Sheng WH2, Tien HF1. PLoS One. 2015 May 14;10(5):e0126037. doi: 10.1371/journal.pone.0126037. eCollection 2015.


  32. Screening for human immunodeficiency virus and other sexually transmitted diseases among u.s. Women with prenatal care
    Ross CE1, Tao G, Patton M, Hoover KW. Obstet Gynecol. 2015 May;125(5):1211-6. doi: 10.1097/AOG.0000000000000756.


  33. Hepatitis B reactivation in the setting of chemotherapy and immunosuppression - prevention is better than cure
    Pattullo V1. World J Hepatol. 2015 May 8;7(7):954-67. doi: 10.4254/wjh.v7.i7.954.


  34. Hepatocellular carcinoma risk in chronic hepatitis B virus-infected compensated cirrhosis patients with low viral load
    Sinn DH1, Lee J1, Goo J2, Kim K2, Gwak GY1, Paik YH1, Choi MS1, Lee JH1, Koh KC1, Yoo BC1, Paik SW1. Hepatology. 2015 May 11. doi: 10.1002/hep.27889. [Epub ahead of print]


  35. Strategies to control hepatitis B: Public policy, epidemiology, vaccine and drugs
    Locarnini S1, Hatzakis A2, Chen DS3, Lok A4. J Hepatol. 2015 Apr;62(1S):S76-S86. doi: 10.1016/j.jhep.2015.01.018.


  36. Tenofovir monotherapy after achieving complete viral suppression on entecavir plus tenofovir combination therapy
    Kim LH1, Chaung KT, Ha NB, Kin KC, Vu VD, Trinh HN, Nguyen HA, Nguyen MH. Eur J Gastroenterol Hepatol. 2015 Apr 21. [Epub ahead of print]


  37. Covalently closed-circular hepatitis B virus DNA reduction with entecavir or lamivudine
    Bowden S1, Locarnini S1, Chang TT1, Chao YC1, Han KH1, Gish RG1, de Man RA1, Yu M1, Llamoso C1, Tang H1. World J Gastroenterol. 2015 Apr 21;21(15):4644-51. doi: 10.3748/wjg.v21.i15.4644.


  38. Acute-on-chronic liver failure: A new syndrome that will re-classify cirrhosis
    Arroyo V1, Moreau R2, Jalan R3, Ginès P4; EASL-CLIF Consortium CANONIC Study. J Hepatol. 2015 Apr;62(1S):S131-S143. doi: 10.1016/j.jhep.2014.11.045.


  39. Outcomes of Infants Born to Women Infected With Hepatitis B
    Schillie S1, Walker T2, Veselsky S3, Crowley S4, Dusek C5, Lazaroff J6, Morris SA7, Onye K8, Ko S3, Fenlon N9, Nelson NP3, Murphy TV3. Pediatrics. 2015 Apr 20. pii: peds.2014-3213. [Epub ahead of print]


  40. The Epidemiology of Acute Hepatitis B in the United States from Population-Based Surveillance, 2006-2011
    Iqbal K1, Klevens RM1, Kainer MA2, Baumgartner J3, Gerard K4, Poissant T5, Sweet K6, Vonderwahl C7, Knickerbocker T8, Khudyakov Y1, Xia GL1, Roberts H1, Teshale E1. Clin Infect Dis. 2015 Apr 22. pii: civ332. [Epub ahead of print]


  41. Poor Recognition of Risk Factors for Hepatitis B by Physicians Prescribing Immunosuppressive Therapy: A Call for Universal Rather than Risk-Based Screening
    Visram A1, Chan KK2, McGee P3, Boro J2, Hicks LK4, Feld JJ1. PLoS One. 2015 Apr 15;10(4):e0120749. doi: 10.1371/journal.pone.0120749.


  42. Intended and unintended effects of large-scale adverse event disclosure: a controlled before-after analysis of five large-scale notifications
    Wagner TH1, Taylor T2, Cowgill E2, Asch SM3, Su P2, Bokhour B4, Durfee J5, Martinello RA6, Maguire E7, Elwy AR4. BMJ Qual Saf. 2015 May;24(5):295-302. doi: 10.1136/bmjqs-2014-003800.


  43. A retrospective study of administration of vaccination for hepatitis B among newborn infants prior to hospital discharge at a midwestern tertiary care center
    Myers HI1, Spracklen CN2, Ryckman KK3, Murray JC4. Vaccine. 2015 Mar 31. pii: S0264-410X(15)00361-8. doi: 10.1016/j.vaccine.2015.03.053. [Epub ahead of print]


  44. A Comparison of Patients With Hepatitis B- or Hepatitis C-Based Advanced-Stage Hepatocellular Carcinoma
    Carr BI1, Guerra V2, Steel JL3, Lu SN4. Semin Oncol. 2015 Apr;42(2):309-315. doi: 10.1053/j.seminoncol.2014.12.019. Epub 2015 Jan 28.


  45. Risk of hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologic treatment: Extending perspective from old to newer drugs
    Nard FD1, Todoerti M1, Grosso V1, Monti S1, Breda S1, Rossi S1, Montecucco C1, Caporali R1. World J Hepatol. 2015 Mar 27;7(3):344-61. doi: 10.4254/wjh.v7.i3.344.


  46. Genotypes and viral variants in chronic hepatitis B: A review of epidemiology and clinical relevance
    Croagh CM1, Desmond PV1, Bell SJ1. World J Hepatol. 2015 Mar 27;7(3):289-303. doi: 10.4254/wjh.v7.i3.289.


  47. Personalized treatment of hepatitis B
    Lok AS1. Clin Mol Hepatol. 2015 Mar;21(1):1-6. Epub 2015 Mar 25.


  48. New insights in the management of chronic hepatitis B
    Gill US1, Kennedy PT2. Clin Med. 2015 Apr;15(2):191-6. doi: 10.7861/clinmedicine.15-2-191.


  49. Association between adefovir dipivoxil treatment and the risk of renal insufficiency in patients with chronic hepatitis B: A meta-analysis
    Yang Q1, Shi YU2, Yang Y2, Lou G2, Lv F1. Biomed Rep. 2015 Mar;3(2):269-275. Epub 2015 Jan 7.


  50. Hepatitis B e Antigen Status and Hepatitis B DNA Levels in Women of Childbearing Age with Chronic Hepatitis B Infection Screening for Clinical Trials
    Tran TT1, Gordon SC2, Fung S3, Dinh P4, Yee L4, Martins EB4, Buti M5, Marcellin P6. PLoS One. 2015 Mar 19;10(3):e0121632. doi: 10.1371/journal.pone.0121632. eCollection 2015.


  51. T-cell exhaustion in chronic hepatitis B infection: current knowledge and clinical significance
    Ye B1, Liu X1, Li X1, Kong H1, Tian L1, Chen Y1. Cell Death Dis. 2015 Mar 19;6:e1694. doi: 10.1038/cddis.2015.42.


  52. Recent advances in use of gene therapy to treat hepatitis B virus infection
    Bloom K1, Ely A, Arbuthnot P. Adv Exp Med Biol. 2015;848:31-49. doi: 10.1007/978-1-4939-2432-5_2.


  53. Prospective study of hepatitis B virus reactivation in patients with hematological malignancies
    Pompili M1, Basso M1, Hohaus S2, Bosco G1, Nosotti L3, D'Andrea M3, Fenu S4, Grieco A1, Laure Ann Hepatol. 2015 Mar-Apr;14(2):168-74.


  54. Sharp truth: health care workers remain at risk of bloodborne infection
    Rice BD1, Tomkins SE2, Ncube FM2. Occup Med (Lond). 2015 Feb 6. pii: kqu206. [Epub ahead of print]


  55. Prognosis in liver transplantation recipients after hepatitis B virus recurrence
    Sun LY, Zhu ZJ, Qu W, Sun XY, Rao W, Liu Y. Hepatogastroenterology. 2014 Oct;61(135):2047-51.


  56. Prospective study of hepatitis B virus reactivation in patients with hematological malignancies
    Linke R1, Ulrich F1, Bechstein WO1, Schnitzbauer AA1. Ann Hepatol. 2015 Mar-Apr;14(2):161-7.


  57. Comparison of the efficacies of entecavir 0.5 and 1.0?mg combined with adefovir in patients with chronic hepatitis B who had failed on prior nucleos(t)ide analogue treatments
    Cho Y1, Lee JH, Yu SJ, Yoon JH, Lee HS, Kim YJ. J Med Virol. 2015 Feb 24. doi: 10.1002/jmv.24150. [Epub ahead of print]


  58. Sharp truth: health care workers remain at risk of bloodborne infection
    Rice BD1, Tomkins SE2, Ncube FM2. Occup Med (Lond). 2015 Feb 6. pii: kqu206. [Epub ahead of print]


  59. Effect of Entecavir and Tenofovir Treatment on Noninvasive Fibrosis Scores: Which One Is Better?
    Koksal AR1, Alkim H, Boga S, Ergun M, Bayram M, Ozguven BY, Alkim C. Am J Ther. 2015 Feb 2. [Epub ahead of print]


  60. Cancer risk in HBV patients with statin and metformin use: a population-based cohort study
    Chen CI1, Kuan CF, Fang YA, Liu SH, Liu JC, Wu LL, Chang CJ, Yang HC, Hwang J, Miser JS, Wu SY. Medicine (Baltimore). 2015 Feb;94(6):e462. doi: 10.1097/MD.0000000000000462.


  61. Efficacy of antiviral therapy with nucleotide/nucleoside analogs after curative treatment for patients with hepatitis B virus-related hepatocellular carcinoma: A systematic review and meta-analysis
    Xia BW1, Zhang YC1, Wang J2, Ding FH2, He XD3.


  62. Acoustic radiation force impulse elastography, FibroScan®, Forns' index and their combination in the assessment of liver fibrosis in patients with chronic hepatitis B, and the impact of inflammatory activity and steatosis on these diagnostic methods
    Dong DR1, Hao MN2, Li C2, Peng Z3, Liu X4, Wang GP1, Ma AL1. Mol Med Rep. 2015 Feb 4. doi: 10.3892/mmr.2015.3299. [Epub ahead of print]


  63. Quantitative hepatitis B core antibody levels in the natural history of hepatitis B virus infection
    Song LW1, Liu PG2, Liu CJ3, Zhang TY1, Cheng XD4, Wu HL3, Yang HC3, Hao XK4, Yuan Q5, Zhang J6, Kao JH3, Chen DS3, Chen PJ7, Xia NS8. Clin Microbiol Infect. 2014 Oct 29. pii: S1198-743X(14)00063-9. doi: 10.1016/j.cmi.2014.10.002. [Epub ahead of print]


  64. The compliance of doctors with viral hepatitis B screening and antiviral prophylaxis in cancer patients receiving cytotoxic chemotherapy using a hospital-based screening reminder system
    Sun WC1, Hsu PI1, Yu HC2, Lin KH1, Tsay FW1, Wang HM1, Tsai TJ1, Chen WC1, Lai KH1, Cheng JS1. PLoS One. 2015 Feb 6;10(2):e0116978. doi: 10.1371/journal.pone.0116978. eCollection 2015.


  65. The efficacy and safety of entecavir in patients with chronic hepatitis B- associated liver failure: a meta-analysis
    Zhang X1, Liu L2, Zhang M1, Gao S1, Du Y1, An Y3, Chen S1. Ann Hepatol. 2015 Mar-Apr;14(2):150-60.


  66. Towards an HBV cure: state-of-the-art and unresolved questions-report of the ANRS workshop on HBV cure
    Zeisel MB1, Lucifora J2, Mason WS3, Sureau C4, Beck J5, Levrero M6, Kann M7, Knolle PA8, Benkirane M9, Durantel D2, Michel ML10, Autran B11, Cosset FL12, Strick-Marchand H13, Trépo C14, Kao JH15, Carrat F16, Lacombe K16, Schinazi RF17, Barré-Sinoussi F18, Delfraissy JF19, Zoulim F14. Gut. 2015 Feb 10. pii: gutjnl-2014-308943. doi: 10.1136/gutjnl-2014-308943. [Epub ahead of print]


  67. Vaccination coverage among adults, excluding influenza vaccination - United States, 2013
    Williams WW, Lu PJ, O'Halloran A, Bridges CB, Kim DK, Pilishvili T, Hales CM, Markowitz LE. MMWR Morb Mortal Wkly Rep. 2015 Feb 6;64(4):95-102.


  68. Hepatitis B virus infection status and risk of type 2 diabetes mellitus: A meta-analysis
    Zhang J1, Shen Y, Cai H, Liu YM, Qin G. Hepatol Res. 2015 Jan 19. doi: 10.1111/hepr.12481. [Epub ahead of print]


  69. Compared efficacy of preservation solutions in liver transplantation: a long-term graft outcome study from the European liver transplant registry
    Adam R1, Delvart V, Karam V, Ducerf C, Navarro F, Letoublon C, Belghiti J, Pezet D, Castaing D, Le Treut YP, Gugenheim J, Bachellier P, Pirenne J, Muiesan P; all the ELTR contributing centres, the European Liver, Intestine Transplant Association (ELITA). Am J Transplant. 2015 Feb;15(2):395-406. doi: 10.1111/ajt.13060.


  70. Baseline quantitative hepatitis B core antibody titre alone strongly predicts HBeAg seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos(t)ide analogues
    Fan R1, Sun J1, Yuan Q2, Xie Q3, Bai X4, Ning Q5, Cheng J6, Yu Y7, Niu J8, Shi G9, Wang H10, Tan D11, Wan M12, Chen S13, Xu M14, Chen X15, Tang H16, Sheng J17, Lu F18, Jia J19, Zhuang H18, Xia N2, Hou J20; Chronic Hepatitis B Study Consortium; Chronic Hepatitis B Study Consortium. Gut. 2015 Jan 13. pii: gutjnl-2014-308546. doi: 10.1136/gutjnl-2014-308546. [Epub ahead of print]


  71. Efficacy of Neonatal HBV Vaccination on Liver Cancer and Other Liver Diseases over 30-Year Follow-up of the Qidong Hepatitis B Intervention Study: A Cluster Randomized Controlled Trial
    Qu C1, Chen T2, Fan C2, Zhan Q1, Wang Y1, Lu J2, Lu LL2, Ni Z2, Huang F2, Yao H2, Zhu J2, Fan J2, Zhu Y2, Wu Z1, Liu G1, Gao W1, Zang M1, Wang D1, Dai M3, Hsia CC1, Zhang Y4, Sun Z1. PLoS Med. 2014 Dec 30;11(12):e1001774. doi: 10.1371/journal.pmed.1001774. eCollection 2014.


  72. Antiviral Treatment among Pregnant Women with Chronic Hepatitis B
    Fan L1, Owusu-Edusei K Jr1, Schillie SF1, Murphy TV1. Infect Dis Obstet Gynecol. 2014;2014:546165. doi: 10.1155/2014/546165. Epub 2014 Dec 7.


  73. Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR/Cas RNA-guided DNA endonuclease
    Kennedy EM1, Bassit LC2, Mueller H3, Kornepati AV1, Bogerd HP1, Nie T2, Chatterjee P2, Javanbakht H3, Schinazi RF4, Cullen BR5. Virology. 2014 Dec 29;476C:196-205. doi: 10.1016/j.virol.2014.12.001. [Epub ahead of print]


  74. Natural history of chronic hepatitis B virus infection
    Busch K1, Thimme R. Med Microbiol Immunol. 2014 Dec 25. [Epub ahead of print]


  75. Discontinuation of antiviral prophylaxis correlates with high prevalence of hepatitis B virus (HBV) reactivation in rheumatoid arthritis patients with HBV carrier state: a real-world clinical practice
    Mo Y, Liang A, Ma J, Chen L, Zheng D, Schumacher HR, Dai L. BMC Musculoskelet Disord. 2014 Dec 22;15(1):449. [Epub ahead of print]


  76. Serum Levels of Hepatitis B Surface Antigen Predict Severity of Fibrosis in Patients with E Antigen-positive Chronic Hepatitis B
    Marcellin P1, Martinot-Peignoux M2, Asselah T2, Batrla R3, Messinger D4, Rothe V4, Lau G5, Liaw Y6. Clin Gastroenterol Hepatol. 2014 Dec 23. pii: S1542-3565(14)01829-1. doi: 10.1016/j.cgh.2014.12.017. [Epub ahead of print]


  77. Optimal therapy of chronic hepatitis B: how do I treat my HBeAg-negative patients?
    Viganò M1, Invernizzi F, Lampertico P. Liver Int. 2015 Jan;35 Suppl 1:107-13. doi: 10.1111/liv.12717.


  78. Early to Phase II drugs currently under investigation for the treatment of liver fibrosis
    Hauff P1, Gottwald U, Ocker M. Expert Opin Investig Drugs. 2014 Dec 30:1-19. [Epub ahead of print]


  79. Recent FDA warnings on hepatitis B reactivation with immune-suppressing and anti-cancer drugs: Just the tip of the iceberg?
    Di Bisceglie AM1, Lok AS, Martin P, Terrault N, Perrillo RP, Hoofnagle JH. Hepatology. 2014 Nov 21. doi: 10.1002/hep.27609. [Epub ahead of print]


  80. Incidence of Hepatocellular Carcinoma after HBsAg Seroclearance in Chronic Hepatitis B Patients: a Need for Surveillance
    Kim GA1, Lee HC2, Kim MJ3, Ha Y1, Park EJ1, An J1, Lee D1, Shim JH1, Kim KM1, Lim YS1. J Hepatol. 2014 Nov 28. pii: S0168-8278(14)00880-0. doi: 10.1016/j.jhep.2014.11.031. [Epub ahead of print]


  81. Combination therapy of interferon and nucleotide/nucleoside analogues for chronic hepatitis B
    Wong GL1, Wong VW, Chan HL. J Viral Hepat. 2014 Dec;21(12):825-34. doi: 10.1111/jvh.12341.


  82. Combination versus sequential monotherapy in chronic HBV infection: a mathematical approach
    Bertacchi D1, Zucca F2, Foresti S3, Mangioni D3, Gori A3. Math Med Biol. 2014 Nov 13. pii: dqu022. [Epub ahead of print]


  83. Combination therapy of interferon and nucleotide/nucleoside analogues for chronic hepatitis B
    Wong GL1, Wong VW, Chan HL. J Viral Hepat. 2014 Dec;21(12):825-34. doi: 10.1111/jvh.12341.


  84. Non-invasive assessment of liver fibrosis in chronic hepatitis B
    Branchi F, Conti CB, Baccarin A, Lampertico P, Conte D, Fraquelli M. World J Gastroenterol. 2014 Oct 28;20(40):14568-14580.


  85. Hepatitis A and B immunity and vaccination in chronic hepatitis B and C patients in a large United States cohort
    Henkle E, Lu M, Rupp LB, Boscarino JA, Vijayadeva V, Schmidt MA, Gordon SC; for the Chronic Hepatitis Cohort Study (CHeCS) Investigators. Clin Infect Dis. 2014 Nov 3. pii: ciu879. [Epub ahead of print]


  86. Long-term prognosis of patients with hepatitis B infection: causes of death and utility of nucleos(t)ide analogue therapy
    Tada T1, Kumada T, Toyoda H, Kiriyama S, Tanikawa M, Hisanaga Y, Kanamori A, Kitabtake S, Ito T. J Gastroenterol. 2014 Nov 7. [Epub ahead of print]


  87. Comparison of Clinical Manifestations and Outcomes between Hepatitis B Virus- and Hepatitis C Virus-Related Hepatocellular Carcinoma: Analysis of a Nationwide Cohort
    Sinn DH1, Gwak GY1, Cho J2, Paik SW1, Yoo BC1. PLoS One. 2014 Nov 5;9(11):e112184. doi: 10.1371/journal.pone.0112184. eCollection 2014.


  88. Chemotherapy-related reactivation of hepatitis B infection: Updates in 2013
    Kim HY, Kim W. World J Gastroenterol. 2014 Oct 28;20(40):14581-14588.


  89. Community-based hepatitis B screening: what works?
    Robotin MC1, George J2. Hepatol Int. 2014 Aug 1;8(4):478-492. eCollection 2014.


  90. Tenofovir Disoproxil Fumarate in Asian or Pacific Islander Chronic Hepatitis B Patients With High Viral Load (? 9 log10 copies/mL)
    Fung S1, Gordon SC, Krastev Z, Horban A, Petersen J, Sperl J, Gane E, Jacobson IM, Yee LJ, Dinh P, Martins EB, Flaherty JF, Kitrinos KM, Dusheiko G, Trinh H, Flisiak R, Rustgi VK, Buti M, Marcellin P. Liver Int. 2014 Oct 2. doi: 10.1111/liv.12694. [Epub ahead of print]


  91. The global burden of liver disease: a challenge for methods and for public health
    Byass P. BMC Med. 2014 Sep 18;12:159. doi: 10.1186/s12916-014-0159-5.


  92. Effects of hepatitis B immunization on prevention of mother-to-infant transmission of hepatitis B virus and on the immune response of infants towards hepatitis B vaccine
    Zhang L1, Gui XE2, Teter C3, Zhong H4, Pang Z5, Ding L6, Li F7, Zhou Y8, Zhang L9. Vaccine. 2014 Sep 18. pii: S0264-410X(14)01242-0. doi: 10.1016/j.vaccine.2014.08.078. [Epub ahead of print]


  93. Type 2 diabetes: a risk factor for liver mortality and complications in hepatitis B cirrhosis patients
    Hsiang JC1, Gane EJ, Bai WW, Gerred SJ. J Gastroenterol Hepatol. 2014 Sep 22. doi: 10.1111/jgh.12790. [Epub ahead of print]


  94. Maternal transmission risk and antibody levels against hepatitis B virus e antigen in pregnant women
    Lu LL1, Chen BX2, Wang J3, Wang D4, Ji Y4, Yi HG4, Chen T4, Zhang Y5, Petersen E6, Li Q7, Qu C8. Int J Infect Dis. 2014 Sep 19. pii: S1201-9712(14)01613-0. doi: 10.1016/j.ijid.2014.07.028. [Epub ahead of print]


  95. Tenofovir disoproxil fumarate vs adefovir dipivoxil in Chinese patients with chronic hepatitis B after 48 weeks: a randomized controlled trial
    Hou JL1, Gao ZL, Xie Q, Zhang JM, Sheng JF, Cheng J, Chen CW, Mao Q, Zhao W, Ren H, Tan DM, Niu JQ, Chen SJ, Pan C, Tang H, Wang H, Mao YM, Jia JD, Ning Q, Xu M, Wu SM, Li J, Zhang XX, Ji Y, Dong J, Li J. J Viral Hepat. 2014 Sep 22. doi: 10.1111/jvh.12313. [Epub ahead of print]


  96. Hepatitis B reactivation during cancer chemotherapy: an international survey of the membership of the American Association for the Study of Liver Diseases
    Hwang JP1, Barbo AG, Perrillo RP. J Viral Hepat. 2014 Sep 15. doi: 10.1111/jvh.12305. [Epub ahead of print]


  97. Risk for hepatitis B and C virus transmission in nail salons and barbershops and state regulatory requirements to prevent such transmission in the United States
    Yang J1, Hall K, Nuriddin A, Woolard D. J Public Health Manag Pract. 2014 Nov-Dec;20(6):E20-30. doi: 10.1097/PHH.0000000000000042.


  98. Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis
    Mokdad AA1, Lopez AD, Shahraz S, Lozano R, Mokdad AH, Stanaway J, Murray CJ, Naghavi M. BMC Med. 2014 Sep 18;12(1):145. [Epub ahead of print]


  99. Effect of hepatitis B virus genotypes on the efficacy of adefovir dipivoxil antiviral therapy
    Wen Z1, Zhang H1, Zhang M2, Tan D3, Li Q4, Zhang H1, Wu P1, Deng L1. Hepat Mon. 2014 Aug 17;14(8):e10813. doi: 10.5812/hepatmon.10813. eCollection 2014.


  100. Hepatitis B and C in pregnancy: a review and recommendations for care
    Dunkelberg JC1, Berkley EM2, Thiel KW3, Leslie KK3. J Perinatol. 2014 Sep 18. doi: 10.1038/jp.2014.167. [Epub ahead of print]


  101. Scoring systems for predicting mortality after liver transplantation
    Pan HC1, Jenq CC2, Lee WC3, Tsai MH4, Fan PC1, Chang CH1, Chang MY2, Tian YC2, Hung CC2, Fang JT2, Yang CW2, Chen YC2. PLoS One. 2014 Sep 12;9(9):e107138. doi: 10.1371/journal.pone.0107138. eCollection 2014.


  102. Long-Term Treatment with Tenofovir in Asian-American Chronic Hepatitis B Patients Is Associated with Abnormal Renal Phosphate Handling
    Tien C1, Xu JJ, Chan LS, Chang M, Lim C, Lee S, Huh B, Shinada S, Bae HS, Fong TL. Dig Dis Sci. 2014 Sep 20. [Epub ahead of print]


  103. Individualized management of pregnant women with high hepatitis B virus DNA levels
    Zhang Z, Chen C, Li Z, Wu YH, Xiao XM. World J Gastroenterol. 2014 Sep 14;20(34):12056-12061.


  104. Hepatitis B viral load affects prognosis of hepatocellular carcinoma
    Yu SJ, Kim YJ. World J Gastroenterol. 2014 Sep 14;20(34):12039-12044.


  105. Interleukin 28B genetic polymorphism and hepatitis B virus infection
    Takahashi T. World J Gastroenterol. 2014 Sep 14;20(34):12026-12030.


  106. Noninvasive assessment of liver fibrosis in patients with chronic hepatitis B
    Enomoto M, Morikawa H, Tamori A, Kawada N. World J Gastroenterol. 2014 Sep 14;20(34):12031-12038.


  107. A Randomized, Open-Label Clinical Study of Combined Peginterferon Alfa-2a (40KD) and Entecavir Treatment for HBeAg-Positive Chronic Hepatitis B
    Xie Q1, Zhou H1, Bai X2, Wu S3, Chen JJ4, Sheng J5, Xie Y6, Chen C7, Chan HL8, Zhao M9. Clin Infect Dis. 2014 Sep 4. pii: ciu702. [Epub ahead of print]


  108. Differences in surgical outcomes between hepatitis B- and hepatitis C-related hepatocellular carcinoma: a retrospective analysis of a single north american center
    Franssen B1, Alshebeeb K, Tabrizian P, Marti J, Pierobon ES, Lubezky N, Roayaie S, Florman S, Schwartz ME. Ann Surg. 2014 Oct;260(4):650-8. doi: 10.1097/SLA.0000000000000917.


  109. Chronic hepatitis B in 2014: Great therapeutic progress, large diagnostic deficit
    Niederau C. World J Gastroenterol. 2014 Sep 7;20(33):11595-11617.


  110. Association between maternal HBsAg carrier status and neonatal adverse outcomes: meta-analysis
    Luo L1, Wu J, Qu Y, Li J, Pan L, Li D, Wang H, Mu D. J Matern Fetal Neonatal Med. 2014 Sep 18:1-10. [Epub ahead of print]


  111. Caesarean section to prevent transmission of hepatitis B: A meta-analysis
    Chang MS, Gavini S, Andrade PC, McNabb-Baltar J. Can J Gastroenterol Hepatol. 2014 Sep;28(8):439-44.


  112. Recent Population Expansions of Hepatitis B Virus in the United States
    Ramachandran S1, Purdy MA2, Xia GL2, Campo DS2, Dimitrova ZE2, Teshale EH2, Teo CG2, Khudyakov YE2. J Virol. 2014 Sep 3. pii: JVI.01594-14. [Epub ahead of print]


  113. Telbivudine or lamivudine use in late pregnancy safely reduces perinatal transmission of hepatitis B virus in real-life practice
    Zhang H, Pan CQ, Pang Q, Tian R, Yan M, Liu X. Hepatology. 2014 Aug;60(2):468-76.


  114. Hepatitis B flares in chronic hepatitis B: pathogenesis, natural course and management
    Chang ML1, Liaw YF2. J Hepatol. 2014 Aug 29. pii: S0168-8278(14)00620-5. doi: 10.1016/j.jhep.2014.08.033. [Epub ahead of print]


  115. Prognostic value of the combined use of transient elastography and FibroTest in patients with chronic hepatitis B
    Park MS1, Kim SU, Kim BK, Park JY, Kim DY, Ahn SH, Shin SH, Kang W, Moon C, Han KH. Liver Int. 2014 Sep 2. doi: 10.1111/liv.12678. [Epub ahead of print]


  116. The immune tolerant phase of chronic HBV infection: new perspectives on an old concept
    Bertoletti A1, Kennedy PT2. Cell Mol Immunol. 2014 Sep 1. doi: 10.1038/cmi.2014.79. [Epub ahead of print]


  117. Diagnostic usefulness of real-time elastography for liver fibrosis in chronic viral hepatitis B and C
    Kim YW1, Kwon JH1, Jang JW2, Kim MJ1, Oh BS1, Chung KW1, Park ES3, Nam SW1. Gastroenterol Res Pract. 2014;2014:210407. doi: 10.1155/2014/210407. Epub 2014 Aug 10.


  118. Efficacy of Entecavir plus Tenofovir Combination Therapy for Chronic Hepatitis B Patients with Multi-Drug Resistant Strains
    Lee YB1, Lee JH2, Lee DH1, Cho H1, Ahn H1, Choi WM1, Cho YY1, Lee M1, Yoo JJ1, Cho Y1, Cho EJ1, Yu SJ1, Kim YJ1, Yoon JH1, Kim CY1, Lee HS1. Antimicrob Agents Chemother. 2014 Aug 25. pii: AAC.03845-14. [Epub ahead of print]


  119. Entecavir Is Safe and Effective in Patients Previously Treated with Adefovir, including Those with Adefovir-Resistance
    Nguyen NH1, Trinh HN, Nguyen TT, Do ST, Tran P, Nguyen HA, Nguyen KK, Garcia RT, Lutchman GA, Nguyen MH. J Gastroenterol Hepatol. 2014 Aug 28. doi: 10.1111/jgh.12728. [Epub ahead of print]


  120. Assessment of Bone Mineral Density in Tenofovir treated Chronic Hepatitis B patients: Can FRAX identify those at greatest risk?
    Gill US1, Zissimopoulos A2, Al-Shamma S2, Burke K2, McPhail MJ3, Barr DA4, Kallis YN2, Marley RT2, Kooner P2, Foster GR1, Kennedy PT1. J Infect Dis. 2014 Aug 25. pii: jiu471. [Epub ahead of print]


  121. Immunogenicity of hepatitis B vaccine in patients with inflammatory bowel disease and the benefits of revaccination
    Yolima CG1, Xavier MG, Magda CM, José Ángel RP, Natalia BS, Francisco RF, Francesc CJ. J Gastroenterol Hepatol. 2014 Aug 26. doi: 10.1111/jgh.12712. [Epub ahead of print]


  122. Quantification of HBsAg in nucleos(t)ide-naïve patients treated for chronic hepatitis B with entecavir with or without tenofovir in the BE-LOW study
    Zoulim F1, Carosi G2, Greenbloom S3, Mazur W4, Nguyen T5, Jeffers L6, Brunetto M7, Yu S8, Llamoso C8. J Hepatol. 2014 Aug 28. pii: S0168-8278(14)00618-7. doi: 10.1016/j.jhep.2014.08.031. [Epub ahead of print]


  123. Telbivudine plus pegylated interferon alfa-2a in a randomized study in chronic hepatitis B was associated with unexpected high rate of peripheral neuropathy
    Marcellin P1, Wursthorn K2, Wedemeyer H2, Chuang WL3, Lau G4, Avila C5, Peng CY6, Gane E7, Gee Lim S8, Fainboim H9, Foster GR10, Safadi R11, Rizzetto M12, Manns M2, Bao W13, Naoumov N5. J Hepatol. 2014 Aug 21. pii: S0168-8278(14)00607-2. doi: 10.1016/j.jhep.2014.08.021. [Epub ahead of print]


  124. Survey of health status, nutrition and geography of food selection of chronic liver disease patients
    Leslie T1, Pawloski L2, Kallman-Price J3, Escheik C4, Hossain N3, Fang Y3, Gerber LH5, Younossi ZM3. Ann Hepatol. 2014 Sep-Oct;13(5):533-40.


  125. Human Immunodeficiency Virus and Coinfection with Hepatitis B and C
    Petty LA1, Steinbeck JL2, Pursell K2, Jensen DM3. Infect Dis Clin North Am. 2014 Sep;28(3):477-499. doi: 10.1016/j.idc.2014.05.005.


  126. Knowledge, Awareness and Medical Practice of Asian Americans/Pacific Islanders on Chronic Hepatitis B Infection: Review of Current Psychosocial Evidence
    Do TN, Nam SG. Pogon Sahoe Yongu. 2011;31(3):341-364.


  127. Temporal Trends of Non-alcoholic Fatty Liver Disease-related Hepatocellular Carcinoma in the Veteran Affairs Population
    Mittal S1, Sada YH2, El-Serag HB3, Kanwal F3, Duan Z2, Temple S2, May SB2, Kramer JR2, Richardson PA2, Davila JA2. Clin Gastroenterol Hepatol. 2014 Aug 19. pii: S1542-3565(14)01228-2. doi: 10.1016/j.cgh.2014.08.013. [Epub ahead of print]


  128. Risk assessment of clinical outcomes in asian patients with chronic hepatitis B using enhanced liver fibrosis test
    Kim BK1, Kim HS, Yoo EJ, Oh EJ, Park JY, Kim DY, Ahn SH, Han KH, Kim SU, Park YN. Hepatology. 2014 Aug 20. doi: 10.1002/hep.27389. [Epub ahead of print]


  129. Antenatal hepatitis B in a large teaching NHS Trust - Implications for future care
    White HA1, Wiselka MJ2, Wilson DJ3. J Infect. 2014 Aug 16. pii: S0163-4453(14)00245-X. doi: 10.1016/j.jinf.2014.07.028. [Epub ahead of print]


  130. Hepatitis B vaccine by intradermal route in non responder patients: An update
    Filippelli M, Lionetti E, Gennaro A, Lanzafame A, Arrigo T, Salpietro C, La Rosa M, Leonardi S. World J Gastroenterol. 2014 Aug 14;20(30):10383-10394.


  131. Natural history of chronic hepatitis B: Phases in a complex relationship
    Croagh CM, Lubel JS. World J Gastroenterol. 2014 Aug 14;20(30):10395-10404.


  132. APRI and FIB-4 are good predictors of the stage of liver fibrosis in chronic hepatitis B: the Chronic Hepatitis Cohort Study (CHeCS)
    Teshale E1, Lu M, Rupp LB, Holmberg SD, Moorman AC, Spradling P, Vijayadeva V, Boscarino JA, Schmidt MA, Gordon SC; the CHeCS Investigators. J Viral Hepat. 2014 Aug 1. doi: 10.1111/jvh.12279. [Epub ahead of print]


  133. Clinicopathological features of hepatitis B virus recurrence after liver transplantation: eleven-year experience
    Zhang D, Jiao Z, Han J, Cao H. Int J Clin Exp Pathol. 2014 Jun 15;7(7):4057-66. eCollection 2014.


  134. Comparison of Diagnostic accuracy of APRI and FIB-4 for detecting liver fibrosis in adult patients with chronic hepatitis B virus infection: A systemic review and meta-analysis
    Xiao G1, Yang J, Yan L. Hepatology. 2014 Aug 18. doi: 10.1002/hep.27382. [Epub ahead of print]


  135. Alpha-fetoprotein level as a biomarker of liver fibrosis status: a cross-sectional study of 619 consecutive patients with chronic hepatitis B
    Liu YR, Lin BB, Zeng DW, Zhu YY, Chen J, Zheng Q, Dong J1, Jiang JJ. BMC Gastroenterol. 2014 Aug 16;14:145. doi: 10.1186/1471-230X-14-145.


  136. Polymorphisms of HLA-DP are associated with response to peginterferon in Caucasian patients with chronic hepatitis B
    Brouwer WP1, Sonneveld MJ, Tabak F, Simon K, Cakaloglu Y, Akarca US, Zeuzem S, Ferenci P, Heathcote JE, de Knegt RJ, Boonstra A, Hansen BE, Janssen HL. Aliment Pharmacol Ther. 2014 Aug 11. doi: 10.1111/apt.12910. [Epub ahead of print]


  137. Hepatitis B virus infection correlates with poor prognosis of extranodal natural killer/T cell lymphoma
    Wang L, Wu-Xiao ZJ, Chen XQ, Zhang YJ, Lu Y, Xia ZJ. Leuk Lymphoma. 2014 Aug 11:1-20. [Epub ahead of print]


  138. Treatment cessation in noncirrhotic, e-antigen negative chronic hepatitis B is safe and effective following prolonged anti-viral suppression with nucleosides/nucleotides
    Patwardhan VR1, Sengupta N, Bonder A, Lau D, Afdhal NH. Aliment Pharmacol Ther. 2014 Aug 11. doi: 10.1111/apt.12908. [Epub ahead of print]


  139. A new model for predicting liver cirrhosis in chronic hepatitis B virus carriers with low serum alanine transaminase activity
    Zeng DW1, Zhang JM2, Liu YR1, Dong J1, Wu YL1, Lin S1, Jiang JJ1, Zhu YY3. Clin Res Hepatol Gastroenterol. 2014 Jul 18. pii: S2210-7401(14)00152-1. doi: 10.1016/j.clinre.2014.06.007. [Epub ahead of print]


  140. Re-appraisal of old and new diagnostic tools in the current management of chronic hepatitis B
    Bessone F. Liver Int. 2014 Aug;34(7):991-1000. doi: 10.1111/liv.12499. Epub 2014 Mar 12.


  141. Understanding early serum hepatitis D virus and HBsAg kinetics during pegylated interferon-alfa therapy via mathematical modeling
    Guedj J1, Rotman Y, Cotler SJ, Koh C, Schmid P, Albrecht J, Haynes-Williams V, Liang JT, Hoofnagle JH, Heller T, Dahari H. Hepatology. 2014 Aug 7. doi: 10.1002/hep.27357. [Epub ahead of print]


  142. A Randomized Study to Evaluate the Immunogenicity and Safety of a Heptavalent Diphtheria, Tetanus, Pertussis, Hepatitis B, Poliomyelitis, Haemophilus influenzae b, and Meningococcal Serogroup C Combination Vaccine Administered to Infants at 2, 4, and 12 Months of Age
    Thollot F1, Scheifele D, Pankow-Culot H, Cheuvart B, Leyssen M, Ulianov L, Miller JM. Pediatr Infect Dis J. 2014 Jul 16. [Epub ahead of print]


  143. Outcomes of Patients with Chronic Hepatitis B Who do not Meet Criteria for Antiviral Treatment at Presentation
    Yapali S1, Talaat N1, Fontana RJ1, Oberhelman K1, Lok AS2. Clin Gastroenterol Hepatol. 2014 Jul 17. pii: S1542-3565(14)01048-9. doi: 10.1016/j.cgh.2014.07.019. [Epub ahead of print]


  144. Kinetics of hepatitis B surface antigen loss in patients with HBeAg-positive chronic hepatitis B treated with tenofovir disoproxil fumarate
    Marcellin P1, Buti M2, Krastev Z3, de Man RA4, Zeuzem S5, Lou L6, Gaggar A6, Flaherty JF6, Massetto B6, Lin L6, Dinh P6, Mani Subramanian G6, McHutchison JG6, Flisiak R7, Gurel S8, Dusheiko GM9, Jenny Heathcote E10. J Hepatol. 2014 Jul 18. pii: S0168-8278(14)00518-2. doi: 10.1016/j.jhep.2014.07.019. [Epub ahead of print]


  145. Platelets promote liver immunopathology contributing to hepatitis B virus-mediated hepatocarcinogenesis
    Sitia G. Semin Oncol. 2014 Jun;41(3):402-5. doi: 10.1053/j.seminoncol.2014.04.013. Epub 2014 Apr 24.


  146. A new model for predicting liver cirrhosis in chronic hepatitis B virus carriers with low serum alanine transaminase activity
    Zeng DW1, Zhang JM2, Liu YR1, Dong J1, Wu YL1, Lin S1, Jiang JJ1, Zhu YY3. Clin Res Hepatol Gastroenterol. 2014 Jul 18. pii: S2210-7401(14)00152-1. doi: 10.1016/j.clinre.2014.06.007. [Epub ahead of print]


  147. Immunological aspects of antiviral therapy of chronic hepatitis B virus and hepatitis C virus infections
    Rehermann B1, Bertoletti A. Hepatology. 2014 Jul 21. doi: 10.1002/hep.27323. [Epub ahead of print]


  148. Prevention of hepatitis B virus reinfection in liver transplant recipients
    Roche B1, Samuel D. Intervirology. 2014;57(3-4):196-201. doi: 10.1159/000360944. Epub 2014 Jul 15.


  149. Chronic hepatitis B virus in young adults: the need for new approaches to management
    Gill US1, Kennedy PT. Expert Rev Anti Infect Ther. 2014 Jul 23:1-9. [Epub ahead of print]


  150. Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C
    Institute of Medicine (US) Committee on the Prevention and Control of Viral Hepatitis Infection; Colvin HM, Mitchell AE, editors.


  151. The impact of type 2 diabetes and obesity on the long-term outcomes of more than 85 000 liver transplant recipients in the US
    Younossi ZM1, Stepanova M, Saab S, Kalwaney S, Clement S, Henry L, Frost S, Hunt S. Aliment Pharmacol Ther. 2014 Jul 16. doi: 10.1111/apt.12881. [Epub ahead of print]


  152. Therapy of acute and fulminant hepatitis B
    Tillmann HL1, Patel K. Intervirology. 2014;57(3-4):181-8. doi: 10.1159/000360939. Epub 2014 Jul 15.


  153. Chronic Hepatitis B Treatment Eligibility and Actual Treatment Rates in Patients in Community Gastroenterology and Primary Care Settings
    Nguyen VG1, Wan K, Trinh HN, Li J, Zhang JQ, Nguyen MH. J Clin Gastroenterol. 2014 Jul 10. [Epub ahead of print]


  154. Hepatitis Viruses and Liver Transplantation: Evolving Trends in Antiviral Management
    Verna EC. Clin Liver Dis. 2014 Aug;18(3):575-601. doi: 10.1016/j.cld.2014.05.002.


  155. Practice Patterns and Attitudes of Primary Care Providers and Barriers to Surveillance of Hepatocellular Carcinoma in Patients with Cirrhosis
    Dalton-Fitzgerald E1, Tiro J2, Kandunoori P1, Halm EA3, Yopp A4, Singal AG5. Clin Gastroenterol Hepatol. 2014 Jul 11. pii: S1542-3565(14)00987-2. doi: 10.1016/j.cgh.2014.06.031. [Epub ahead of print]


  156. Residual Amount of HBV DNA in Serum is Related to Relapse in Chronic Hepatitis B Patients After Cessation of Nucleos(t)ide Analogs
    Jiang JN1, Huang ZL, He LX, Huang YH, Su MH, Xie R, Liang YX, Fu WD, Huang XH, Guo WW, Zhong SH, Liu ZH, Li SH, Zhu TF, Gao ZL. J Clin Gastroenterol. 2014 Jul 10. [Epub ahead of print]


  157. Clinical impact of occult hepatitis B virus infection in immunosuppressed patients
    Sagnelli E, Pisaturo M, Martini S, Filippini P, Sagnelli C, Coppola N. World J Hepatol. 2014 Jun 27;6(6):384-93. doi: 10.4254/wjh.v6.i6.384.


  158. Effect of Menarche Onset on the Clinical Course in Females with Chronic Hepatitis B Virus Infection
    Wu JF1, Tsai WY1, Tung YC1, Chen HL2, Ni YH3, Hsu HY1, Chang MH4. J Pediatr. 2014 Jun 24. pii: S0022-3476(14)00499-5. doi: 10.1016/j.jpeds.2014.05.049. [Epub ahead of print]


  159. Staging chronic hepatitis B into seven categories, defining inactive carriers and assessing treatment impact using a fibrosis biomarker (FibroTest) and elastography (FibroScan)
    Poynard T1, Vergniol J2, Ngo Y3, Foucher J2, Thibault V4, Munteanu M3, Merrouche W2, Lebray P5, Rudler M5, Deckmyn O3, Perazzo H5, Thabut D5, Ratziu V5, de Ledinghen V2. J Hepatol. 2014 Jul 9. pii: S0168-8278(14)00457-7. doi: 10.1016/j.jhep.2014.06.027. [Epub ahead of print]


  160. Chronic hepatitis B infection and risk of preterm labor: A meta-analysis of observational studies
    Huang QT1, Wei SS2, Zhong M3, Hang LL2, Xu YY2, Cai GX2, Liu Q4, Yu YH2. J Clin Virol. 2014 Jun 16. pii: S1386-6532(14)00222-4. doi: 10.1016/j.jcv.2014.06.006. [Epub ahead of print]


  161. Association between infection of hepatitis B virus and onset risk of B-cell non-Hodgkin's lymphoma: a systematic review and a meta-analysis
    Yi HZ1, Chen JJ, Cen H, Yan W, Tan XH. Med Oncol. 2014 Aug;31(8):84. doi: 10.1007/s12032-014-0084-7. Epub 2014 Jun 28.


  162. Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians
    Arends P1, Sonneveld MJ1, Zoutendijk R1, Carey I2, Brown A3, Fasano M4, Mutimer D5, Deterding K6, Reijnders JG1, Oo Y5, Petersen J7, van Bömmel F8, de Knegt RJ1, Santantonio T4, Berg T8, Welzel TM9, Wedemeyer H6, Buti M10, Pradat P11, Zoulim F11, Hansen B1, Janssen HL12; for the VIRGIL Surveillance Study Group. Gut. 2014 Jul 10. pii: gutjnl-2014-307023. doi: 10.1136/gutjnl-2014-307023. [Epub ahead of print]


  163. Vertical transmission of hepatitis B virus: challenges and solutions
    Gentile I, Borgia G. Int J Womens Health. 2014 Jun 10;6:605-11. doi: 10.2147/IJWH.S51138. eCollection 2014.


  164. The bloodborne pathogen standard in private practice
    Davis D1, Carlton A, Wisch JS. Community Support Oncol. 2014 Mar;12(3):82-3.


  165. Prediction of Development of Liver-Related Events by Transient Elastography in Hepatitis B Patients With Complete Virological Response on Antiviral Therapy
    Lee HW1, Yoo EJ1, Kim BK2, Kim SU2, Park JY2, Kim DY2, Ahn SH3, Han KH3. Am J Gastroenterol. 2014 Jun 24. doi: 10.1038/ajg.2014.157. [Epub ahead of print]


  166. The impact of oral antiviral therapy on long-term survival of hepatitis B surface antigen-positive patients on haemodialysis
    Ow MM1, de Zoysa JR, Gane EJ. N Z Med J. 2014 Jun 20;127(1396):34-42.


  167. Hepatitis B virus reactivation in patients with hepatocellular carcinoma undergoing anti-cancer therapy
    Jang JW. World J Gastroenterol. 2014 Jun 28;20(24):7675-7685.


  168. Incidence of hepatitis in patients with evidence of past or current hepatitis B or C during chemotherapy for early breast cancer
    Levaggi A1, DE Maria A2, Dozin B3, Iacono G4, Bighin C5, Giraudi S4, Lambertini M5, D'Alonzo A4, Poggio F5, Pronzato P5, Del Mastro L4. Anticancer Res. 2014 Jul;34(7):3715-20.


  169. Screening, detecting and enhancing the yield of previously undiagnosed hepatitis B and C in patients with acute medical admissions to hospital: A pilot project undertaken at the Vancouver General Hospital
    Kapeluto J, Kadatz M, Wormsbecker A, Sidhu K, Yoshida EM. Can J Gastroenterol Hepatol. 2014 Jun;28(6):315-8.


  170. Hepatitis B in Pregnancy
    Whittaker G, Herrera JL. South Med J. 2014 Mar;107(3):195-200.


  171. Screening for Hepatitis B Virus Infection in Nonpregnant Adolescents and Adults: U.S. Preventive Services Task Force Recommendation Statement
    LeFevre ML. Ann Intern Med. 2014 May 27. doi: 10.7326/M14-1018. [Epub ahead of print]


  172. Hepatitis B virus DNA quantification with the three-in-one (3io) method allows accurate single-step differentiation of total HBV DNA and cccDNA in biopsy-size liver samples
    Taranta A1, Tien Sy B2, Zacher BJ1, Rogalska-Taranta M3, Manns MP1, Bock CT4, Wursthorn K5. J Clin Virol. 2014 May 2. pii: S1386-6532(14)00148-6. doi: 10.1016/j.jcv.2014.04.015. [Epub ahead of print]


  173. Management of chronic hepatitis B in children: an unresolved issue
    Della Corte C1, Nobili V, Comparcola D, Cainelli F, Vento S. J Gastroenterol Hepatol. 2014 May;29(5):912-9. doi: 10.1111/jgh.12550.


  174. Current recommendations of managing HBV infection in preconception or pregnancy
    Park JS1, Pan C. Front Med. 2014 Jun;8(2):158-65. doi: 10.1007/s11684-014-0340-4. Epub 2014 May 29.


  175. Cirrhosis Regression in Patients With Viral Hepatitis B and C: A Systematic Review
    Manne V1, Akhtar E, Saab S. J Clin Gastroenterol. 2014 Jun 11. [Epub ahead of print]


  176. Prevalence and causes of elevated serum aminotransferase levels in a population-based cohort of persons with chronic hepatitis B virus infection
    Spradling PR1, Bulkow L2, Teshale EH3, Negus S4, Homan C4, Simons B4, McMahon BJ5. J Hepatol. 2014 Jun 6. pii: S0168-8278(14)00393-6. doi: 10.1016/j.jhep.2014.05.045. [Epub ahead of print]


  177. Bridging Basic Science and Clinical Research - The EASL Monothematic Conference on Translational Research in Viral Hepatitis
    Boettler T1, Moradpour D2, Thimme R1, Zoulim F3. J Hepatol. 2014 May 15. pii: S0168-8278(14)00357-2. doi: 10.1016/j.jhep.2014.05.016. [Epub ahead of print]


  178. Hepatic Steatosis Is Highly Prevalent in Hepatitis B Patients and Negatively Associated with Virological Factors
    Wang MM1, Wang GS, Shen F, Chen GY, Pan Q, Fan JG. Dig Dis Sci. 2014 May 18. [Epub ahead of print]


  179. Current Treatment Guidelines for Chronic Hepatitis B and Their Application.
    Uribe LA1, O'Brien CG, Wong RJ, Gish RR, Tsai N, Nguyen MH. J Clin Gastroenterol. 2014 May 22. [Epub ahead of print]


  180. Effect of Antiviral Prophylaxis Strategy for Chemotherapy-Associated Hepatitis B Reactivation in Non-Hodgkin's Lymphoma Patients with Hepatitis B Virus Infection: A Retrospective Cohort Study
    Yang F1, Zhu HL2, He C2, Li JJ2, Xiang B2, Cui X2, Huang J2, Ji J2, Ma HB2, Liu T2. Indian J Hematol Blood Transfus. 2014 Jun;30(2):97-104. doi: 10.1007/s12288-012-0195-2. Epub 2012 Oct 30.


  181. Prevention of Liver Cancer Through the Early Detection of Risk-Related Behavior Among Hepatitis B or C Carriers
    Fan JY1, Huang TJ, Jane SW, Chen MY. Cancer Nurs. 2014 May 15. [Epub ahead of print]


  182. Strategies for the prevention of recurrent hepatitis B virus infection after liver transplantation
    Manne V, Allen RM, Saab S. Gastroenterol Hepatol (N Y). 2014 Mar;10(3):175-9.


  183. Hepatitis B virus genotypes: Global distribution and clinical importance
    Sunbul M. World J Gastroenterol. 2014 May 14;20(18):5427-5434.


  184. A drug safety evaluation of rituximab and risk of hepatitis B
    Riedell P1, Carson KR. Expert Opin Drug Saf. 2014 May 12:1-11. [Epub ahead of print]


  185. Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicentre prospective study
    Seto WK1, Hui AJ2, Wong VW3, Wong GL3, Liu KS1, Lai CL1, Yuen MF1, Chan HL3. Gut. 2014 May 15. pii: gutjnl-2014-307237. doi: 10.1136/gutjnl-2014-307237. [Epub ahead of print]


  186. Efficacy and safety of tenofovir disoproxil fumarate in pregnancy to prevent perinatal transmission of Hepatitis B Virus
    Greenup AJ1, Tan PK1, Nguyen V1, Glass A1, Davison S1, Chatterjee U2, Holdaway S3, Samarasinghe D3, Jackson K4, Locarnini S4, Levy MT5. J Hepatol. 2014 May 3. pii: S0168-8278(14)00301-8. doi: 10.1016/j.jhep.2014.04.038. [Epub ahead of print]


  187. Impact of Viral Hepatitis on Outcomes after Liver Resection for Hepatocellular Carcinoma: Results from a North American Center
    Lee JJ1, Kim PT, Fischer S, Fung S, Gallinger S, McGilvray I, Moulton CA, Wei AC, Greig PD, Cleary SP. Ann Surg Oncol. 2014 May 8. [Epub ahead of print]


  188. Early identification and linkage to care of persons with chronic hepatitis B virus infection - three u.s. Sites, 2012-2014
    Beckett GA, Ramirez G, Vanderhoff A, Nichols K, Chute SM, Wyles DL, Schoenbachler BT, Bedell DT, Cabra R, Ward JW; Division of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC. MMWR Morb Mortal Wkly Rep. 2014 May 9;63(18):399-401.


  189. Telbivudine during the second and third trimester of pregnancy interrupts HBV intrauterine transmission: a systematic review and meta-analysis
    Lu YP, Liang XJ, Xiao XM, Huang SM, Liu ZW, Li J, Hocher B, Chen YP. Clin Lab. 2014;60(4):571-86.


  190. Cost-Effectiveness of Testing Hepatitis B-Positive Pregnant Women for Hepatitis B e Antigen or Viral Load
    Fan L1, Owusu-Edusei K Jr, Schillie SF, Murphy TV. Obstet Gynecol. 2014 May;123(5):929-37. doi: 10.1097/AOG.0000000000000124.


  191. Notes from the field: investigation of infectious disease risks associated with a nontransplant anatomical donation center - Arizona, 2014
    de Perio MA, Bernard BP, Delaney LJ, Pesik N, Cohen NJ; National Institute for Occupational Safety and Health, CDC. MMWR Morb Mortal Wkly Rep. 2014 May 2;63(17):384-5.


  192. Prognostic Evaluation of Patients Undergoing Living-Donor Liver Transplant By APACHE II and MELD Scores
    Zhang ZY1, Chen R, Zhou ZQ, Peng CH, Zhou GW. Exp Clin Transplant. 2014 Apr 28. doi: 10.6002/ect.2013.0289. [Epub ahead of print]


  193. A simple and inexpensive point-of-care test for hepatitis B surface antigen detection: serological and molecular evaluation
    Gish RG1, Gutierrez JA, Navarro-Cazarez N, Giang K, Adler D, Tran B, Locarnini S, Hammond R, Bowden S. J Viral Hepat. 2014 Apr 30. doi: 10.1111/jvh.12257. [Epub ahead of print]


  194. Advances in the treatment of hepatitis B virus/hepatitis C virus coinfection
    Sagnelli E1, Pisaturo M, Martini S, Sagnelli C, Filippini P, Coppola N.


  195. Strategies to Inhibit Entry of HBV and HDV into Hepatocytes
    Urban S1, Bartenschlager R2, Kubitz R3, Zoulim F4. Gastroenterology. 2014 Apr 24. pii: S0016-5085(14)00556-3. doi: 10.1053/j.gastro.2014.04.030. [Epub ahead of print]


  196. Liver stiffness by transient elastography predicts liver-related complications and mortality in patients with chronic liver disease
    Pang JX1, Zimmer S2, Niu S2, Crotty P3, Tracey J3, Pradhan F3, Shaheen AA3, Coffin CS3, Heitman SJ1, Kaplan GG1, Swain MG3, Myers RP1. PLoS One. 2014 Apr 22;9(4):e95776. doi: 10.1371/journal.pone.0095776. eCollection 2014.


  197. Scoring systems predict the prognosis of acute-on-chronic hepatitis B liver failure: an evidence-based review
    Wu FL1, Shi KQ, Chen YP, Braddock M, Zou H, Zheng MH. Expert Rev Gastroenterol Hepatol. 2014 Apr 24. [Epub ahead of print]


  198. Viral infections in pregnancy: advice for healthcare workers
    Chin TL1, Macgowan AP2, Jacobson SK2, Donati M3. J Hosp Infect. 2014 Mar 12. pii: S0195-6701(14)00066-8. doi: 10.1016/j.jhin.2013.12.011. [Epub ahead of print]


  199. The impact of hepatitis B on heart transplantation: 19 years of national experience in Korea
    Shin HS1, Cho HJ1, Jeon ES2, Hwang HY3, Kim JJ4, Kim KB3, Oh BH1, Lee HY1. Ann Transplant. 2014 Apr 23;19:182-7. doi: 10.12659/AOT.889680.


  200. Performance of Enhanced Liver Fibrosis test and comparison with transient elastography in the identification of liver fibrosis in patients with chronic hepatitis B infection
    Trembling PM1, Lampertico P, Parkes J, Tanwar S, Viganò M, Facchetti F, Colombo M, Rosenberg WM. J Viral Hepat. 2013 Aug 15. doi: 10.1111/jvh.12161. [Epub ahead of print]


  201. Hepatitis B vaccination and screening awareness in primary care practitioners
    Said A1, Jou JH2. Hepat Res Treat2014;2014:373212. doi: 10.1155/2014/373212. Epub. 2014 Mar 6.


  202. Characteristics and Management of Patients with Chronic Hepatitis B in an Integrated Care Setting
    Sarkar M1, Shvachko VA, Ready JB, Pauly MP, Terrault NA, Peters MG, Manos MM. Dig Dis Sci. 2014 Apr 12. [Epub ahead of print]


  203. The impact of hepatitis screening on diagnosis and treatment in rheumatoid arthritis
    Conway R1, Doran MF, O'Shea FD, Crowley B, Cunnane G. Clin Rheumatol. 2014 Apr 13. [Epub ahead of print]


  204. The clinical significance of occult HBV infection
    Squadrito G, Spinella R, Raimondo G. Ann Gastroenterol. 2014;27(1):15-19.


  205. A prospective long-term study of hepatitis B virus reactivation in patients with hematologic malignancy
    Tamori A1, Hino M, Kawamura E, Fujii H, Uchida-Kobayashi S, Morikawa H, Nakamae H, Enomoto M, Murakami Y, Kawada N. J Gastroenterol Hepatol. 2014 Apr 14. doi: 10.1111/jgh.12604. [Epub ahead of print]


  206. Characterization of Chronic Hepatitis B Cases Among Foreign-Born Persons in Six Population-Based Surveillance Sites, United States 2001-2010
    Liu SJ1, Iqbal K, Shallow S, Speers S, Rizzo E, Gerard K, Poissant T, Klevens RM. J Immigr Minor Health. 2014 Apr 5. [Epub ahead of print]


  207. Distinct Seromarkers Predict Different Milestones of Chronic Hepatitis B Progression
    Liu J1, Yang HI, Lee MH, Batrla-Utermann R, Jen CL, Lu SN, Wang LY, You SL, Hsiao CK, Chen CJ; for the R.E.V.E.A.L.-HBV Study Group. Hepatology. 2014 Feb 20. doi: 10.1002/hep.27083. [Epub ahead of print]


  208. Prevalence of diagnosed chronic hepatitis B infection among U.S. Medicaid enrollees, 2000-2007
    Byrne DD1, Newcomb CW2, Carbonari DM3, Nezamzadeh MS3, Leidl KB2, Herlim M2, Yang YX4, Hennessy S3, Kostman JR5, Leonard MB6, Localio R2, Lo Re V 3rd7. Ann Epidemiol. 2014 Mar 5. pii: S1047-2797(14)00075-1. doi: 10.1016/j.annepidem.2014.02.013. [Epub ahead of print]


  209. Risk of Hip Fracture Associated with Untreated and Treated Chronic Hepatitis B Virus Infection
    Byrne DD1, Newcomb CW2, Carbonari DM3, Nezamzadeh MS3, Leidl KB2, Herlim M2, Yang YX1, Hennessy S3, Kostman JR4, Leonard MB5, Russell Localio A2, Lo Re V 3rd6. J Hepatol. 2014 Apr 5. pii: S0168-8278(14)00218-9. doi: 10.1016/j.jhep.2014.04.001. [Epub ahead of print]


  210. Association of Nucleos(t)ide Analogue Therapy with Reduced Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B-a Nationwide Cohort Study
    Wu CY1, Lin JT2, Ho HJ3, Su CW4, Lee TY5, Wang SY6, Wu C6, Wu JC7. Gastroenterology. 2014 Apr 1. pii: S0016-5085(14)00445-4. doi: 10.1053/j.gastro.2014.03.048. [Epub ahead of print]


  211. Early Detection, Curative Treatment, and Survival Rates for Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis: A Meta-analysis
    Singal AG1, Pillai A2, Tiro J3. PLoS Med. 2014 Apr 1;11(4):e1001624. doi: 10.1371/journal.pmed.1001624. eCollection 2014.


  212. Hepatitis B in pregnancy
    Dyson JK1, Waller J2, Turley A3, Michael E3, Moses S4, Valappil M4, Hudson M5, Bassendine M5, McPherson S5. Frontline Gastroenterol. 2014 Apr;5(2):111-117. Epub 2013 Oct 17.


  213. Management of hepatitis B during pregnancy
    Patton H1, Tran TT2. Nat Rev Gastroenterol Hepatol. 2014 Apr 1. doi: 10.1038/nrgastro.2014.30. [Epub ahead of print]


  214. Prevention of Neonatal Hepatitis B Virus Transmission
    Bleich LM1, Swenson ES. J Clin Gastroenterol. 2014 Mar 24. [Epub ahead of print]


  215. Efficacy and resistance in de novo combination lamivudine and adefovir dipivoxil therapy versus entecavir monotherapy for the treatment-naive patients with chronic hepatitis B: a meta-analysis
    Liu F, Wang X, Wei F, Hu H, Zhang D, Hu P1, Ren H. Virol J. 2014 Mar 28;11(1):59. doi: 10.1186/1743-422X-11-59.


  216. Current state of and needs for hepatitis B screening: results of a large screening study in a low-prevalent, metropolitan region
    Bottero J1, Boyd A2, Lemoine M3, Carrat F4, Gozlan J5, Collignon A6, Boo N7, Dhotte P8, Varsat B9, Muller G10, Cha O11, Valin N12, Nau J13, Campa P12, Silbermann B14, Bary M15, Girard PM1, Lacombe K1. PLoS One. 2014 Mar 24;9(3):e92266. doi: 10.1371/journal.pone.0092266. eCollection 2014.


  217. Immune response to hepatitis B vaccination in drug using populations: A systematic review and meta-regression analysis
    Kamath G1, Shah DP1, Hwang LY2. Vaccine. 2014 Mar 11. pii: S0264-410X(14)00299-0. doi: 10.1016/j.vaccine.2014.02.072. [Epub ahead of print]


  218. The importance of baseline viral load when assessing relative efficacy in treatment-naive HBeAg-positive chronic hepatitis B: a systematic review and network meta-analysis
    Mealing S, Ghement I, Hawkins N, Scott DA, Lescrauwaet B, Watt M, Thursz M, Lampertico P, Mantovani L, Morais E, Bregman B, Cucherat M. Syst Rev. 2014 Mar 7;3(1):21. [Epub ahead of print]


  219. Student vaccination requirements of u.s. Health professional schools: a national survey
    Libby TE1, Lindley MC, Ahmed F, Stevenson J, Grabowsky M, Strikas RA. J Allied Health. 2014 Spring;43(1):12-21.


  220. Efficacy and safety of tenofovir disoproxil fumarate in asian-americans with chronic hepatitis B in community settings
    Pan CQ1, Trinh H2, Yao A3, Bae H4, Lou L5, Chan S6; Study 123 Group. PLoS One. 2014 Mar 4;9(3):e89789. doi: 10.1371/journal.pone.0089789. eCollection 2014.


  221. Hepatitis B Reactivation and Rituximab: A New Boxed Warning and Considerations for Solid Organ Transplantation
    Martin ST1, Cardwell SM, Nailor MD, Gabardi S. Am J Transplant. 2014 Mar 4. doi: 10.1111/ajt.12649. [Epub ahead of print]


  222. Economic Evaluation of the Routine Childhood Immunization Program in the United States, 2009
    Zhou F1, Shefer A, Wenger J, Messonnier M, Wang LY, Lopez A, Moore M, Murphy TV, Cortese M, Rodewald L. Pediatrics. 2014 Mar 3. [Epub ahead of print]


  223. Efficacy of entecavir in chronic hepatitis B patients with persistently normal alanine aminotransferase: randomized, double-blind, placebo-controlled study
    Tseng KC, Chen CY, Tsai HW, Chang TT, Chuang WL, Hsu PI, Liu WC, Cheng PN. Antivir Ther. 2014 Feb 28. doi: 10.3851/IMP2754. [Epub ahead of print]


  224. Reported reasons for testing among hepatitis B virus infected patients, - Chronic Hepatitis Cohort Study (CHeCS), United States, 2006-2010
    Gerbi GB1, Rupp LB, Ko SC, Moorman A, Holmberg SD, Xu F; The CHeCS Investigators. Liver Int. 2014 Mar 3. doi: 10.1111/liv.12509. [Epub ahead of print]


  225. An update on hepatitis B, d, and e viruses
    Price J. Top Antivir Med. 2013 Dec;21(5):157-63.


  226. The pharmaceuticalization of sexual risk: Vaccine development and the new politics of cancer prevention
    Mamo L1, Epstein S2. Soc Sci Med. 2014 Jan;101:155-65. doi: 10.1016/j.socscimed.2013.11.028. Epub 2013 Nov 21.


  227. WHO guidance on the prevention of viral hepatitis B and C among people who inject drugs
    Walsh N1, Verster A2, Rodolph M2, Akl EA3. Int J Drug Policy. 2014 Jan 26. pii: S0955-3959(14)00012-7. doi: 10.1016/j.drugpo.2014.01.009. [Epub ahead of print]


  228. Prognostic Benefit of the Addition of a Quantitative Index of Hepatic Encephalopathy to the MELD score: the MELD-EEG
    Montagnese S, De Rui M, Schiff S, Ceranto E, Valenti P, Angeli P, Cillo U, Zanus G, Gatta A, Amodio P, Merkel C. Liver Int. 2014 Feb 12. doi: 10.1111/liv.12490. [Epub ahead of print]


  229. Incomplete Hepatitis B Immunization, Maternal Carrier Status and Increased Risk of Liver Diseases: A 20-year Cohort Study of 3.8 Million Vaccinees
    Chien YC, Jan CF, Chiang CJ, Kuo HS, You SL, Chen CJ. Hepatology. 2014 Feb 4. doi: 10.1002/hep.27048. [Epub ahead of print]


  230. Effect of a liver cancer education program on hepatitis B screening among asian americans in the Baltimore-washington metropolitan area, 2009-2010
    Juon HS1, Lee S2, Strong C3, Rimal R4, Kirk GD5, Bowie J5. Prev Chronic Dis. 2014 Feb 6;11:E18. doi: 10.5888/pcd11.130258.


  231. Effects of Tenofovir Disoproxil Fumarate in Hepatitis B e Antigen-Positive Patients with Normal Levels of Alanine Aminotransferase and High Levels of HBV DNA
    Chan HL1, Chan CK2, Hui AJ3, Chan S4, Poordad F5, Chang TT6, Mathurin P7, Flaherty JF8, Lin L8, Corsa A8, Gaggar A8, Subramanian GM8, McHutchison JG8, Lee S9, Gane EJ10. Gastroenterology. 2014 Jan 23. pii: S0016-5085(14)00103-6. doi: 10.1053/j.gastro.2014.01.044. [Epub ahead of print]


  232. The validity of serum markers for fibrosis staging in chronic hepatitis B and C
    Li J, Gordon SC, Rupp LB, Zhang T, Boscarino JA, Vijayadeva V, Schmidt MA, Lu M; the Chronic Hepatitis Cohort Study (CHeCS) Investigators. J Viral Hepat. 2014 Jan 29. doi: 10.1111/jvh.12224. [Epub ahead of print]


  233. Lamivudine Compared With Newer Antivirals for Prophylaxis of Hepatitis B Core Antibody Positive Livers: A Cost-Effectiveness Analysis
    Wright AJ, Fishman JA, Chung RT. Am J Transplant. 2014 Jan 24. doi: 10.1111/ajt.12598. [Epub ahead of print]


  234. Telbivudine protects renal function in patients with chronic hepatitis B infection in conjunction with adefovir-based combination therapy
    Lee M, Oh S, Lee HJ, Yeum TS, Lee JH, Yu SJ, Kim HY, Yoon JH, Lee HS, Kim YJ. J Viral Hepat. 2013 Dec 18. doi: 10.1111/jvh.12217. [Epub ahead of print]


  235. Latent hepatitis B is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C
    Reddy A, May E, Ehrinpreis M, Mutchnick M. World J Gastroenterol. 2013 Dec 28;19(48):9328-33. doi: 10.3748/wjg.v19.i48.9328.


  236. Risk of Hepatobiliary Cancer After Solid Organ Transplant in the United States
    Koshiol J1, Pawlish K2, Goodman MT3, McGlynn KA4, Engels EA5. Clin Gastroenterol Hepatol. 2013 Dec 19. pii: S1542-3565(13)01964-2. doi: 10.1016/j.cgh.2013.12.018. [Epub ahead of print]


  237. Extra-hepatic Effects of Nucleoside and Nucleotide Analogues in Chronic Hepatitis B Treatment
    Fung J, Seto WK, Lai CL, Yuen MF. J Gastroenterol Hepatol. 2013 Dec 27. doi: 10.1111/jgh.12499. [Epub ahead of print]


  238. Biomarkers of liver cell deat.
    Eguchi A1, Wree A2, Feldstein AE2. J Hepatol. 2014 Jan 8. pii: S0168-8278(14)00006-3. doi: 10.1016/j.jhep.2013.12.026. [Epub ahead of print]


  239. Durability of efficacy after telbivudine off-treatment in chronic hepatitis B patients
    Chen DB1, Chen YM1, Liu J1, Xie DY1, Lu CR1, Huang ZL1, Zhu RH1, Gao ZL2. J Clin Virol. 2014 Jan;59(1):50-4. doi: 10.1016/j.jcv.2013.11.002. Epub 2013 Nov 13.


  240. Sexual transmission of viral hepatitis
    Gorgos L. Infect Dis Clin North Am. 2013 Dec;27(4):811-36. doi: 10.1016/j.idc.2013.08.002. Epub 2013 Oct 31.


  241. Slow response to entecavir treatment in treatment-naive HBV patients is conditioned by immune response rather than by the presence or selection of refractory variants
    Solmone M, Giombini E, Vincenti D, Rozera G, Testa A, Moscetti A, Catalano M, Abbate I, Capobianchi MR, Menzo S. Antivir Ther. 2013 Nov 25. doi: 10.3851/IMP2700. [Epub ahead of print]


  242. A Rationalized Approach to the Treatment of Patients Infected with Hepatitis B
    Cox NR, Patel K, Tillmann HL. Mol Diagn Ther. 2013 Dec 3. [Epub ahead of print]


  243. Management of hepatitis B in pregnant women and infants: a multicentre audit from four London hospitals
    Godbole G, Irish D, Basarab M, Mahungu T, Fox-Lewis A, Thorne C, Jacobs M, Dusheiko G, Rosenberg WM, Suri D, Millar AD, Nastouli E. BMC Pregnancy Childbirth. 2013 Dec 1;13:222. doi: 10.1186/1471-2393-13-222.


  244. The impact of obesity and metabolic syndrome on chronic hepatitis B and drug-induced liver disease
    Pais R, Rusu E, Ratziu V. Clin Liver Dis. 2014 Feb;18(1):165-78. doi: 10.1016/j.cld.2013.09.015.


  245. Hepatitis B Virus (HBV) Infection, Immunity and Susceptibility Among Men Who Have Sex with Men (MSM), Los Angeles County, USA
    Pitasi MA, Bingham TA, Sey EK, Smith AJ, Teshale EH. AIDS Behav. 2013 Nov 26. [Epub ahead of print]


  246. Presence of anti-interferon antibodies is not associated with non-response to peginterferon treatment in chronic hepatitis B
    Arends P, van der Eijk AA, Sonneveld MJ, Hansen BE, Janssen HL, Haagmans BL. Antivir Ther. 2013 Dec 3. doi: 10.3851/IMP2711. [Epub ahead of print]


  247. Long-term efficacy and safety of emtricitabine plus tenofovir DF vs tenofovir DF monotherapy in adefovir-experienced chronic hepatitis B patients
    Berg T, Zoulim F, Moeller B, Trinh H, Marcellin P, Chan S, Kitrinos KM, Dinh P, Flaherty Jr JF, McHutchison JG, Manns M. J Hepatol. 2013 Nov 29. pii: S0168-8278(13)00826-X. doi: 10.1016/j.jhep.2013.11.024. [Epub ahead of print]


  248. Non-invasive assessment of liver fibrosis using real-time tissue elastography in patients with chronic hepatitis B
    Hu Q1, Zhu SY2, Kang LK1, Wang XY1, Lun HM3, Xu CM1. Clin Radiol. 2014 Feb;69(2):194-9. doi: 10.1016/j.crad.2013.10.003. Epub 2013 Nov 26.


  249. Similar Response to Entecavir 0.5 and 1.0 Mg in Treatment-Naïve Chronic Hepatitis B Patients: A Case-Control Study
    Ha NB, Ha NB, Chaung KT, Trinh HN, Nguyen HA, Nguyen KK, Nguyen MH. Dig Dis Sci. 2013 Nov 19. [Epub ahead of print]


  250. Antiviral therapy delays esophageal variceal bleeding in hepatitis B virus-related cirrhosis
    Li CZ, Cheng LF, Li QS, Wang ZQ, Yan JH. World J Gastroenterol. 2013 Oct 28;19(40):6849-56. doi: 10.3748/wjg.v19.i40.6849.


  251. Hepatitis B vaccination coverage among health-care personnel in the United States
    Byrd KK, Lu PJ, Murphy TV. Public Health Rep. 2013 Nov-Dec;128(6):498-509.


  252. The ratios of Treg/Th17 and TGF-?1/IL-17 are associated with the development of HBV-associated liver cirrhosis
    Yu X, Guo R, Ming D, Su M, Lin C, Deng Y, Lin Z, Su Z. J Gastroenterol Hepatol. 2013 Nov 15. doi: 10.1111/jgh.12459. [Epub ahead of print]


  253. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability
    Kim GA, Lim YS, An J, Lee D, Shim JH, Kim KM, Lee HC, Chung YH, Lee YS, Suh DJ. Gut. 2013 Oct 25. doi: 10.1136/gutjnl-2013-305517. [Epub ahead of print]


  254. Spontaneous seroclearance of hepatitis B seromarkers and subsequent risk of hepatocellular carcinoma
    Liu J, Yang HI, Lee MH, Lu SN, Jen CL, Batrla-Utermann R, Wang LY, You SL, Hsiao CK, Chen PJ, Chen CJ; for the R.E.V.E.A.L.-HBV Study Group. Gut. 2013 Nov 13. doi: 10.1136/gutjnl-2013-305785. [Epub ahead of print]


  255. Risk factors for hepatocellular carcinoma in patients with drug-resistant chronic hepatitis B
    Jun CH, Hong HJ, Chung MW, Park SY, Cho SB, Park CH, Joo YE, Kim HS, Choi SK, Rew JS. World J Gastroenterol. 2013 Oct 28;19(40):6834-41. doi: 10.3748/wjg.v19.i40.6834.


  256. HBV- and HCV-related infections and risk of pancreatic cancer
    Fiorino S, Cuppini A, Castellani G, Bacchi-Reggiani ML, Jovine E. JOP. 2013 Nov 10;14(6):603-9. doi: 10.6092/1590-8577/1948.


  257. Measures to Reduce Mother-to-Child Transmission of Hepatitis B Virus in China: A Meta-Analysis
    Xu H, Zeng T, Liu JY, Lei Y, Zhong S, Sheng YJ, Zhou Z, Ren H. Dig Dis Sci. 2013 Nov 6. [Epub ahead of print]


  258. Efficient identification of low-income Asian American women at high risk for hepatitis B
    Joseph G, Nguyen K, Nguyen T, Stewart S, Davis S, Kevany S, Marquez T, Pasick R. J Health Care Poor Underserved. 2013 Nov;24(4):1701-16. doi: 10.1353/hpu.2013.0159.


  259. Treatment of patients with dual hepatitis C virus and hepatitis B virus infection: Resolved and unresolved issues
    Liu CJ. J Gastroenterol Hepatol. 2014 Jan;29(1):26-30. doi: 10.1111/jgh.12421


  260. Entecavir-associated myopathy: a case report and literature review
    Yuan K, Wang G, Huang Z, Lin B, Zhou H, Lu X. Muscle Nerve. 2013 Nov 12. doi: 10.1002/mus.24118. [Epub ahead of print]


  261. Antiviral efficacy of entecavir in nucleos(t)ide-naïve patients of Black/African descent with chronic hepatitis B
    Jeffers L, Van Rensburg CJ, Banks A, Schechter M, Schmidt SJ, Hu W, Llamoso C, Parana R. J Viral Hepat. 2014 Jan;21(1):74-6. doi: 10.1111/jvh.12144. Epub 2013 Sep 24.


  262. Hepatitis B: global scientific development from a critical point of view
    Schmidt S, Bundschuh M, Scutaru C, Klingelhoefer D, Groneberg DA, Gerber A. J Viral Hepat. 2013 Nov 10. doi: 10.1111/jvh.12205. [Epub ahead of print]


  263. Chronic hepatitis B virus infection
    McMahon BJ. Med Clin North Am. 2014 Jan;98(1):39-54. doi: 10.1016/j.mcna.2013.08.004. Epub 2013 Oct 20.


  264. Risk of vertical transmission of hepatitis B after amniocentesis in HBs antigen-positive mothers
    Yi W, Pan CQ, Hao J, Hu Y, Liu M, Li L, Liang D. J Hepatol. 2013 Nov 19. pii: S0168-8278(13)00801-5. doi: 10.1016/j.jhep.2013.11.008. [Epub ahead of print]


  265. Prognostic factors affecting survival at recurrence of hepatocellular carcinoma after living-donor liver transplantation: with special reference to neutrophil/lymphocyte ratio
    Harimoto N, Shirabe K, Nakagawara H, Toshima T, Yamashita Y, Ikegami T, Yoshizumi T, Soejima Y, Ikeda T, Maehara Y. Transplantation. 2013 Dec 15;96(11):1008-12. doi: 10.1097/TP.0b013e3182a53f2b.


  266. Knowledge of HBV and HCV and individuals' attitudes toward HBV- and HCV-infected colleagues: a national cross-sectional study among a working population in Japan
    Eguchi H, Wada K. PLoS One. 2013 Sep 26;8(9):e76921. doi: 10.1371/journal.pone.0076921.


  267. Hepatitis B virus gene mutations and hepatocarcinogenesis
    Liang T, Chen EQ, Tang H. Asian Pac J Cancer Prev. 2013;14(8):4509-13.


  268. Trends in the knowledge, attitudes and practices of travel risk groups toward prevention of hepatitis B: Results from the repeated cross-sectional Dutch Schiphol Airport Survey 2002-2009
    van Genderen PJ, van Thiel PP, Mulder PG, Overbosch D; Dutch Schiphol Airport Study Group. Travel Med Infect Dis. 2013 Sep 29. pii: S1477-8939(13)00140-3. doi: 10.1016/j.tmaid.2013.09.002. [Epub ahead of print]


  269. Anti-TNF therapy in patients with HBV infection-analysis of 87 patients with inflammatory arthritis
    Ye H, Zhang XW, Mu R, Fang LK, Gu JR, Lin J, Du JF, Chen JW, Chen YJ, Wu LJ, Pang XF, Li ZG. Clin Rheumatol. 2013 Sep 29. [Epub ahead of print]


  270. Quality of life, depression, and anxiety among hepatitis B patients
    Keskin G, Gümüs AB, Orgun F. Gastroenterol Nurs. 2013 Sep-Oct;36(5):346-56. doi: 10.1097/SGA.0b013e3182a788cc.


  271. Comparison of hepatitis B prophylactic outcomes in living donor liver transplantation recipients who meet the Milan or UCSF criteria
    Jiang L, Yan LN, Wen TF, Li B, Yang JY. Hepatobiliary Pancreat Dis Int. 2013 Oct;12(5):494-9.


  272. Prevention of recurrent hepatitis B infection after liver transplantation
    Wong TC, Fung JY, Lo CM. Hepatobiliary Pancreat Dis Int. 2013 Oct;12(5):465-72.


  273. Efficacy of lamivudine combined with adefovir dipivoxil versus entecavir monotherapy in patients with hepatitis B-associated decompensated cirrhosis: A meta-analysis
    Peng H, Liu J, Yang M, Tong S, Yin W, Tang H, Hu P, Hu H, Ren H. J Clin Pharmacol. 2013 Sep 16. doi: 10.1002/jcph.181. [Epub ahead of print]


  274. High hepatitis B virus surface antigen levels and favorable interleukin 28B genotype predict spontaneous hepatitis C virus clearance in uremic patients
    Yu ML, Dai CY, Huang CF, Lee JJ, Yeh ML, Yeh SM, Kuo HT, Huang JF, Chang JM, Chen HC, Juo SH, Hwang SJ, Chuang WL; FORMOSA-LIKE group. J Hepatol. 2013 Oct 2. pii: S0168-8278(13)00683-1. doi: 10.1016/j.jhep.2013.09.023. [Epub ahead of print]


  275. Role of interleukin 28-B in the spontaneous and treatment-related clearance of HCV infection in patients with chronic HBV/HCV dual infection
    Coppola N, Marrone A, Pisaturo M, Starace M, Signoriello G, Gentile I, Adinolfi LE, Sagnelli E, Zampino R. Eur J Clin Microbiol Infect Dis. 2013 Oct 1. [Epub ahead of print]


  276. Antiviral Therapy for Chronic Hepatitis B Virus Infection and Development of Hepatocellular Carcinoma in a US Population
    Gordon SC, Lamerato LE, Rupp LB, Li J, Holmberg SD, Moorman AC, Spradling PR, Teshale EH, Vijayadeva V, Boscarino JA, Henkle EM, Oja-Tebbe N, Lu M; Checs Investigators. Clin Gastroenterol Hepatol. 2013 Oct 6. pii: S1542-3565(13)01511-5. doi: 10.1016/j.cgh.2013.09.062. [Epub ahead of print]


  277. Hepatitis B virus gene mutations and hepatocarcinogenesis
    Liang T, Chen EQ, Tang H. Asian Pac J Cancer Prev. 2013;14(8):4509-13.


  278. Efficacy of adefovir-based combination therapy for patients with Lamivudine- and entecavir-resistant chronic hepatitis B virus infection
    Lee YB, Lee JH, Choi WM, Cho YY, Yoo JJ, Lee M, Lee DH, Cho Y, Yu SJ, Kim YJ, Yoon JH, Kim CY, Lee HS. Antimicrob Agents Chemother. 2013 Dec;57(12):6325-32. doi: 10.1128/AAC.01742-13. Epub 2013 Oct 7.


  279. Hepatitis B and C in the armed forces
    Freshwater DA. J R Army Med Corps. 2013 Sep;159(3):169-74. doi: 10.1136/jramc-2013-000096. Epub 2013 Jun 3.


  280. Hepatitis B vaccination with or without hepatitis B immunoglobulin at birth to babies born of HBsAg-positive mothers prevents overt HBV transmission but may not prevent occult HBV infection in babies: a randomized controlled trial
    Pande C, Sarin SK, Patra S, Kumar A, Mishra S, Srivastava S, Bhutia K, Gupta E, Mukhopadhyay CK, Dutta AK, Trivedi SS. J Viral Hepat. 2013 Nov;20(11):801-10. doi: 10.1111/jvh.12102. Epub 2013 Apr 23.


  281. Analysis of rheumatoid factor according to various hepatitis B virus infectious statuses
    Choi ST, Lee HW, Song JS, Lee SK, Park YB.


  282. Options for the management of antiviral resistance during hepatitis B therapy: reflections on battles over a decade
    Yim HJ, Hwang SG. Clin Mol Hepatol. 2013 Sep;19(3):195-209. doi: 10.3350/cmh.2013.19.3.195. Epub 2013 Sep 30.


  283. De novo combination therapy adefovir plus lamivudine as a treatment for women of child-bearing age with HBeAg-positive chronic hepatitis B Before Pregnancy
    Li-Na M, Xiang-Chun D, Xiao-Yan L, Chun-Qiong X, Liu SW, Yan X. J Med Virol. 2013 Oct 25. doi: 10.1002/jmv.23828. [Epub ahead of print]


  284. Compromised Function of Natural Killer Cells in Acute and Chronic Viral Hepatitis
    Lunemann S, Malone DF, Hengst J, Port K, Grabowski J, Deterding K, Markova A, Bremer B, Schlaphoff V, Cornberg M, Manns MP, Sandberg JK, Ljunggren HG, Björkström NK, Wedemeyer H. J Infect Dis. 2013 Nov 1. [Epub ahead of print]


  285. Hepatitis viruses and non-Hodgkin's lymphoma: A review
    Datta S, Chatterjee S, Policegoudra RS, Gogoi HK, Singh L. World J Virol. 2012 Dec 12;1(6):162-173.


  286. Prevalence of Hepatitis-B Viral Markers in Patients With Inflammatory Bowel Disease in a Hepatitis-B-Endemic Area: Inadequate Protective Antibody Levels in Young Patients
    Kim ES, Cho KB, Park KS, Jang BI, Kim KO, Jeon SW, Kim EY, Yang CH, Kim WJ; Daegugyeongbuk Gastrointestinal Study Group (DGSG). J Clin Gastroenterol. 2013 Oct 24. [Epub ahead of print]


  287. Risk prediction of hepatitis B virus-related hepatocellular carcinoma in the era of antiviral therapy
    Wong GL, Wong VW. World J Gastroenterol. 2013 Oct 21;19(39):6515-22. doi: 10.3748/wjg.v19.i39.6515.


  288. Differences Between Hepatocellular Carcinoma and Hepatitis B Virus Infection in Patients With and Without Cirrhosis
    Kim JM, Kwon CH, Joh JW, Park JB, Lee JH, Kim SJ, Paik SW, Park CK, Yoo BC. Ann Surg Oncol. 2013 Oct 17. [Epub ahead of print]


  289. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability
    Kim GA, Lim YS, An J, Lee D, Shim JH, Kim KM, Lee HC, Chung YH, Lee YS, Suh DJ. Gut. 2013 Oct 25. doi: 10.1136/gutjnl-2013-305517. [Epub ahead of print]


  290. Analysis of S gene mutation of the hepatitis B virus in adult liver transplant recipients showing resistance to hepatitis B immunoglobulin therapy
    Park GC, Hwang S, Ahn CS, Kim KH, Moon DB, Ha TY, Song GW, Jung DH, Shin YW, Kim SH, Chang KH, Namgoong JM, Park CS, Park HW, Park YH, Kang SH, Jung BH, Lee SG. Transplant Proc. 2013 Oct;45(8):3047-51. doi: 10.1016/j.transproceed.2013.08.055.


  291. Adjuvant Therapy after Curative Resection for Hepatocellular Carcinoma Associated with Hepatitis Virus
    Kubo S, Takemura S, Sakata C, Urata Y, Uenishi T. Liver Cancer. 2013 Jan;2(1):40-46.


  292. Effects of entecavir and lamivudine for hepatitis B decompensated cirrhosis: meta-analysis
    Ye XG, Su QM. World J Gastroenterol. 2013 Oct 21;19(39):6665-78. doi: 10.3748/wjg.v19.i39.6665.


  293. Assessment of current criteria for primary non-response in chronic hepatitis B patients receiving entecavir therapy
    Yang YJ, Shim JH, Kim KM, Lim YS, Lee HC. Hepatology. 2013 Oct 29. doi: 10.1002/hep.26910. [Epub ahead of print]


  294. Clinical outcomes and risk factors of hepatitis B virus recurrence in patients who received prophylaxis with entecavir and hepatitis B immunoglobulin following liver transplantation
    Kim YK, Kim SH, Lee SD, Park SJ. Transplant Proc. 2013 Oct;45(8):3052-6. doi: 10.1016/j.transproceed.2013.08.065.


  295. Durability after discontinuation of nucleos(t)ide therapy in chronic HBeAg negative hepatitis patients
    Kim YJ, Kim K, Hwang SH, Kim SS, Lee D, Cheong JY, Cho SW. Clin Mol Hepatol. 2013 Sep;19(3):300-4. doi: 10.3350/cmh.2013.19.3.300. Epub 2013 Sep 30.


  296. Hepatitis B virus reactivation in HBsAg-positive patients with rheumatic diseases undergoing anti-tumor necrosis factor therapy or DMARDs
    Lee YH, Bae SC, Song GG. Int J Rheum Dis. 2013 Oct;16(5):527-31. doi: 10.1111/1756-185X.12154.


  297. Antiviral Therapy for Chronic Hepatitis B Virus Infection and Development of Hepatocellular Carcinoma in a US Population
    Gordon SC, Lamerato LE, Rupp LB, Li J, Holmberg SD, Moorman AC, Spradling PR, Teshale EH, Vijayadeva V, Boscarino JA, Henkle EM, Oja-Tebbe N, Lu M; Checs Investigators. Clin Gastroenterol Hepatol. 2013 Oct 6. pii: S1542-3565(13)01511-5. doi: 10.1016/j.cgh.2013.09.062. [Epub ahead of print]


  298. Prevention and Risk Factors of Hepatitis B Recurrence after Living Donor Liver Transplantation
    Na GH, Kim DG, Han JH, Kim EY, Lee SH, Hong TH, You YK, Choi JY. J Gastroenterol Hepatol. 2013 Oct 3. doi: 10.1111/jgh.12403. [Epub ahead of print]


  299. Clinical and virological features of occult hepatitis B in patients with HBsAg seroclearance post-treatment or spontaneously
    Cheng HR, Kao JH, Wu HL, Chen TC, Tseng TC, Liu CH, Su TH, Chen PJ, Chen DS, Liu CJ. Liver Int. 2013 Sep 11. doi: 10.1111/liv.12324. [Epub ahead of print]


  300. Clinical implications of the titer of serum hepatitis B surface antigen during the natural history of hepatitis B virus infection
    Suh SJ, Bae SI, Kim JH, Kang K, Yeon JE, Byun KS. J Med Virol. 2014 Jan;86(1):117-23. doi: 10.1002/jmv.23767. Epub 2013 Sep 30.


  301. Antihepatitis B therapy: a review of current medications and novel small molecule inhibitors
    Qiu LP, Chen L, Chen KP. Fundam Clin Pharmacol. 2013 Oct 4. doi: 10.1111/fcp.12053. [Epub ahead of print]


  302. Lamivudine resistance leading to de novo hepatitis B infection in recipients of hepatitis B core antibody positive liver allografts
    Leong J, Coty P, Fiel MI, Chang C, Florman S, Schiano T. Hepatol Res. 2013 Sep 25. doi: 10.1111/hepr.12249. [Epub ahead of print]


  303. IFNL3 (IL28B) polymorphism does not predict long-term response to interferon therapy in HBeAg-positive chronic hepatitis B patients
    Zhang Q, Lapalus M, Asselah T, Laouénan C, Moucari R, Martinot-Peignoux M, Bieche I, Estrabaud E, De Muynck S, Boyer N, Bedossa P, Vidaud M, Marcellin P, Lada O. J Viral Hepat. 2013 Oct 10. doi: 10.1111/jvh.12177. [Epub ahead of print]


  304. Does Anti-HBV Therapy Benefit the Prognosis of HBV-Related Hepatocellular Carcinoma Following Hepatectomy?
    Yu LH, Li N, Shi J, Guo WX, Wu MC, Cheng SQ. Ann Surg Oncol. 2013 Oct 12. [Epub ahead of print]


  305. Chronic Hepatitis B Management Based on Standard Guidelines in Community Primary Care and Specialty Clinics
    Ku KC, Li J, Ha NB, Martin M, Nguyen VG, Nguyen MH. Dig Dis Sci. 2013 Oct 13. [Epub ahead of print]


  306. Association between Mannose-binding lectin gene polymorphisms and hepatitis B virus infection: a meta-analysis
    Xu HD, Zhao MF, Wan TH, Song GZ, He JL, Chen Z. PLoS One. 2013 Oct 8;8(10):e75371. doi: 10.1371/journal.pone.0075371.


  307. HBsAg quantification for identification of liver disease in chronic hepatitis B virus carriers
    Larsson SB, Eilard A, Malmström S, Hannoun C, Dhillon AP, Norkrans G, Lindh M. Liver Int. 2013 Oct 1. doi: 10.1111/liv.12345. [Epub ahead of print]


  308. On-treatment alpha-fetoprotein is a specific tumor marker for hepatocellular carcinoma in patients with chronic hepatitis B receiving entecavir
    Wong GL, Chan HL, Tse YK, Chan HY, Tse CH, Lo AO, Wong VW. Hepatology. 2013 Oct 1. doi: 10.1002/hep.26739. [Epub ahead of print]


  309. Correlation between hepatitis B virus surface antigen level and alpha-fetoprotein in patients free of hepatocellular carcinoma or severe hepatitis
    Akuta N, Suzuki F, Kobayashi M, Hara T, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Saitoh S, Ikeda K, Kumada H. J Med Virol. 2014 Jan;86(1):131-8. doi: 10.1002/jmv.23790. Epub 2013 Oct 12.


  310. De novo combined lamivudine and adefovir dipivoxil therapy vs entecavir monotherapy for hepatitis B virus-related decompensated cirrhosis
    Lian JS, Zeng LY, Chen JY, Jia HY, Zhang YM, Xiang DR, Yu L, Hu JH, Lu YF, Zheng L, Li LJ, Yang YD. World J Gastroenterol. 2013 Oct 7;19(37):6278-83. doi: 10.3748/wjg.v19.i37.6278.


  311. De novo combined lamivudine and adefovir dipivoxil therapy vs entecavir monotherapy for hepatitis B virus-related decompensated cirrhosis
    Lian JS, Zeng LY, Chen JY, Jia HY, Zhang YM, Xiang DR, Yu L, Hu JH, Lu YF, Zheng L, Li LJ, Yang YD. World J Gastroenterol. 2013 Oct 7;19(37):6278-83. doi: 10.3748/wjg.v19.i37.6278.


  312. Elevation in Serum Concentration of Bone-Specific Alkaline Phosphatase without Elevation in Serum Creatinine Concentration Secondary to Adefovir Dipivoxil Therapy in Chronic Hepatitis B Virus Infection
    Abe H, Seki N, Sugita T, Aida Y, Ishiguro H, Miyazaki T, Itagaki M, Sutoh S, Aizawa Y. Hepat Res Treat. 2013;2013:739247. doi: 10.1155/2013/739247. Epub 2013 Sep 9.


  313. Adjuvant therapy for hepatocellular carcinoma: Current situation and prospect
    Wang ZG, Zhang GF, Wu JC, Jia MK. Drug Discov Ther. 2013 Aug;7(4):137-143.


  314. Association between survivin -31G>C polymorphism and cancer risk: meta-analysis of 29 studies
    Qin Q, Zhang C, Zhu H, Yang X, Xu L, Liu J, Lu J, Zhan L, Cheng H, Sun X. J Cancer Res Clin Oncol. 2013 Sep 28. [Epub ahead of print]


  315. The 2013 WHO guidelines for antiretroviral therapy: evidence-based recommendations to face new epidemic realities
    Doherty M, Ford N, Vitoria M, Weiler G, Hirnschall G. Curr Opin HIV AIDS. 2013 Nov;8(6):528-34. doi: 10.1097/COH.0000000000000008.


  316. Effects of comprehensive intervention on health-related quality of life in patients with chronic hepatitis B in China
    Chao J, Song L, Zhang H, Zhu L, Tian L, Jin H, Liu P. BMC Health Serv Res. 2013 Oct 4;13:386. doi: 10.1186/1472-6963-13-386.


  317. Comparison of hepatitis B prophylactic outcomes in living donor liver transplantation recipients who meet the Milan or UCSF criteria
    Jiang L, Yan LN, Wen TF, Li B, Yang JY. Hepatobiliary Pancreat Dis Int. 2013 Oct;12(5):494-9.


  318. Pathogenesis of viruses-associated human cancers: Epstein-Barr virus and hepatitis B virus as two examples
    Chang KC, Chang Y, Wang LH, Tsai HW, Huang W, Su IJ. J Formos Med Assoc. 2013 Oct 2. pii: S0929-6646(13)00300-8. doi: 10.1016/j.jfma.2013.09.001. [Epub ahead of print]


  319. Efficacy of lamivudine combined with adefovir dipivoxil versus entecavir monotherapy in patients with hepatitis B-associated decompensated cirrhosis: A meta-analysis
    Peng H, Liu J, Yang M, Tong S, Yin W, Tang H, Hu P, Hu H, Ren H. J Clin Pharmacol. 2013 Sep 16. doi: 10.1002/jcph.181. [Epub ahead of print]


  320. Prevention of recurrent hepatitis B infection after liver transplantation
    Wong TC, Fung JY, Lo CM. Hepatobiliary Pancreat Dis Int. 2013 Oct;12(5):465-72.


  321. Why does living donor liver transplantation flourish in Asia?
    Chen CL, Kabiling CS, Concejero AM. Nat Rev Gastroenterol Hepatol. 2013 Dec;10(12):746-51. doi: 10.1038/nrgastro.2013.194. Epub 2013 Oct 8.


  322. Developing an evidence-based guideline for the management of exposure to hepatitis B at a Victorian tertiary hospital
    Pierce AB, Armishaw J, Aitchison S. Aust N Z J Public Health. 2013 Oct;37(5):411-5. doi: 10.1111/1753-6405.12107.


  323. Molecular Epidemiology and Clinical Characteristics of Hepatitis B Identified through the French Mandatory Notification System
    Thibault V, Laperche S, Thiers V, Sayon S, Letort MJ, Delarocque-Astagneau E, Antona D. PLoS One. 2013 Sep 25;8(9):e75267. doi: 10.1371/journal.pone.0075267.


  324. A review of molecular mechanisms in the development of hepatocellular carcinoma by aflatoxin and hepatitis B and C viruses
    Moudgil V, Redhu D, Dhanda S, Singh J. J Environ Pathol Toxicol Oncol. 2013;32(2):165-75.


  325. Anti-TNF therapy in patients with HBV infection-analysis of 87 patients with inflammatory arthritis
    Ye H, Zhang XW, Mu R, Fang LK, Gu JR, Lin J, Du JF, Chen JW, Chen YJ, Wu LJ, Pang XF, Li ZG. Clin Rheumatol. 2013 Sep 29. [Epub ahead of print]


  326. Comparison of tenofovir and entecavir in patients with chronic HBV infection
    Ceylan B, Yardimci C, Fincanci M, Eren G, Tozalgan U, Muderrisoglu C, Akkoyunlu Y. Eur Rev Med Pharmacol Sci. 2013 Sep;17(18):2467-73.


  327. Real-world application of the roadmap model in chronic hepatitis B patients with telbivudine therapy
    Yu HC, Lin KH, Hsu PI, Tsay FW, Wang HM, Tsai TJ, Lai KH. Clin Ther. 2013 Sep;35(9):1386-99. doi: 10.1016/j.clinthera.2013.07.329.


  328. Telbivudine Improves Renal Function in Patients With Chronic Hepatitis B
    Gane EJ, Deray G, Liaw YF, Lim SG, Lai CL, Rasenack J, Wang Y, Papaptheodoridis G, Di Bisceglie A, Buti M, Samuel D, Uddin A, Bosset S, Trylesinski A. Gastroenterology. 2013 Sep 22. pii: S0016-5085(13)01359-0. doi: 10.1053/j.gastro.2013.09.031. [Epub ahead of print]


  329. Antiviral treatment for hepatitis B virus recurrence following liver transplantation
    Lee S, Kwon CH, Moon HH, Kim TS, Roh Y, Song S, Shin M, Kim JM, Park JB, Kim SJ, Joh JW, Lee SK. Clin Transplant. 2013 Sep-Oct;27(5):E597-604. doi: 10.1111/ctr.12212.


  330. Quality of life, depression, and anxiety among hepatitis B patients
    Keskin G, Gümüs AB, Orgun F. Gastroenterol Nurs. 2013 Sep-Oct;36(5):346-56. doi: 10.1097/SGA.0b013e3182a788cc.


  331. Prognostic indicators and treatment outcome in 94 cases of fibrolamellar hepatocellular carcinoma
    Kaseb AO, Shama M, Sahin IH, Nooka A, Hassabo HM, Vauthey JN, Aloia T, Abbruzzese JL, Subbiah IM, Janku F, Curley S, Hassan MM. Oncology. 2013;85(4):197-203. doi: 10.1159/000354698. Epub 2013 Sep 19.


  332. Lingmao Formula Combined with Entecavir for HBeAg-Positive Chronic Hepatitis B Patients with Mildly Elevated Alanine Aminotransferase: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
    Zhu XJ, Sun XH, Zhou ZH, Liu SQ, Lv H, Li M, Li L, Gao YQ. Evid Based Complement Alternat Med. 2013;2013:620230. doi: 10.1155/2013/620230. Epub 2013 Aug 24.


  333. Kinetics of Hepatitis B Virus Load During Haemodialysis Sessions and ?-Interferon: A Prospective Study
    Fabrizi F, Lunghi G, Alongi G, Aucella F, Barbisoni F, Bisegna S, Mangano S, Romei-Longhena G, Artoni A, Bettoni G, Messa P, Martin P. Kidney Blood Press Res. 2013 Sep 4;37(4-5):286-294. [Epub ahead of print]


  334. Decreased antigenicity profiles of immune-escaped and drug-resistant hepatitis B surface antigen (HBsAg) double mutants
    Zhang M, Ge G, Yang Y, Cai X, Fu Q, Cai J, Huang Z. Virol J. 2013 Sep 22;10:292. doi: 10.1186/1743-422X-10-292.


  335. Long-term outcomes after nucleos(t)ide analogues discontinuation in chronic hepatitis B patients with HBeAg-negative
    He D, Guo S, Chen W, Chen X, Yan G, Wang J, Li M, Zhu P, Huang H, Wang Y. BMC Infect Dis. 2013 Oct 3;13:458. doi: 10.1186/1471-2334-13-458.


  336. Predictors of Significant Fibrosis in Chronic Hepatitis B Patients With Low Viremia
    Abdo AA, Bzeizi KI, Babatin MA, Alsohaibani F, Almana H, Alsaad KO, Alghamdi H, Al-Hamoudi W, Alswat K, Alfaleh FZ, Myers RP, Sanai FM. J Clin Gastroenterol. 2013 Sep 25. [Epub ahead of print]


  337. Thrombocytopenia in patients with hepatitis B virus-related chronic hepatitis: Evaluation of the immature platelet fraction
    Dou J, Lou Y, Wu J, Lu Y, Jin Y. Platelets. 2013 Sep 18. [Epub ahead of print]


  338. Safety of tenofovir during pregnancy for the mother and fetus: a systematic review
    Wang L, Kourtis AP, Ellington S, Legardy-Williams J, Bulterys M. Clin Infect Dis. 2013 Dec;57(12):1773-81. doi: 10.1093/cid/cit601. Epub 2013 Sep 17.


  339. Does prolidase indicate worsening of hepatitis B infection?
    Duygu F, Aksoy N, Cicek AC, Butun I, Unlu S. J Clin Lab Anal. 2013 Sep;27(5):398-401. doi: 10.1002/jcla.21617.


  340. Association between viral hepatitis B infection and halitosis
    Han DH, Lee SM, Lee JG, Kim YJ, Kim JB. Acta Odontol Scand. 2013 Sep 23. [Epub ahead of print]


  341. Role of Hepatitis B Surface Antigen (HBsAg) in Identifying True Inactive HBsAg Carriers Infected With Genotype C Hepatitis B Virus
    Yim SY, Um SH, Jung JY, Seo YS, Yim HJ, Ryu HS, Chun HJ, Jeen YT, Kim CD, Keum B, Lee HS. J Clin Gastroenterol. 2013 Sep 16. [Epub ahead of print]


  342. Hepatitis B Management in Vulnerable Populations: Gaps in Disease Monitoring and Opportunities for Improved Care
    Burman BE, Mukhtar NA, Toy BC, Nguyen TT, Chen AH, Yu A, Berman P, Hammer H, Chan D, McCulloch CE, Khalili M. Dig Dis Sci. 2013 Sep 20. [Epub ahead of print]


  343. Effect of a carbohydrate-containing late-evening snack on energy metabolism and fasting substrate utilization in adults with acute-on-chronic liver failure due to Hepatitis B
    Hou W, Li J, Lu J, Wang JH, Zhang FY, Yu HW, Zhang J, Yao QW, Wu J, Shi SY, Mager DR, Meng QH. Eur J Clin Nutr. 2013 Sep 18. doi: 10.1038/ejcn.2013.163. [Epub ahead of print]


  344. Increased risk of cirrhosis and its decompensation in chronic hepatitis B patients with newly diagnosed diabetes: a nationwide cohort study
    Huang YW, Wang TC, Lin SC, Chang HY, Chen DS, Hu JT, Yang SS, Kao JH. Clin Infect Dis. 2013 Dec;57(12):1695-702. doi: 10.1093/cid/cit603. Epub 2013 Sep 18.


  345. The presence of hepatitis B core antibody is associated with more advanced liver disease in alcoholic patients with cirrhosis
    Zhang M, Wu R, Jiang J, Minuk GY, Niu J. Alcohol. 2013 Nov;47(7):553-8. doi: 10.1016/j.alcohol.2013.07.003. Epub 2013 Sep 13.


  346. Plasma Levels of Adiponectin and Primary Liver Cancer Risk in Middle-Aged Japanese Adults with Hepatitis Virus Infection: A Nested Case-Control Study
    Michikawa T, Inoue M, Sawada N, Sasazuki S, Tanaka Y, Iwasaki M, Shimazu T, Yamaji T, Mizokami M, Tsugane S; for the Japan Public Health Center?based Prospective Study Group. Cancer Epidemiol Biomarkers Prev. 2013 Nov 19. [Epub ahead of print]


  347. National, state, and local area vaccination coverage among children aged 19-35 months - United States, 2012
    Centers for Disease Control and Prevention (CDC).


  348. Efficacy and Safety of Telbivudine Compared to Entecavir Among HBeAg+ Chronic Hepatitis B Patients: a Meta-Analysis Study
    Liang J, Jiang MJ, Deng X, Xiao Zhou X. Hepat Mon. 2013 May 23;13(6):e7862. doi: 10.5812/hepatmon.7862.


  349. Lactic acidosis during telbivudine treatment for HBV: a case report and literature review
    Jin JL, Hu P, Lu JH, Luo SS, Huang XY, Weng XH, Zhang JM. World J Gastroenterol. 2013 Sep 7;19(33):5575-80. doi: 10.3748/wjg.v19.i33.5575.


  350. Prognostic value of preoperative peripheral neutrophil-to-lymphocyte ratio in patients with HBV-associated hepatocellular carcinoma after radical hepatectomy
    Fu SJ, Shen SL, Li SQ, Hua YP, Hu WJ, Liang LJ, Peng BG. Med Oncol. 2013 Dec;30(4):721. doi: 10.1007/s12032-013-0721-6. Epub 2013 Sep 13.


  351. Association of polymorphisms in interleukin-18 and interleukin-28B genes with outcomes of hepatitis B virus infections: a meta-analysis
    Xia P, Zhou M, Dong DS, Xing YN, Bai Y. Tumour Biol. 2013 Sep 12. [Epub ahead of print]


  352. Impact of lamivudine-resistance mutations on entecavir treatment outcome in hepatitis B
    Koffi J, Egounlety R, Pradat P, Lebosse F, Si-Ahmed SN, Lussier V, Chevallier P, Bailly F, Zoulim F. Eur J Gastroenterol Hepatol. 2013 Sep 9. [Epub ahead of print]


  353. Predictors of survival in hepatitis B virus related decompensated cirrhosis on tenofovir therapy: An Indian perspective
    Srivastava M, Rungta S, Dixit VK, Shukla SK, Singh TB, Jain AK. Antiviral Res. 2013 Nov;100(2):300-5. doi: 10.1016/j.antiviral.2013.08.020. Epub 2013 Sep 5.


  354. Effects of hepatitis B virus X protein on human T cell cytokines
    Lou X, Hou Y, Liang D. Can J Microbiol. 2013 Sep;59(9):620-6. doi: 10.1139/cjm-2013-0259. Epub 2013 Jul 12.


  355. Hepatitis B antivirals and resistance
    Devi U, Locarnini S. Curr Opin Virol. 2013 Oct;3(5):495-500. doi: 10.1016/j.coviro.2013.08.006. Epub 2013 Sep 7.


  356. Quantification of serum hepatitis B surface antigen in predicting the response of pegylated interferon alfa-2a in HBeAg-positive chronic hepatitis B with prior lamivudine exposure
    Weng M, Zeng WZ, Wu XL, Zhang Y, Jiang MD, Wang Z, Zhou DJ, He X. Virol J. 2013 Sep 6;10(1):277. [Epub ahead of print]


  357. Possible origins and evolution of the hepatitis B virus (HBV)
    Locarnini S, Littlejohn M, Aziz MN, Yuen L. Semin Cancer Biol. 2013 Sep 3. pii: S1044-579X(13)00082-5. doi: 10.1016/j.semcancer.2013.08.006. [Epub ahead of print]


  358. An Overview of Hepatitis B Virus Surface Antigen Mutant in the Asia Pacific
    Hudu SA, Malik YA, Niazlin MT, Harmal NS, Sekawi Z. Curr Issues Mol Biol. 2013 Sep 6;16(2):69-78. [Epub ahead of print]


  359. Chronic hepatitis D at a standstill: where do we go from here?
    Ciancio A, Rizzetto M. Nat Rev Gastroenterol Hepatol. 2013 Sep 10. doi: 10.1038/nrgastro.2013.164. [Epub ahead of print]


  360. Changes of HBsAg and interferon-inducible protein 10 serum levels in naive HBeAg-negative chronic hepatitis B patients under 4-year entecavir therapy
    Papatheodoridis G, Goulis J, Manolakopoulos S, Margariti A, Exarchos X, Kokkonis G, Hadziyiannis E, Papaioannou C, Manesis E, Pectasides D, Akriviadis E. J Hepatol. 2013 Sep 6. pii: S0168-8278(13)00646-6. doi: 10.1016/j.jhep.2013.08.023. [Epub ahead of print]


  361. Combination lamivudine and adefovir versus entecavir for the treatment of naïve chronic hepatitis B patients: a pilot study
    Du QW, Ding JG, Sun QF, Hong L, Cai FJ, Zhou QQ, Wu YH, Fu RQ. Med Sci Monit. 2013 Sep 9;19:751-6. doi: 10.12659/MSM.889443.


  362. Prediction of disease reactivation in asymptomatic hepatitis B e antigen-negative chronic hepatitis B patients using baseline serum measurements of HBsAg and HBV-DNA
    Martinot-Peignoux M, Lapalus M, Laouénan C, Lada O, Netto-Cardoso AC, Boyer N, Ripault MP, Carvalho-Filho R, Asselah T, Marcellin P. J Clin Virol. 2013 Oct;58(2):401-7. doi: 10.1016/j.jcv.2013.08.010. Epub 2013 Aug 16.


  363. Racial disparities in hepatitis B infection in Ohio: screening and immunization are critical for early clinical management
    Misra R, Jiobu K, Zhang J, Liu Q, Li F, Kirkpatrick R, Ho J. J Investig Med. 2013 Oct;61(7):1121-8. doi: 10.231/JIM.0b013e3182a70f10.


  364. On-treatment mortality predictors in chronic hepatitis B patients experiencing severe acute exacerbation: a prospective observational study
    Chen YC, Hsu CW, Chang MY, Yeh CT.


  365. Current role of Lamivudine regarding therapeutic response and resistance in children with chronic hepatitis B
    Hong SJ, Kim YH, Choe BH, Park HJ, Tak WY, Kweon YO. Pediatr Gastroenterol Hepatol Nutr. 2013 Jun;16(2):80-8. doi: 10.5223/pghn.2013.16.2.80. Epub 2013 Jun 30.


  366. Hepatitis B virus-induced hepatocellular carcinoma: functional roles of MICA variants
    Tong HV, Toan NL, Song LH, Bock CT, Kremsner PG, Velavan TP. J Viral Hepat. 2013 Oct;20(10):687-98. doi: 10.1111/jvh.12089. Epub 2013 May 7.


  367. The oncogenic role of hepatitis B virus
    Rivière L, Ducroux A, Buendia MA. Recent Results Cancer Res. 2014;193:59-74. doi: 10.1007/978-3-642-38965-8_4.


  368. Prevention of hepatitis B virus infection and liver cancer
    Chang MH. Recent Results Cancer Res. 2014;193:75-95. doi: 10.1007/978-3-642-38965-8_5.


  369. Change in hepatitis B virus large surface antigen variant prevalence 13 years after implementation of a universal vaccination program in china
    Bian T, Yan H, Shen L, Wang F, Zhang S, Cao Y, Zhang S, Zhang Y, Bi S. J Virol. 2013 Nov;87(22):12196-206. doi: 10.1128/JVI.02127-13. Epub 2013 Sep 4.


  370. Safety and Efficacy of Protease Inhibitors to Treat Hepatitis C After Liver Transplantation, a Multicenter Experience
    Coilly A, Roche B, Dumortier J, Leroy V, Botta-Fridlund D, Radenne S, Pageaux GP, Si-Ahmed SN, Guillaud O, Antonini TM, Haim-Boukobza S, Roque-Afonso AM, Samuel D, Duclos-Vallee JC. J Hepatol. 2013 Aug 29. pii: S0168-8278(13)00613-2. doi: 10.1016/j.jhep.2013.08.018. [Epub ahead of print]


  371. Update on rescue therapies in patients with lamivudine-resistant chronic hepatitis B
    Chao DC, Hu KQ. Drug Des Devel Ther. 2013 Aug 20;7:777-88. doi: 10.2147/DDDT.S33947.


  372. Rates and risk factors for hepatitis B reactivation in a cohort of persons in the inactive phase of chronic hepatitis B-Alaska, 2001-2010
    Tohme RA, Bulkow L, Homan CE, Negus S, McMahon BJ. J Clin Virol. 2013 Oct;58(2):396-400. doi: 10.1016/j.jcv.2013.08.012. Epub 2013 Aug 16.


  373. Inverse association between hepatitis B virus infection and fatty liver disease: a large-scale study in populations seeking for check-up
    Cheng YL, Wang YJ, Kao WY, Chen PH, Huo TI, Huang YH, Lan KH, Su CW, Chan WL, Lin HC, Lee FY, Wu JC. PLoS One. 2013 Aug 22;8(8):e72049. doi: 10.1371/journal.pone.0072049.


  374. Safety of infliximab therapy in rheumatoid arthritis patients with previous exposure to hepatitis B virus
    Zhang X, Zhang F, Wu D, Bao C, Zhu P, Zhang X, Huang C, He D, Tao Y, Fang Y, Gu J, Wu H, Sun L, Yang X, Huang F, Xu H, Zhao D, Zhang M, Zheng Y, Li Z. Int J Rheum Dis. 2013 Aug;16(4):408-12. doi: 10.1111/1756-185X.12125. Epub 2013 Jul 2.


  375. Hepatitis B virus-induced hepatocellular carcinoma
    Xu C, Zhou W, Wang Y, Qiao L. Cancer Lett. 2013 Aug 25. pii: S0304-3835(13)00610-1. doi: 10.1016/j.canlet.2013.08.035. [Epub ahead of print]


  376. Effect of occult hepatitis B virus infection on the early-onset of hepatocellular carcinoma in patients with hepatitis C virus infection
    Nakano M, Kawaguchi T, Nakamoto S, Kawaguchi A, Kanda T, Imazeki F, Kuromatsu R, Sumie S, Satani M, Yamada S, Torimura T, Kakuma T, Yokosuka O, Sata M. Oncol Rep. 2013 Nov;30(5):2049-55. doi: 10.3892/or.2013.2700. Epub 2013 Aug 27.


  377. HBV induced HCC: major risk factors from genetic to molecular level
    Ayub A, Ashfaq UA, Haque A. Biomed Res Int. 2013;2013:810461. doi: 10.1155/2013/810461. Epub 2013 Aug 7.


  378. Long-Term Efficacy of Entecavir Plus Adefovir Combination Therapy versus Entecavir Monotherapy in Adefovir Refractory Chronic Hepatitis B Patients with Prior Lamivudine Resistance
    Seo SY, Kim IH, Sohn JY, Lee S, Kim SH, Kim SW, Lee SO, Lee ST, Kim DG. Intervirology. 2013 Aug 24. [Epub ahead of print]


  379. Effect of Tenofovir With and Without Interferon on Hepatitis D Virus Replication in HIV-Hepatitis B Virus-Hepatitis D Virus-Infected Patients
    Boyd A, Miailhes P, Brichler S, Scholtès C, Maylin S, Delaugerre C, Chevallier-Queyron P, Gordien E, Girard PM, Lacombe K. AIDS Res Hum Retroviruses. 2013 Sep 24. [Epub ahead of print]


  380. An assessment of the performance of self-reported vaccination status for hepatitis B, National Health and Nutrition Examination Survey 1999-2008
    Denniston MM, Byrd KK, Klevens RM, Drobeniuc J, Kamili S, Jiles RB. Am J Public Health. 2013 Oct;103(10):1865-73. doi: 10.2105/AJPH.2013.301313. Epub 2013 Aug 15.


  381. Screening for hepatitis B virus and hepatitis C virus at a community fair: a single-center experience
    Woo GA, Hill MA, de Medina MD, Schiff ER. Gastroenterol Hepatol (N Y). 2013 May;9(5):293-9.


  382. MicroRNAs may solve the mystery of chronic hepatitis B virus infection
    Wei YF, Cui GY, Ye P, Chen JN, Diao HY. World J Gastroenterol. 2013 Aug 14;19(30):4867-76. doi: 10.3748/wjg.v19.i30.4867.


  383. Expert recommendations on application of interferon for chronic hepatitis B
    Wan MB, Weng XH. J Dig Dis. 2013 Aug 23. doi: 10.1111/1751-2980.12096. [Epub ahead of print]


  384. Antiviral therapy for prevention of hepatocellular carcinoma and mortality in chronic hepatitis B: systematic review and meta-analysis
    Thiele M, Gluud LL, Dahl EK, Krag A. BMJ Open. 2013 Aug 14;3(8). pii: e003265. doi: 10.1136/bmjopen-2013-003265.


  385. Is HBsAg quantification ready, for prime time?
    Chevaliez S. Clin Res Hepatol Gastroenterol. 2013 Aug 7. pii: S2210-7401(13)00147-2. doi: 10.1016/j.clinre.2013.07.004. [Epub ahead of print]


  386. Reactivation of hepatitis B virus in patients with undetectable HBsAg undergoing chemotherapy for malignant lymphoma or multiple myeloma
    Matsui T, Kang JH, Nojima M, Tomonari A, Aoki H, Yamazaki H, Yane K, Tsuji K, Andoh S, Andoh S, Sakai H, Maemori M, Maguchi H, Tanaka Y. J Med Virol. 2013 Nov;85(11):1900-6. doi: 10.1002/jmv.23694. Epub 2013 Aug 7.


  387. Phase IIb multicentred randomised trial of besifovir (LB80380) versus entecavir in Asian patients with chronic hepatitis B
    Lai CL, Ahn SH, Lee KS, Um SH, Cho M, Yoon SK, Lee JW, Park NH, Kweon YO, Sohn JH, Lee J, Kim JA, Han KH, Yuen MF. Gut. 2013 Aug 31. doi: 10.1136/gutjnl-2013-305138. [Epub ahead of print]


  388. The Hepatitis B Vaccine Protects Re-Exposed Health Care Workers, But Does Not Provide Sterilizing Immunity
    Werner JM, Abdalla A, Gara N, Ghany MG, Rehermann B. Gastroenterology. 2013 Jul 31. pii: S0016-5085(13)01134-7. doi: 10.1053/j.gastro.2013.07.044. [Epub ahead of print]


  389. Physicians infrequently adhere to hepatitis vaccination guidelines for chronic liver disease
    Thudi K, Yadav D, Sweeney K, Behari J. PLoS One. 2013 Jul 26;8(7):e71124. doi: 10.1371/journal.pone.0071124. Print 2013.


  390. Targeted case finding for hepatitis B using dry blood spot testing in the British-Chinese and South Asian populations of the North-East of England
    McPherson S, Valappil M, Moses SE, Eltringham G, Miller C, Baxter K, Chan A, Shafiq K, Saeed A, Qureshi R, Hudson M, Bassendine MF. J Viral Hepat. 2013 Sep;20(9):638-44. doi: 10.1111/jvh.12084. Epub 2013 Mar 12.


  391. Hepatitis B virus reverse transcriptase mutations in treatment Naïve chronic hepatitis B patients
    Singla B, Chakraborti A, Sharma BK, Kapil S, Chawla YK, Arora SK, Das A, Dhiman RK, Duseja A. J Med Virol. 2013 Jul;85(7):1155-62. doi: 10.1002/jmv.23608.


  392. Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: Analysis from the Asia Lymphoma Study Group
    Kim SJ, Hsu C, Song YQ, Tay K, Hong XN, Cao J, Kim JS, Eom HS, Lee JH, Zhu J, Chang KM, Reksodiputro AH, Tan D, Goh YT, Lee J, Intragumtornchai T, Chng WJ, Cheng AL, Lim ST, Suh C, Kwong YL, Kim WS. Eur J Cancer. 2013 Nov;49(16):3486-3496. doi: 10.1016/j.ejca.2013.07.006. Epub 2013 Aug 1.


  393. Nanoparticles encapsulating HBV-CpG induce therapeutic immunity against hepatitis B virus infection
    Lv S, Wang J, Dou S, Yang X, Ni X, Sun R, Tian Z, Wei H. Hepatology. 2013 Aug 1. doi: 10.1002/hep.26654. [Epub ahead of print]


  394. Magnetic resonance elastography for the detection and staging of liver fibrosis in chronic hepatitis B
    Venkatesh SK, Wang G, Lim SG, Wee A. Eur Radiol. 2013 Aug 9. [Epub ahead of print]


  395. Hospitalizations due to hepatitis C in Los Angeles County, 2007-2009: case characteristics and factors associated with mortality
    Sie L, Gatto NM, Bancroft E. J Viral Hepat. 2013 Sep;20(9):628-37. doi: 10.1111/jvh.12086. Epub 2013 Mar 20.


  396. Baseline hepatitis B surface antigen quantitation can predict virologic response in entecavir-treated chronic hepatitis B patients
    Wang CC, Tseng TC, Wang PC, Lin HH, Kao JH. J Formos Med Assoc. 2013 Aug 1. pii: S0929-6646(13)00205-2. doi: 10.1016/j.jfma.2013.06.003. [Epub ahead of print]


  397. Hepatitis B surface antigen seroclearance in patients with chronic hepatitis B infection: A clinical study
    Ruan P, Xu SY, Zhou BP, Huang J, Gong ZJ. J Int Med Res. 2013 Oct;41(5):1732-1739. Epub 2013 Aug 1.


  398. Survey of Asian Patients with Hepatitis B Infection: Limited Knowledge of Transmission and Screening of Family Members
    Vijayan T, Zheng P, Nguyen C, Brown AM, Chen YW, Peters MG. J Immigr Minor Health. 2013 Aug 3. [Epub ahead of print]


  399. Why isn't evidence based practice improving health care for minorities in the United States?
    Lee H, Fitzpatrick JJ, Baik SY. Appl Nurs Res. 2013 Aug 5. pii: S0897-1897(13)00041-4. doi: 10.1016/j.apnr.2013.05.004. [Epub ahead of print]


  400. Quantitative Elastography of Liver Fibrosis and Spleen Stiffness in Chronic Hepatitis B Carriers: Comparison of Shear-Wave Elastography and Transient Elastography with Liver Biopsy Correlation
    Leung VY, Shen J, Wong VW, Abrigo J, Wong GL, Chim AM, Chu SH, Chan AW, Choi PC, Ahuja AT, Chan HL, Chu WC. Radiology. 2013 Aug 2. [Epub ahead of print]


  401. Age-dependent hepatic lymphoid organization directs successful immunity to hepatitis B
    Publicover J, Gaggar A, Nishimura S, Van Horn CM, Goodsell A, Muench MO, Reinhardt RL, van Rooijen N, Wakil AE, Peters M, Cyster JG, Erle DJ, Rosenthal P, Cooper S, Baron JL. J Clin Invest. 2013 Sep 3;123(9):3728-39. doi: 10.1172/JCI68182. Epub 2013 Aug 8.


  402. Prognostic impact of telomere maintenance gene polymorphisms in hepatocellular carcinoma patients with chronic Hepatitis B
    Jung SW, Park NH, Shin JW, Park BR, Kim CJ, Lee JE, Shin ES, Kim JA, Chung YH. Hepatology. 2013 Aug 1. doi: 10.1002/hep.26655. [Epub ahead of print]


  403. Results of treatment of chronic hepatitis B with pegylated interferon
    Viganò M, Mangia G, Lampertico P. Clin Liver Dis. 2013 Aug;17(3):425-43. doi: 10.1016/j.cld.2013.05.004. Epub 2013 Jul 3.


  404. Long-term results of treatment with nucleoside and nucleotide analogues (entecavir and tenofovir) for chronic hepatitis B
    Asselah T, Marcellin P. Clin Liver Dis. 2013 Aug;17(3):445-50. doi: 10.1016/j.cld.2013.05.001. Epub 2013 Jul 3.


  405. Impact of therapy on the long-term outcome of chronic hepatitis B
    Liaw YF. Clin Liver Dis. 2013 Aug;17(3):413-23. doi: 10.1016/j.cld.2013.05.005. Epub 2013 Jun 21.


  406. Hepatitis B in HIV-infected patients
    Soriano V, Poveda E, Vispo E, Barreiro P. Clin Liver Dis. 2013 Aug;17(3):489-501. doi: 10.1016/j.cld.2013.05.008. Epub 2013 Jul 8


  407. The importance of hemovigilance in the transmission of infectious diseases
    Martins PR, Martins RA, Barbosa Vde F, Pereira Gde A, Moraes-Souza H, Silva SS. Rev Bras Hematol Hemoter. 2013;35(3):180-4. doi: 10.5581/1516-8484.20130040.


  408. HBsAg quantification to predict natural history and treatment outcome in chronic hepatitis B patients
    Martinot-Peignoux M, Asselah T, Marcellin P. Clin Liver Dis. 2013 Aug;17(3):399-412. doi: 10.1016/j.cld.2013.05.006. Epub 2013 Jun 27.


  409. Diabetes mellitus, metabolic syndrome and obesity are not significant risk factors for hepatocellular carcinoma in an HBV- and HCV-endemic area of Southern Taiwan
    Chen CT, Chen JY, Wang JH, Chang KC, Tseng PL, Kee KM, Chen PF, Tsai LS, Chen SC, Lin SC, Lu SN. Kaohsiung J Med Sci. 2013 Aug;29(8):451-9. doi: 10.1016/j.kjms.2012.12.006. Epub 2013 Feb 9.


  410. Treatment of patients with HBV-related decompensated cirrhosis and liver transplanted patients
    Roche B, Samuel D. Clin Liver Dis. 2013 Aug;17(3):451-73. doi: 10.1016/j.cld.2013.05.003. Epub 2013 Jun 27.


  411. Efficacy and safety of entecavir treatment in a heterogeneous CHB population from a 'real-world' clinical practice setting in China
    Hou JL, Jia JD, Wei L, Zhao W, Wang YM, Cheng M, Tang X, Tan DM, Ren H, Tang H, Cohen D, Llamoso C. J Viral Hepat. 2013 May 29. doi: 10.1111/jvh.12115. [Epub ahead of print]


  412. Epigenetic Mechanism Involved in the HBV/HCV-Related Hepatocellular Carcinoma Tumorigenesis
    Rongrui L, Na H, Zongfang L, Fanpu J, Shiwen J. Curr Pharm Des. 2013 Jul 19. [Epub ahead of print]


  413. Cost-effectiveness of questionnaires in preventing transfusion-transmitted infections
    de Kort W, van den Burg P, Geerligs H, Pasker-de Jong P, Marijt-van der Kreek T. Transfusion. 2013 Jul 25. doi: 10.1111/trf.12349. [Epub ahead of print]


  414. The current status of combination therapy of Chronic Hepatitis B
    Chen EQ, Tang H. Eur Rev Med Pharmacol Sci. 2013 Aug;17(15):2023-31.


  415. Hepatitis B and C reactivation with tumor necrosis factor inhibitors: synopsis and interpretation of screening and prophylaxis recommendations
    Fuchs I, Abu-Shakra M, Sikuler E. Isr Med Assoc J. 2013 Jun;15(6):303-7.


  416. The natural course of chronic hepatitis B virus infection and its management
    Hadziyannis SJ, Vassilopoulos D, Hadziyannis E. Adv Pharmacol. 2013;67:247-91. doi: 10.1016/B978-0-12-405880-4.00007-X.


  417. Nucleoside plus nucleotide analogs and cessation of hepatitis B immunoglobulin after liver transplantation in chronic hepatitis B is safe and effective
    Wesdorp DJ, Knoester M, Braat AE, Coenraad MJ, Vossen AC, Claas EC, van Hoek B. J Clin Virol. 2013 Sep;58(1):67-73. doi: 10.1016/j.jcv.2013.06.035. Epub 2013 Jul 20.


  418. Impact of transient elastography on clinical decision-making in patients with chronic viral hepatitis
    Feuth T, Arends JE, Lieveld FI, Mundt MW, Hoepelman AI, Siersema PD, van Erpecum KJ. Scand J Gastroenterol. 2013 Sep;48(9):1074-81. doi: 10.3109/00365521.2013.819441. Epub 2013 Jul 25.


  419. Response to peginterferon alfa-2a (40KD) in HBeAg-negative CHB: On-treatment kinetics of HBsAg serum levels vary by HBV genotype
    Brunetto MR, Marcellin P, Cherubini B, Yurdaydin C, Farci P, Hadziyannis SJ, Rothe V, Regep L, Bonino F. J Hepatol. 2013 Jul 18. pii: S0168-8278(13)00528-X. doi: 10.1016/j.jhep.2013.07.017. [Epub ahead of print]


  420. Suppression of HBV by tenofovir in HBV/HIV coinfected patients: a systematic review and meta-analysis
    Price H, Dunn D, Pillay D, Bani-Sadr F, de Vries-Sluijs T, Jain MK, Kuzushita N, Mauss S, Núñez M, Nüesch R, Peters M, Reiberger T, Stephan C, Tan L, Gilson R. PLoS One. 2013 Jul 10;8(7):e68152. doi: 10.1371/journal.pone.0068152. Print 2013.


  421. Association of treatment and outcomes of doctor-shopping behavior in patients with hepatocellular carcinoma
    Hsieh CI, Chung KP, Yang MC, Li TC. Patient Prefer Adherence. 2013 Jul 11;7:693-701. doi: 10.2147/PPA.S43631. Print 2013.


  422. RDW to platelet ratio: a novel noninvasive index for predicting hepatic fibrosis and cirrhosis in chronic hepatitis B
    Chen B, Ye B, Zhang J, Ying L, Chen Y.


  423. Hepatitis B or C viral infection and risk of pancreatic cancer: a meta-analysis of observational studies
    Xu JH, Fu JJ, Wang XL, Zhu JY, Ye XH, Chen SD.


  424. Association between IL28B polymorphisms and spontaneous clearance of hepatitis B virus infection
    Kim SU, Song KJ, Chang HY, Shin EC, Park JY, Kim do Y, Han KH, Chon CY, Ahn SH. PLoS One. 2013 Jul 17;8(7):e69166. doi: 10.1371/journal.pone.0069166. Print 2013.


  425. Imbalance between circulating CD4+ regulatory T and conventional T lymphocytes in patients with HBV-related acute-on-chronic liver failure
    Dong X, Gong Y, Zeng H, Hao Y, Wang X, Hou J, Wang J, Li J, Zhu Y, Liu H, Han J, Zhou H, Shen L, Gao T, Zhou T, Yang S, Li S, Chen Y, Meng Q, Li H. Liver Int. 2013 Jun 19. doi: 10.1111/liv.12248. [Epub ahead of print]


  426. A Chinese Medicine, Kuan-Sin-Yin Decoction, Improves Liver Function in Hepatitis B Virus Carriers: A Randomized, Controlled Study
    Lee CJ, Cheng CH, Li YH, Liu CY, Hsu CH. J Altern Complement Med. 2013 Jul 17. [Epub ahead of print]


  427. Too much of a good thing? When to stop catch-up vaccination
    Hutton DW, Brandeau ML. Med Decis Making. 2013 Oct;33(7):920-36. doi: 10.1177/0272989X13493142. Epub 2013 Jul 15.


  428. Efficacy and safety of telbivudine therapy in liver failure patients with chronic hepatitis B virus infection
    Wang L, Chen H, Fan C, Gong Z. J Med Virol. 2013 Nov;85(11):1907-12. doi: 10.1002/jmv.23689. Epub 2013 Jul 12.


  429. Chronic hepatitis B prognostic markers other than pre-treatment viral load predicted composite treatment outcome
    Aung MN, Leowattana W, Win KN, Tangpukdee N, Muangnoicharoen S. J Infect Dev Ctries. 2013 Jul 15;7(7):541-9. doi: 10.3855/jidc.2759.


  430. Characteristics and prediction of hepatitis B e-antigen negative hepatitis following seroconversion in patients with chronic hepatitis B
    Morita S, Matsumoto A, Umemura T, Shibata S, Kamijo N, Ichikawa Y, Kimura T, Joshita S, Komatsu M, Yoshizawa K, Tanaka E. Hepatol Res. 2013 Jul 16. doi: 10.1111/hepr.12208. [Epub ahead of print]


  431. Predictors of hepatitis B cure using gene therapy to deliver DNA cleavage enzymes: a mathematical modeling approach
    Schiffer JT, Swan DA, Stone D, Jerome KR. PLoS Comput Biol. 2013 Jul;9(7):e1003131. doi: 10.1371/journal.pcbi.1003131. Epub 2013 Jul 4.


  432. A new model using platelet indices to predict liver fibrosis in patients with chronic hepatitis B infection
    Ceylan B, Mete B, Fincanci M, Aslan T, Akkoyunlu Y, Ozgune? N, Colak O, Gunduz A, Senates E, Ozaras R, Inci A, Tabak F. Wien Klin Wochenschr. 2013 Aug;125(15-16):453-460. Epub 2013 Jul 17.


  433. Telbivudine and adefovir combination therapy for patients with chronic lamivudine-resistant hepatitis B virus infections
    Lin MT, Chou YP, Hu TH, Yu HC, Hsu YC, Tsai MC, Tseng PL, Chang KC, Yen YH, Chiu KW. Arch Virol. 2013 Jul 16. [Epub ahead of print]


  434. Safety and efficacy of hepatitis B vaccination in cirrhosis of liver
    Roni DA, Pathapati RM, Kumar AS, Nihal L, Sridhar K, Tumkur Rajashekar S. Adv Virol. 2013;2013:196704. doi: 10.1155/2013/196704. Epub 2013 Jun 6.


  435. Relapse rate and associated-factor of recurrence after stopping NUCs therapy with different prolonged consolidation therapy in HBeAg positive CHB patients
    Pan X, Zhang K, Yang X, Liang J, Sun H, Li X, Zou Y, Xu Q, An G, Li G, Xu Q. PLoS One. 2013 Jul 3;8(7):e68568. doi: 10.1371/journal.pone.0068568. Print 2013.


  436. Liver transplantation for hepatitis B liver disease and concomitant hepatocellular carcinoma in the United States with hepatitis B immunoglobulin and nucleoside/nucleotide analogues
    Campsen J, Zimmerman M, Trotter J, Hong J, Freise C, Brown R, Cameron A, Ghobrial M, Kam I, Busuttil R, Saab S, Holt C, Emond J, Stiles J, Lukose T, Chang M, Klintmalm G. Liver Transpl. 2013 Jul 15. doi: 10.1002/lt.23703. [Epub ahead of print]


  437. Impact of HBV Integration Into Liver Tissue on the Efficacy of Peginterferon and Ribavirin Therapy in Hepatitis B Virus-negative Chronic Hepatitis C Patients
    Toyoda H, Kumada T, Tada T, Murakami Y. J Clin Gastroenterol. 2013 Jul 8. [Epub ahead of print]


  438. Impact of liver fibrosis on prognosis following liver resection for hepatitis B-associated hepatocellular carcinoma
    Wang Q, Fiel MI, Blank S, Luan W, Kadri H, Kim KW, Manizate F, Rosenblatt AG, Labow DM, Schwartz ME, Hiotis SP. Br J Cancer. 2013 Aug 6;109(3):573-81. doi: 10.1038/bjc.2013.352. Epub 2013 Jul 11.


  439. Frequent Emergency Department Visits are More Prevalent in Psychiatric, Alcohol Abuse, and Dual Diagnosis Conditions than in Chronic Viral Illnesses Such as Hepatitis and Human Immunodeficiency Virus
    Minassian A, Vilke GM, Wilson MP. J Emerg Med. 2013 Jul 8. pii: S0736-4679(13)00467-8. doi: 10.1016/j.jemermed.2013.05.007. [Epub ahead of print]


  440. Hepatitis B virus (HBV)-specific T-cell responses to recombinant HBV core protein in patients with normal liver function and co-infected with chronic HBV and human immunodeficiency virus 1 (HIV-1)
    Zhang X, Xing H, Feng X, Zhang H, Wang Y, Yan H. Virol J. 2013 Jul 12;10(1):232. [Epub ahead of print]


  441. The reliability of HBV core antibody in serological screening for hepatitis B virus
    Ba Alawi F, Robertson PW, LePage AK, Jayamaha J, Baleriola C, Rawlinson WD. Pathology. 2013 Aug;45(5):501-5. doi: 10.1097/PAT.0b013e3283631cf9.


  442. Relationship between hepatocellular carcinoma and hepatitis B virus genotype with spontaneous YMDD mutations
    Yang JH, Zhang H, Chen XB, Chen G, Wang X. World J Gastroenterol. 2013 Jun 28;19(24):3861-5. doi: 10.3748/wjg.v19.i24.3861.


  443. Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells
    Rehermann B. Nat Med. 2013 Jul;19(7):859-68. doi: 10.1038/nm.3251.


  444. Gaps in Pre-rituximab Hepatitis B Screening: An Institutional Experience
    Abbi KK, Gorris M, Skeel RT. Am J Ther. 2013 Jun 28. [Epub ahead of print]


  445. Chronic hepatitis B--what's new?
    MacLachlan J, Cowie B. Aust Fam Physician. 2013 Jul;42(7):448-51.


  446. Clinical Relevance of Minimal Residual Viremia during Long-Term Therapy with Nucleos(t)ide Analogues in Patients with Chronic Hepatitis B
    Maier M, Liebert UG, Wittekind C, Kaiser T, Berg T, Wiegand J. PLoS One. 2013 Jun 27;8(6):e67481. Print 2013.


  447. Role of viral genotypes and hepatitis B viral mutants in the risk of hepatocellular carcinoma associated with hepatitis B and C dual infection
    Hung CH, Chen CH, Lee CM, Hu TH, Lu SN, Wang JH, Huang CM. Intervirology. 2013;56(5):316-24. doi: 10.1159/000350738. Epub 2013 Jul 2.


  448. Efficacy and safety of entecavir plus carnitine complex (GODEX®) compared to entecavir monotherapy in patient with ALT elevated chronic hepatitis B: randomized, multicenter open-label trials. The GOAL study
    Jun DW, Kim BI, Cho YK, Kim HJ, Kwon YO, Park SY, Han SY, Baek YH, Jung YJ, Kim HY, Kim W, Heo J, Woo HY, Hwang SG, Rim KS, Choi JY, Bae SH, Lee YS, Lim YS, Cheong JY, Cho SW, Lee BS, Kim SH, Sohn JH, Kim TY, Paik YH, Kim JK, Lee KS. Clin Mol Hepatol. 2013 Jun;19(2):165-72. doi: 10.3350/cmh.2013.19.2.165. Epub 2013 Jun 27.


  449. Therapeutic advances in the management of chronic hepatitis B infection
    Brooks J, Gelson W, Rushbrook SM. Ther Adv Chronic Dis. 2013 Jul;4(4):157-66. doi: 10.1177/2040622313484647.


  450. Unraveling the complexity of hepatitis B virus: From molecular understanding to therapeutic strategy in 50 years
    Liu B, Wen X, Huang C, Wei Y. Int J Biochem Cell Biol. 2013 Sep;45(9):1987-96. doi: 10.1016/j.biocel.2013.06.017. Epub 2013 Jun 29.


  451. Increased regulatory T cells and impaired functions of circulating CD8 T lymphocytes is associated with viral persistence in Hepatitis B virus-positive newborns
    Shrivastava S, TrehanPati N, Patra S, Kottilil S, Pande C, Trivedi SS, Sarin SK. J Viral Hepat. 2013 Aug;20(8):582-91. doi: 10.1111/jvh.12078. Epub 2013 Feb 14.


  452. Hepatitis B virus splicing is enhanced prior to development of hepatocellular carcinoma
    Bayliss J, Lim L, Thompson AJ, Desmond P, Angus P, Locarnini S, Revill PA. J Hepatol. 2013 Jun 25. pii: S0168-8278(13)00434-0. doi: 10.1016/j.jhep.2013.06.018. [Epub ahead of print]


  453. Prophylaxis of hepatitis B infection in solid organ transplant recipients
    John S, Andersson KL, Kotton CN, Hertl M, Markmann JF, Cosimi AB, Chung RT. Therap Adv Gastroenterol. 2013 Jul;6(4):309-19. doi: 10.1177/1756283X13487942.


  454. Hepatitis B infection increases the risk of non-Hodgkin lymphoma: A meta-analysis of observational studies
    Dalia S, Chavez J, Castillo JJ, Sokol L. Leuk Res. 2013 Sep;37(9):1107-15. doi: 10.1016/j.leukres.2013.06.007. Epub 2013 Jun 26.


  455. Identification of ?-taxilin as an essential factor for the life cycle of hepatitis B virus
    Hoffmann J, Boehm C, Himmelsbach K, Donnerhak C, Roettger H, Weiss TS, Ploen D, Hildt E. J Hepatol. 2013 Jun 28. pii: S0168-8278(13)00437-6. doi: 10.1016/j.jhep.2013.06.020. [Epub ahead of print]


  456. Occult hepatitis B in patients on hemodialysis: a review
    Fontenele AM, Filho NS, Ferreira AS. Ann Hepatol. 2013 Jul-Aug;12(4):527-31.


  457. Accuracy of International Guidelines for Identifying Significant Fibrosis in Hepatitis B e Antigen-negative Patients With Chronic Hepatitis
    Sanai FM, Babatin MA, Bzeizi KI, Alsuhaibani F, Al-Hamoudi W, Alsaad KS, Almana H, Handoo FA, Al-Ashgar H, Alghamdi H, Ibrahim A, Aljumah A, Alalwan A, Altraif IH, Al-Hussaini H, Myers RP, Abdo AA. Clin Gastroenterol Hepatol. 2013 Jun 28. pii: S1542-3565(13)00876-8. doi: 10.1016/j.cgh.2013.05.038. [Epub ahead of print]


  458. As an independent prognostic factor, FAT10 promotes hepatitis B virus-related hepatocellular carcinoma progression via Akt/GSK3? pathway
    Liu L, Dong Z, Liang J, Cao C, Sun J, Ding Y, Wu D. Oncogene. 2013 Jul 1. doi: 10.1038/onc.2013.236. [Epub ahead of print]


  459. Risk Assessment of Liver-related Events Using Transient Elastography in Patients With Chronic Hepatitis B Receiving Entecavir
    Kim MN, Kim SU, Park JY, Kim DY, Han KH, Chon CY, Ahn SH. J Clin Gastroenterol. 2013 Jun 26. [Epub ahead of print]


  460. Demographic and serological characteristics of Asian Americans with hepatitis B infection diagnosed at community screenings
    Xu JJ, Tien C, Chang M, Rhee J, Tien A, Bae HS, Ho FC, Chan LS, Fong TL. J Viral Hepat. 2013 Aug;20(8):575-81. doi: 10.1111/jvh.12073. Epub 2013 Mar 25.


  461. Normal vitamin D levels are associated with spontaneous hepatitis B surface antigen seroclearance
    Mahamid M, Nseir W, Abu Elhija O, Shteingart S, Mahamid A, Smamra M, Koslowsky B. World J Hepatol. 2013 Jun 27;5(6):328-31. doi: 10.4254/wjh.v5.i6.328.


  462. The Influence of Hepatitis B Viral Load and Pre-S Deletion Mutations on Post-Operative Recurrence of Hepatocellular Carcinoma and the Tertiary Preventive Effects by Anti-Viral Therapy
    Su CW, Chiou YW, Tsai YH, Teng RD, Chau GY, Lei HJ, Hung HH, Huo TI, Wu JC. PLoS One. 2013 Jun 21;8(6):e66457. Print 2013.


  463. Ultrasensitive Amplification Refractory Mutation System Real-Time PCR (ARMS RT-PCR) Assay for Detection of Minority Hepatitis B Virus-Resistant Strains in the Era of Personalized Medicine
    Ntziora F, Paraskevis D, Haida C, Manesis E, Papatheodoridis G, Manolakopoulos S, Elefsiniotis I, Karamitros T, Vassilakis A, Hatzakis A. J Clin Microbiol. 2013 Sep;51(9):2893-900. doi: 10.1128/JCM.00936-13. Epub 2013 Jun 26.


  464. Complementary laboratory indices for predicting the disease status of patients with hepatitis B virus infection
    Chen F, He JL, Zheng M, Zhu HH, Li SP, Wang K, Zhang XX, Zhao YR, Wu SS, Chen Z. J Viral Hepat. 2013 Aug;20(8):566-74. doi: 10.1111/jvh.12067. Epub 2013 Feb 6.


  465. Correlation between interleukin?23 receptor gene polymorphisms and risk of hepatitis B virus infection in patients
    Peng Q, Qin Y, Chen Z, Deng Y, Xu J, Li S, Qin X. Mol Med Rep. 2013 Aug;8(2):613-20. doi: 10.3892/mmr.2013.1558. Epub 2013 Jun 26.


  466. Liver fibrosis progression in chronic hepatitis B patients positive for hepatitis B e antigen - a prospective cohort study with paired transient elastography examination
    Wong GL, Chan HL, Yu Z, Chan HY, Tse CH, Wong VW. J Gastroenterol Hepatol. 2013 Jun 28. doi: 10.1111/jgh.12312. [Epub ahead of print]


  467. Fibroscan can avoid liver biopsy in Indian patients with Chronic Hepatitis B
    Goyal R, Mallick SR, Mahanta M, Kedia S, Shalimar, Dhingra R, Sharma H, Das P, Gupta SD, Panda S, Acharya SK. J Gastroenterol Hepatol. 2013 Jun 28. doi: 10.1111/jgh.12318. [Epub ahead of print]


  468. Virological Response and Muscular Adverse Events during Long-Term Clevudine Therapy in Chronic Hepatitis B Patients
    Kim BK, Ko SY, Kwon SY, Park E, Kim JH, Choe WH, Lee CH. Hepat Mon. 2013 Apr 1;13(4):e6056. doi: 10.5812/hepatmon.6056. Print 2013 Apr.


  469. Prophylactic Lamivudine to Improve the Outcome of Breast Cancer Patients With HBsAg Positive During Chemotherapy: A Meta-Analysis
    Zheng Y, Zhang S, Tan Grahn HM, Ye C, Gong Z, Zhang Q. Hepat Mon. 2013 Apr 1;13(4):e6496. doi: 10.5812/hepatmon.6496. Print 2013 Apr.


  470. Suppression of interferon-mediated antiviral immunity by hepatitis B virus: an overview of research progress
    Peng G. Scand J Immunol. 2013 Jun 24. doi: 10.1111/sji.12086. [Epub ahead of print]


  471. Living related liver Transplant in hepatitis B related liver disease without Hepatitis B Immunoglobulin prophylaxis
    Wadhawan M, Goyal S, Goyal N, Taneja S, Kumar A. Liver Transpl. 2013 Jun 21. doi: 10.1002/lt.23692. [Epub ahead of print]


  472. Serum HBsAg Quantification as a useful assessment for significant fibrosis in HBeAg positive hepatitis B virus carriers
    Xun YH, Zang GQ, Guo JC, Yu XL, Liu H, Xiang J, Liu J, Shi JP. J Gastroenterol Hepatol. 2013 Jun 25. doi: 10.1111/jgh.12304. [Epub ahead of print]


  473. HBV genotype F: natural history and treatment
    Marciano S, Galdame OA, Gadano AC. Antivir Ther. 2013;18(3 Pt B):485-8. doi: 10.3851/IMP2604. Epub 2013 Jun 21.


  474. Successful treatment of chronic hepatitis B and D with pegylated-interferon plus entecavir
    Chen GY, Su TH, Kao JH. J Formos Med Assoc. 2013 Jun 20. pii: S0929-6646(13)00178-2. doi: 10.1016/j.jfma.2013.05.011. [Epub ahead of print]


  475. Connexin-43 can delay early recurrence and metastasis in patients with hepatitis B-related hepatocellular carcinoma and low serum alpha-fetoprotein after radical hepatectomy
    Wang ZS, Wu LQ, Yi X, Geng C, Li YJ, Yao RY. BMC Cancer. 2013 Jun 24;13:306. doi: 10.1186/1471-2407-13-306.


  476. Efficacy of combined therapy in patients with hepatitis B virus-related decompensated cirrhosis
    Lv GC, Yao JM, Yang YD, Zheng L, Sheng JF, Chen Y, Li LJ. World J Gastroenterol. 2013 Jun 14;19(22):3481-6. doi: 10.3748/wjg.v19.i22.3481.


  477. Direct effects of hepatitis B virus-encoded proteins and chronic infection in liver cancer development
    Ringelhan M, Heikenwalder M, Protzer U. Dig Dis. 2013;31(1):138-51. doi: 10.1159/000347209. Epub 2013 Jun 17.


  478. Patterns of hepatitis B surface antigen decline and HBV DNA suppression in Asian treatment-experienced chronic hepatitis B patients after three years of tenofovir treatment
    Seto WK, Liu K, Wong DK, Fung J, Huang FY, Hung IF, Lai CL, Yuen MF. J Hepatol. 2013 Jun 17. pii: S0168-8278(13)00417-0. doi: 10.1016/j.jhep.2013.06.007. [Epub ahead of print]


  479. Perioperative antiviral therapy for chronic hepatitis B-related hepatocellular carcinoma
    Wei Q, Xu X, Ling Q, Zhou B, Zheng SS. Hepatobiliary Pancreat Dis Int. 2013 Jun;12(3):251-5.


  480. Serum HBV DNA level at week 12 is superior to viral response at week 24 in predicting long-term treatment outcome of telbivudine for chronic hepatitis B patients
    Lü W, Yang HH, Fan YM, Li T, Zhang LF, Mui C, Fan HW, Zhou BT, Liu ZY, Ng H, Liu XQ. Chin Med J (Engl). 2013 Jun;126(12):2333-6.


  481. Hepatitis B viral factors and treatment responses in chronic hepatitis B
    Lin CL, Kao JH. J Formos Med Assoc. 2013 Jun;112(6):302-11. doi: 10.1016/j.jfma.2013.02.001. Epub 2013 Mar 17.


  482. Analysis of hepatitis B virus genotyping and drug resistance gene mutations based on massively parallel sequencing
    Han Y, Zhang Y, Mei Y, Wang Y, Liu T, Guan Y, Tan D, Liang Y, Yang L, Yi X. J Virol Methods. 2013 Jun 14;193(2):341-347. doi: 10.1016/j.jviromet.2013.06.015. [Epub ahead of print]


  483. Association between the hepatitis B and C viruses and metabolic diseases in patients stratified by age
    Li WC, Lee YY, Chen IC, Sun C, Chiu FH, Chuang CH. Liver Int. 2013 May 20. doi: 10.1111/liv.12224. [Epub ahead of print]


  484. Liver transplantation for hepatitis B-induced liver disease: long-term outcome and effectiveness of antiviral therapy for prevention of recurrent hepatitis B infection
    Perrakis A, Förtsch T, Del Medico A, Croner RS, Vassos N, Yedibela S, Lohmüller C, Zopf S, Hohenberger W, Müller V. Transplant Proc. 2013 Jun;45(5):1953-6. doi: 10.1016/j.transproceed.2012.11.020.


  485. Comparison of survival and tumor recurrence rates in patients undergoing liver transplantation for hepatitis B-related hepatocellular carcinoma using Milan, Shanghai Fudan and Hangzhou Criteria
    Gao T, Xia Q, Qiu DK, Feng YY, Chi JC, Wang SY, Xi ZF, Zhang JJ, Xu N, Chen SY, Qiu YL, Shen LW, Zhou TT, Dong XJ, Li QG, Li H. J Dig Dis. 2013 Jun 19. doi: 10.1111/1751-2980.12083. [Epub ahead of print]


  486. Viral status at the time of liver transplantation for hepatocellular carcinoma: a modern predictor of longterm survival
    Groeschl RT, Hong JC, Christians KK, Turaga KK, Tsai S, Pilgrim CH, Gamblin TC. HPB (Oxford). 2013 Jun 19. doi: 10.1111/hpb.12134. [Epub ahead of print]


  487. Entecavir and hepatitis B immune globulin in patients undergoing liver transplantation for chronic hepatitis B
    Perrillo R, Buti M, Durand F, Charlton M, Gadano A, Cantisani G, Loong CC, Brown K, Hu W, Lopez-Talavera JC, Llamoso C. Liver Transpl. 2013 Aug;19(8):887-95. doi: 10.1002/lt.23690.


  488. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B
    Huang YH, Hsiao LT, Hong YC, Chiou TJ, Yu YB, Gau JP, Liu CY, Yang MH, Tzeng CH, Lee PC, Lin HC, Lee SD. J Clin Oncol. 2013 Aug 1;31(22):2765-72. doi: 10.1200/JCO.2012.48.5938. Epub 2013 Jun 17.


  489. The Efficacy and Safety of Nucleos(t)ide Analogues in Patients with Spontaneous Acute Exacerbation of Chronic Hepatitis B: A Systematic Review and Meta-Analysis
    Yu W, Zhao C, Shen C, Wang Y, Lu H, Fan J. PLoS One. 2013 Jun 11;8(6):e65952. doi: 10.1371/journal.pone.0065952. Print 2013.


  490. Molecular mechanisms of HBV-associated hepatocarcinogenesis
    Guerrieri F, Belloni L, Pediconi N, Levrero M. Semin Liver Dis. 2013 May;33(2):147-56. doi: 10.1055/s-0033-1345721. Epub 2013 Jun 8.


  491. Virus-specific immune response in HBeAg-negative chronic hepatitis B: relationship with clinical profile and HBsAg serum levels
    Loggi E, Bihl FK, Cursaro C, Granieri C, Galli S, Brodosi L, Furlini G, Bernardi M, Brander C, Andreone P. PLoS One. 2013 Jun 4;8(6):e65327. doi: 10.1371/journal.pone.0065327. Print 2013.


  492. Topographical Impact of Hepatitis B-related Hepatocellular Carcinoma on Local Recurrence After Radiofrequency Ablation
    Kim JS, Kim W, So YH, Yu SJ, Kim BG. J Clin Gastroenterol. 2013 Jun 6. [Epub ahead of print]


  493. Does antiviral therapy for chronic hepatitis B reduce the risk of hepatocellular carcinoma?
    Abu-Amara M, Feld JJ. Semin Liver Dis. 2013 May;33(2):157-66. doi: 10.1055/s-0033-1345719. Epub 2013 Jun 8.


  494. Comparison of prednisolone and lamivudine combined therapy with prednisolone monotherapy on carriers of hepatitis B virus with IgA nephropathy: a prospective cohort study
    Fang J, Li W, Tan Z, Li D. Int Urol Nephrol. 2013 Jun 12. [Epub ahead of print]


  495. Immunosuppression and HBV reactivation
    Shouval D, Shibolet O. Semin Liver Dis. 2013 May;33(2):167-77. doi: 10.1055/s-0033-1345722. Epub 2013 Jun 8.


  496. Antiviral therapy for chronic hepatitis B in pregnancy
    Pan CQ, Lee HM. Semin Liver Dis. 2013 May;33(2):138-46. doi: 10.1055/s-0033-1345718. Epub 2013 Jun 8.


  497. Past Exposure to Hepatitis B: A Risk Factor for Increase in Mortality?
    Jinjuvadia R, Liangpunsakul S, Antaki F. J Clin Gastroenterol. 2013 Jun 6. [Epub ahead of print]


  498. Resolving ambiguity in the phylogenetic relationship of genotypes A, B, and C of hepatitis B virus
    Jiang Y, Wang M, Zheng H, Wang WR, Jin L, He Y. BMC Evol Biol. 2013 Jun 11;13:120. doi: 10.1186/1471-2148-13-120.


  499. A genome-wide association study identified new variants associated with the risk of chronic hepatitis B
    Kim YJ, Young Kim H, Lee JH, Jong Yu S, Yoon JH, Lee HS, Yong Kim C, Youn Cheong J, Won Cho S, Hwa Park N, Lae Park B, Namgoong S, Hyo Kim L, Sub Cheong H, Doo Shin H. Hum Mol Genet. 2013 Jun 26. [Epub ahead of print]


  500. Chronic hepatitis B: a treatment update
    Wong V, Chan H. Semin Liver Dis. 2013 May;33(2):122-9. doi: 10.1055/s-0033-1345715. Epub 2013 Jun 8.


  501. Changes in the balance between Treg and Th17 cells in patients with chronic hepatitis B
    Su ZJ, Yu XP, Guo RY, Ming DS, Huang LY, Su ML, Deng Y, Lin ZZ. Diagn Microbiol Infect Dis. 2013 Aug;76(4):437-44. doi: 10.1016/j.diagmicrobio.2013.04.026. Epub 2013 Jun 7.


  502. A trivial role of STAT4 variant in chronic hepatitis B induced hepatocellular carcinoma
    Clark A, Gerlach F, Tong HV, Hoan NX, Song LH, Toan NL, Bock CT, Kremsner PG, Velavan TP. Infect Genet Evol. 2013 Jun 6;18C:257-261. doi: 10.1016/j.meegid.2013.05.025. [Epub ahead of print]


  503. Reduced Toll-like receptor-3 expression in chronic hepatitis B patients and its restoration by interferon therapy
    Huang YW, Lin SC, Wei SC, Hu JT, Chang HY, Huang SH, Chen DS, Chen PJ, Hsu PN, Yang SS, Kao JH. Antivir Ther. 2013 Jun 6. doi: 10.3851/IMP2630. [Epub ahead of print]


  504. Long-term persistence of immunity after vaccination of pre-adolescents with low doses of a recombinant hepatitis B vaccine
    Gilca V, De Serres G, Boulianne N, Murphy D, Ouakki M, De Wals P, Trudeau G, Massé R, Dionne M. Hum Vaccin Immunother. 2013 Jun 6;9(8). [Epub ahead of print]


  505. Anti-platelet therapy in the prevention of hepatitis B virus-associated hepatocellular carcinoma
    Sitia G, Iannacone M, Guidotti LG. J Hepatol. 2013 Jun 3. pii: S0168-8278(13)00373-5. doi: 10.1016/j.jhep.2013.05.040. [Epub ahead of print]


  506. New therapeutic targets and drugs for the treatment of chronic hepatitis B
    Fletcher SP, Delaney WE 4th. Semin Liver Dis. 2013 May;33(2):130-7. doi: 10.1055/s-0033-1345713. Epub 2013 Jun 8.


  507. The molecular virology of hepatitis B virus
    Glebe D, Bremer CM. Semin Liver Dis. 2013 May;33(2):103-12. doi: 10.1055/s-0033-1345717. Epub 2013 Jun 8.


  508. Serum hepatitis B surface antigen kinetics in severe reactivation of hepatitis e antigen negative chronic hepatitis B patients receiving nucleos(t)ide analogues
    Wong GL, Chan HL, Lo AO, Chan HY, Tse CH, Chim AM, Wong VW. Antivir Ther. 2013 Jun 5. doi: 10.3851/IMP2615. [Epub ahead of print]


  509. Global perspective on the natural history of chronic hepatitis B: role of hepatitis B virus genotypes a to j
    Liu CJ, Kao JH. Semin Liver Dis. 2013 May;33(2):97-102. doi: 10.1055/s-0033-1345716. Epub 2013 Jun 8.


  510. Off therapy durability of response to Entecavir therapy in hepatitis B e antigen negative chronic hepatitis B patients
    Jeng WJ, Sheen IS, Chen YC, Hsu CW, Chien RN, Chu CM, Liaw YF. Hepatology. 2013 Jun 6. doi: 10.1002/hep.26549. [Epub ahead of print]


  511. Similar evolution of Hepatitis B virus quasispecies in patients with incomplete adefovir response receiving tenofovir/emtricitabine combination or tenofovir monotherapy
    Lavocat F, Dény P, Pichoud C, Hawajri NA, Kitrinos K, Borroto-Esoda K, Zoulim F. J Hepatol. 2013 Jun 3. pii: S0168-8278(13)00371-1. doi: 10.1016/j.jhep.2013.05.038. [Epub ahead of print]


  512. Albumin Fusion of Interleukin-28B: Production and Characterization of Its Biological Activities and Protein Stability
    Zhao J, Si Y, Cheng M, Yang Y, Niu Y, Li X, Liu X, Yang W. PLoS One. 2013 May 31;8(5):e64301. doi: 10.1371/journal.pone.0064301. Print 2013.


  513. Responses to booster hepatitis B vaccination are significantly correlated with genotypes of human leukocyte antigen (HLA)-DPB1 in neonatally vaccinated adolescents
    Wu TW, Chu CC, Ho TY, Chang Liao HW, Lin SK, Lin M, Lin HH, Wang LY. Hum Genet. 2013 Jun 6. [Epub ahead of print]


  514. Editorial: Prophylaxis in HBV-Infected Liver Transplant Patients: End of the HBIG Era?
    Terrault N. Am J Gastroenterol. 2013 Jun;108(6):949-51. doi: 10.1038/ajg.2013.122.


  515. Acute hepatitis B outbreaks in 2 skilled nursing facilities and possible sources of transmission: north Carolina, 2009-2010
    Seña AC, Moorman A, Njord L, Williams RE, Colborn J, Khudyakov Y, Drobenuic J, Xia GL, Wood H, Moore Z. Infect Control Hosp Epidemiol. 2013 Jul;34(7):709-16. doi: 10.1086/670996. Epub 2013 May 16.


  516. The potential of 1018 ISS adjuvant in hepatitis B vaccines: Introduction
    Eng NF, Bhardwaj N, Mulligan R, Diaz-Mitoma F. Hum Vaccin Immunother. 2013 May 31;9(8). [Epub ahead of print]


  517. Trends in Utilization of Transarterial Treatments for Hepatocellular Carcinoma: Results of a Survey by the Italian Society of Interventional Radiology
    Bargellini I, Florio F, Golfieri R, Grosso M, Lauretti DL, Cioni R. Cardiovasc Intervent Radiol. 2013 May 30. [Epub ahead of print]


  518. Long-term outcome of hepatitis B virus-related Chronic Hepatitis under protracted nucleos(t)ide analogues
    Niro GA, Ippolito AM, Fontana R, Valvano MR, Gioffreda D, Iacobellis A, Merla A, Durazzo M, Lotti G, Di Mauro L, Andriulli A. J Viral Hepat. 2013 Jul;20(7):502-9. doi: 10.1111/jvh.12054. Epub 2013 Feb 6.


  519. The Metabolomic Window into Hepatobiliary Disease
    Beyo?lu D, Idle JR. J Hepatol. 2013 May 25. pii: S0168-8278(13)00362-0. doi: 10.1016/j.jhep.2013.05.030. [Epub ahead of print]


  520. Hepatitis B Knowledge, Screening, and Vaccination among Hmong Americans
    Kue J, Thorburn S. J Health Care Poor Underserved. 2013;24(2):566-78. doi: 10.1353/hpu.2013.0081.


  521. Differential roles of serum HBV DNA and HBsAg level in predicting virological breakthrough in patients receiving lamivudine therapy
    Su CW, Wu CY, Hung HH, Wu CH, Sheen IJ, Wu JC. J Gastroenterol Hepatol. 2013 Jun 4. doi: 10.1111/jgh.12283. [Epub ahead of print]


  522. Clinical significance of serum HBsAg levels and association with liver histology in HBeAg positive chronic hepatitis B
    Cheng PN, Tsai HW, Chiu YC, Ho CH, Wu IC, Chang TT. J Clin Virol. 2013 Aug;57(4):323-30. doi: 10.1016/j.jcv.2013.04.012. Epub 2013 Jun 2.


  523. Incidence of diabetes mellitus in a population-based cohort of persons with chronic hepatitis B virus infection
    Spradling PR, Simons B, Narayanan M, Xing J, Homan C, Bulkow L, Cagle H, Schraer CD, McMahon BJ. J Viral Hepat. 2013 Jul;20(7):510-3. doi: 10.1111/jvh.12071. Epub 2013 Mar 25.


  524. Role of serum dehydroepiandrosterone sulfate level on the clearance of chronic hepatitis B virus infection
    Wu JF, Tsai WY, Tung YC, Chen HL, Ni YH, Hsu HY, Chang MH. J Gastroenterol. 2013 Jun 1. [Epub ahead of print]


  525. Hepatitis B virus reactivation associated with atorvastatin
    Wu DC. Int J Infect Dis. 2013 May 29. pii: S1201-9712(13)00169-0. doi: 10.1016/j.ijid.2013.04.001. [Epub ahead of print]


  526. Long-term anti-HBs antibody persistence following infant vaccination against hepatitis B and evaluation of anamnestic response: A 20-year follow-up study in Thailand
    Poovorawan Y, Chongsrisawat V, Theamboonlers A, Crasta PD, Messier M, Hardt K. Hum Vaccin Immunother. 2013 May 31;9(8). [Epub ahead of print]


  527. Deceased Organ Donor Screening for HIV, Hepatitis B, and Hepatitis C Viruses: A Survey of Organ Procurement Organization Practices
    Theodoropoulos N, Jaramillo A, Ladner DP, Ison MG. Am J Transplant. 2013 May 24. doi: 10.1111/ajt.12260. [Epub ahead of print]


  528. Entecavir plus adefovir rescue therapy for chronic hepatitis B patients after multiple treatment failures in real-life practice
    Xu XH, Li GL, Qin Y, Li Q, He FQ, Li JY, Pan QR, Deng JY. Virol J. 2013 May 25;10(1):162. [Epub ahead of print]


  529. Significance of viral status on recurrence of hepatitis B-related hepatocellular carcinoma after curative therapy: A meta-analysis
    Qu LS, Liu JX, Kuai XL, Xu ZF, Jin F, Zhou GX. Hepatol Res. 2013 May 27. doi: 10.1111/hepr.12172. [Epub ahead of print]


  530. Quasispecies and pre-existing drug-resistant mutations of hepatitis B virus in patients with chronic hepatitis B
    Kim do Y, Chang HY, Lim SM, Kim SU, Park JY, Kim JK, Lee KS, Han KH, Chon CY, Ahn SH. Gut Liver. 2013 May;7(3):329-34. doi: 10.5009/gnl.2013.7.3.329. Epub 2013 Apr 9.


  531. Prevalence and estimation of hepatitis B and C infections in the WHO European Region: a review of data focusing on the countries outside the European Union and the European Free Trade Association
    Hope VD, Eramova I, Capurro D, Donoghoe MC. Epidemiol Infect. 2013 May 29:1-17. [Epub ahead of print]


  532. Meta-analysis: the impact of oral anti-viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B
    Singal AK, Salameh H, Kuo YF, Fontana RJ. Aliment Pharmacol Ther. 2013 Jul;38(2):98-106. doi: 10.1111/apt.12344. Epub 2013 May 28.


  533. Development of a non-invasive fibrosis test for chronic hepatitis B patients and comparison with other unpatented scores
    Hsu CW, Liang KH, Huang SF, Tsao KC, Yeh CT. BMC Res Notes. 2013 May 27;6:212. doi: 10.1186/1756-0500-6-212.


  534. Effect of elective cesarean section on the risk of mother-to-child transmission of hepatitis B virus
    Hu Y, Chen J, Wen J, Xu C, Zhang S, Xu B, Zhou YH. BMC Pregnancy Childbirth. 2013 May 24;13(1):119. [Epub ahead of print]


  535. Challenges in Cancer Vaccine Development for Hepatocellular Carcinoma
    Buonaguro L, Petrizzo A, Tagliamonte M, Lina Tornesello M, Buonaguro FM. J Hepatol. 2013 May 25. pii: S0168-8278(13)00363-2. doi: 10.1016/j.jhep.2013.05.031. [Epub ahead of print]


  536. Differences in metabolites of different tongue coatings in patients with chronic hepatitis B
    Zhao Y, Gou XJ, Dai JY, Peng JH, Feng Q, Sun SJ, Cao HJ, Zheng NN, Fang JW, Jiang J, Su SB, Liu P, Hu YY, Zhang YY. Evid Based Complement Alternat Med. 2013;2013:204908. doi: 10.1155/2013/204908. Epub 2013 Apr 17.


  537. Progression from Excessive to Deficient Syndromes in Chronic Hepatitis B: A Dynamical Network Analysis of miRNA Array Data
    Chen QL, Lu YY, Zhang GB, Song YN, Zhou QM, Zhang H, Zhang W, Su SB. Evid Based Complement Alternat Med. 2013;2013:945245. doi: 10.1155/2013/945245. Epub 2013 Apr 16.


  538. Breast feeding and immunoprophylaxis efficacy of mother-to-child transmission of hepatitis B virus
    Zhang L, Gui X, Fan J, Wang B, Ji H, Yisilafu R, Li F, Zhou Y, Tong Y, Kong X, Ye P, Zong L. J Matern Fetal Neonatal Med. 2013 Jun 20. [Epub ahead of print]


  539. Comparison of the AdvanSure HBV Real-time PCR Test with Three Other HBV DNA Quantification Assays
    Kim H, Shin S, Oh EJ, Kahng J, Kim Y, Lee HK, Kwon HJ. Ann Clin Lab Sci. 2013 Spring;43(2):230-7.


  540. Partial virological response to adefovir add-on Lamivudine rescue therapy in patients with Lamivudine-resistant chronic hepatitis B
    Chon YE, Park JY, Ahn SH, Kim do Y, Han KH, Chon CY, Choi A, Kim SU. Digestion. 2013;87(3):196-203. doi: 10.1159/000348853. Epub 2013 May 9.


  541. High Levels of HBV after the Onset Lead to Chronic Infection in Patients with Acute Hepatitis B
    Yotsuyanagi H, Ito K, Yamada N, Takahashi H, Okuse C, Yasuda K, Suzuki M, Moriya K, Mizokami M, Miyakawa Y, Koike K. Clin Infect Dis. 2013 May 23. [Epub ahead of print]


  542. Results of a phase III clinical trial with an HBsAg-HBIG immunogenic complex therapeutic vaccine for chronic hepatitis B patients: Experiences and findings
    Xu DZ, Wang XY, Shen XL, Gong GZ, Ren H, Guo LM, Sun AM, Xu M, Li LJ, Guo XH, Zhen Z, Wang HF, Gong HY, Xu C, Jiang N, Pan C, Gong ZJ, Zhang JM, Shang J, Xu J, Xie Q, Wu TF, Huang WX, Li YG, Xu J, Yuan ZH, Wang B, Zhao K, Wen YM; for the YIC Efficacy Trial Study Team. J Hepatol. 2013 May 11. pii: S0168-8278(13)00295-X. doi: 10.1016/j.jhep.2013.05.003. [Epub ahead of print]


  543. Treatment of patients with dual hepatitis C and B by peginterferon ? and ribavirin reduced risk of hepatocellular carcinoma and mortality
    Liu CJ, Chu YT, Shau WY, Kuo RN, Chen PJ, Lai MS. Gut. 2013 May 15. [Epub ahead of print]


  544. Association between cytotoxic T-lymphocyte associated protein 4 gene +49 A/G polymorphism and chronic infection with hepatitis B virus: A meta-analysis
    Xu H, Zhao M, He J, Chen Z. J Int Med Res. 2013 Jun;41(3):559-67. doi: 10.1177/0300060513483387. Epub 2013 May 13.


  545. Reversal of cirrhosis: An achievable goal of hepatitis B antiviral therapy
    Liaw YF. J Hepatol. 2013 May 11. pii: S0168-8278(13)00333-4. doi: 10.1016/j.jhep.2013.05.007. [Epub ahead of print]


  546. Notes from the field: transmission of HBV among assisted-living-facility residents - virginia, 2012
    Centers for Disease Control and Prevention (CDC). MMWR Morb Mortal Wkly Rep. 2013 May 17;62(19):389.


  547. A comparison of efficacy and safety of 2-year telbivudine and entecavir treatment in patients with chronic hepatitis B: a match-control study
    Tsai MC, Chen CH, Hung CH, Lee CM, Chiu KW, Wang JH, Lu SN, Tseng PL, Chang KC, Yen YH, Hu TH. Clin Microbiol Infect. 2013 May 10. doi: 10.1111/1469-0691.12220. [Epub ahead of print]


  548. Hepatitis B virus reactivation risk varies with different chemotherapy regimens commonly used in solid tumours
    Ling WH, Soe PP, Pang AS, Lee SC. Br J Cancer. 2013 May 28;108(10):1931-5. doi: 10.1038/bjc.2013.225. Epub 2013 May 7.


  549. Association of polymorphisms in the interleukin-4 gene with response to hepatitis B vaccine and susceptibility to hepatitis B virus infection: A meta-analysis
    Cui W, Sun CM, Deng BC, Liu P. Gene. 2013 Aug 1;525(1):35-40. doi: 10.1016/j.gene.2013.04.065. Epub 2013 May 4.


  550. The comparison of the efficacy of pegylated interferon ?-2a and ?-2b in chronic hepatitis B patients
    Dogan UB, Golge N, Akin MS. Eur J Gastroenterol Hepatol. 2013 May 4. [Epub ahead of print]


  551. Treatment and non-treatment related ocular manifestations in patients with chronic hepatitis B or C
    Tsoumani A, Theopistos V, Katsanos K, Asproudis I, Tsianos EV. Eur Rev Med Pharmacol Sci. 2013 Apr;17(8):1123-31.


  552. Specific amino acid substitutions in the S protein prevent its excretion in vitro and may contribute to occult hepatitis B virus infection
    Biswas S, Candotti D, Allain JP. J Virol. 2013 May 8. [Epub ahead of print]


  553. Management of Hepatitis B: My Practice and how it relates to the Guidelines
    Yapali S, Talaat N, Lok AS. Clin Gastroenterol Hepatol. 2013 May 6. pii: S1542-3565(13)00606-X. doi: 10.1016/j.cgh.2013.04.036. [Epub ahead of print]


  554. Antiviral activity of Bifidobacterium adolescentis SPM0212 against Hepatitis B virus
    Lee DK, Kang JY, Shin HS, Park IH, Ha NJ. Arch Pharm Res. 2013 May 9. [Epub ahead of print]


  555. Early serum hepatitis B virus large surface protein level: A stronger predictor of virological response to peginterferon alfa-2a than that to entecavir in HBeAg-positive patients with chronic hepatitis B
    Zhu X, Gong Q, Yu D, Zhang D, Gu L, Han Y, Chen J, Zhang Y, Zhang X. J Clin Virol. 2013 Apr 29. pii: S1386-6532(13)00123-6. doi: 10.1016/j.jcv.2013.04.003. [Epub ahead of print]


  556. Cesarean Section Reduces Perinatal Transmission of HBV Infection from Hepatitis B Surface Antigen-Positive Women to Their Infants
    Pan CQ, Zou HB, Chen Y, Zhang X, Zhang H, Li J, Duan Z. Clin Gastroenterol Hepatol. 2013 Apr 29. pii: S1542-3565(13)00586-7. doi: 10.1016/j.cgh.2013.04.026. [Epub ahead of print]


  557. High Prevalence of Occult Hepatitis C Virus Infection in Patients with Chronic Hepatitis B Virus Infection
    Castillo I, Bartolomé J, Quiroga JA, Carreño V. J Med Microbiol. 2013 May 2. [Epub ahead of print]


  558. Meta-analysis of the short-term effects of lamivudine treatment for severe chronic hepatitis B
    Zhang L, Hao CQ, Liu JF, Wang M. Virol J. 2013 Apr 29;10:134. doi: 10.1186/1743-422X-10-134.


  559. Baseline hepatitis B surface antigen (HBsAg) as predictor of sustained HBsAg loss in chronic hepatitis B patients treated with peginterferon alfa-2a and adefovir
    Takkenberg RB, Jansen L, de Niet A, Zaaijer HL, Weegink CJ, Terpstra V, Dijkgraaf MG, Molenkamp R, Jansen PL, Koot M, Rijckborst V, Janssen HL, Beld MG, Reesink HW. Antivir Ther. 2013 May 2. doi: 10.3851/IMP2580. [Epub ahead of print]


  560. Education Provides Significant Benefits to Patients with Hepatitis B Virus or Hepatitis C Virus Infection: A Systematic Review
    Shah HA, Abu-Amara M. Clin Gastroenterol Hepatol. 2013 Apr 29. pii: S1542-3565(13)00584-3. doi: 10.1016/j.cgh.2013.04.024. [Epub ahead of print]


  561. Relation between antibody to hepatitis B core antigen and survival after curative therapy for non-B non-C hepatocellular carcinoma
    Nishikawa H, Osaki Y, Arimoto A, Kita R, Kimura T. Anticancer Res. 2013 May;33(5):2211-9.


  562. Virologic response during up to 2 years of entecavir plus adefovir combination therapy in multiple drug-refractory chronic hepatitis B patients: A Randomized Trial.
    Lim YS, Lee JY, Lee D, Shim JH, Lee HC, Lee YS, Suh DJ. Antimicrob Agents Chemother. 2013 May 6. [Epub ahead of print]


  563. The effect of coffee consumption on the development of hepatocellular carcinoma in hepatitis B virus endemic area
    Jang ES, Jeong SH, Lee SH, Hwang SH, Ahn SY, Lee J, Park YS, Hwang JH, Kim JW, Kim N, Lee DH, Kim HY. Liver Int. 2013 Apr 4. doi: 10.1111/liv.12186. [Epub ahead of print]


  564. Prevalence of occult hepatitis B virus infection in hemodialysis patients
    Yoo JH, Hwang SG, Yang DH, Son MS, Kwon CI, Ko KH, Hong SP, Park PW, Rim KS. Korean J Gastroenterol. 2013 Apr 25;61(4):209-14.


  565. Sensitivity of individual-donation and minipool nucleic acid amplification test options in detecting window period and occult hepatitis B virus infections
    Vermeulen M, Coleman C, Mitchel J, Reddy R, van Drimmelen H, Ficket T, Lelie N. Transfusion. 2013 Apr 29. doi: 10.1111/trf.12218. [Epub ahead of print]


  566. Excellent liver transplantation survival and prevention of hepatitis B recurrence using hepatitis B immunoglobulin and nucleoside or nucleotide analogue along with treating physician adherence to treatment protocol
    Lindenger C, Castedal M, Cahlin C, Friman S. Transplant Proc. 2013 Apr;45(3):1188-92. doi: 10.1016/j.transproceed.2012.10.007.


  567. Are liver transplant recipients protected against hepatitis a and B?
    Andersson D, Castedal M, Friman V. Transplant Proc. 2013 Apr;45(3):1193-7. doi: 10.1016/j.transproceed.2012.10.012.


  568. Country of birth and other factors associated with hepatitis B prevalence in a population with high levels of immigration
    Reekie J, Gidding HF, Kaldor JM, Liu B. J Gastroenterol Hepatol. 2013 Apr 26. doi: 10.1111/jgh.12245. [Epub ahead of print]


  569. Contributing factors to colorectal cancer and hepatitis B screening among vietnamese americans
    Nguyen-Truong CK, Lee-Lin F, Gedaly-Duff V. Oncol Nurs Forum. 2013 May 1;40(3):238-51. doi: 10.1188/13.ONF.238-251.


  570. Extended treatment with peginterferon ?-2a in combination with lamivudine or adefovir for 96 weeks yields high rates of HBeAg and HBsAg seroconversion
    Cao ZH, Ma LN, Zhang HW, Liu YL, Chen XY. J Dig Dis. 2013 Apr 25. doi: 10.1111/1751-2980.12065. [Epub ahead of print]


  571. The efficacy and safety of nucleos(t)ide analogues in the treatment of HBV-related acute-on-chronic liver failure: a meta-analysis
    Yu S, Jianqin H, Wei W, Jianrong H, Yida Y, Jifang S, Liang Y, Zhi C, Hongyu J. Ann Hepatol. 2013 May-Jun;12(3):364-72.


  572. Virological response to entecavir reduces the risk of liver disease progression in nucleos(t)ide analogue-experienced HBV-infected patients with prior resistant mutants
    Yang SC, Lee CM, Hu TH, Wang JH, Lu SN, Hung CH, Changchien CS, Chen CH. J Antimicrob Chemother. 2013 Apr 25. [Epub ahead of print]


  573. Dynamics of lamivudine-resistant hepatitis B virus strains in patients with entecavir rescue therapy
    Deng XL, Li QL, Guo JJ. Virus Genes. 2013 Apr 25. [Epub ahead of print]


  574. Lack of correlation between the antibody to hepatitis B core antigen and survival after surgical resection for hepatitis C virus-related hepatocellular carcinoma
    Nishikawa H, Arimoto A, Wakasa T, Kita R, Kimura T, Osaki Y. Oncol Rep. 2013 Apr 24. doi: 10.3892/or.2013.2422. [Epub ahead of print]


  575. Patient adherence to antiviral treatment for chronic hepatitis B and C: a systematic review
    Lieveld FI, van Vlerken LG, Siersema PD, van Erpecum KJ. Ann Hepatol. 2013 May-Jun;12(3):380-91.


  576. Predictability of liver-related seromarkers for the risk of hepatocellular carcinoma in chronic hepatitis B patients
    Lin YJ, Lee MH, Yang HI, Jen CL, You SL, Wang LY, Lu SN, Liu J, Chen CJ. PLoS One. 2013 Apr 17;8(4):e61448. doi: 10.1371/journal.pone.0061448. Print 2013.


  577. Increasing hepatitis B screening for hmong adults: results from a randomized controlled community-based study
    Chen MS Jr, Fang DM, Stewart SL, Ly MY, Lee S, Dang JH, Nguyen TT, Maxwell AE, Bowlus CL, Bastani R, Nguyen TT. Cancer Epidemiol Biomarkers Prev. 2013 May;22(5):782-91. doi: 10.1158/1055-9965.EPI-12-1399. Epub 2013 Apr 23.


  578. Survival in liver transplant recipients with hepatitis B- or hepatitis C-associated hepatocellular carcinoma: the chinese experience from 1999 to 2010
    Hu Z, Zhou J, Wang H, Zhang M, Li S, Huang Y, Wu J, Li Z, Zhou L, Zheng S. PLoS One. 2013 Apr 16;8(4):e61620. doi: 10.1371/journal.pone.0061620. Print 2013.


  579. Association between Interferon-Inducible Protein 6 (IFI6) Polymorphisms and Hepatitis B Virus Clearance
    Park GH, Kim KY, Cho SW, Cheong JY, Yu GI, Shin DH, Kwack KB. Genomics Inform. 2013 Mar;11(1):15-23. doi: 10.5808/GI.2013.11.1.15. Epub 2013 Mar 31.


  580. Dried blood spot sampling for hepatitis B virus serology and molecular testing
    Mohamed S, Raimondo A, Pénaranda G, Camus C, Ouzan D, Ravet S, Bourlière M, Khiri H, Dukan P, Olive D, Halfon P. PLoS One. 2013 Apr 16;8(4):e61077. doi: 10.1371/journal.pone.0061077. Print 2013.


  581. Antiviral therapy after curative treatment of hepatitis B/C virus-related hepatocellular carcinoma: A systematic review of randomized trials.
    Sun P, Yang X, He RQ, Hu QG, Song ZF, Xiong J, Zheng QC. Hepatol Res. 2013 Apr 2. doi: 10.1111/hepr.12115. [Epub ahead of print]


  582. Advance in molecular diagnostic tools for hepatitis B virus detection
    Pazienza V, Niro GA, Fontana R, Vinciguerra M, Andriulli A. Clin Chem Lab Med. 2013 Apr 6:1-11. doi: 10.1515/cclm-2013-0136. [Epub ahead of print]


  583. Liver Imaging with a Novel Hepatitis B Surface Protein Derived SPECT-Tracer
    Müller T, Mehrle S, Schieck A, Haberkorn U, Urban S, Mier W. Mol Pharm. 2013 May 3. [Epub ahead of print]


  584. Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma
    Cho JY, Paik YH, Lim HY, Kim YG, Lim HK, Min YW, Gwak GY, Choi MS, Lee JH, Koh KC, Paik SW, Yoo BC. Liver Int. 2013 Apr 2. doi: 10.1111/liv.12168. [Epub ahead of print]


  585. Optimal Testing of the Live Organ Donor for Blood-Borne Viral Pathogens: The Report of a Consensus Conference
    Blumberg EA, Ison MG, Pruett TL, Segev DL; on behalf of the Optimal Testing of the Live Organ Donor Consensus Conference Participants. Am J Transplant. 2013 Apr 19. doi: 10.1111/ajt.12205. [Epub ahead of print]


  586. Correlation of hepatitis B surface antigen level with response to telbivudine in naive patients with chronic hepatitis B
    Li X, Wang Y, Han D, Zhang W, Zhang Z, Ye X, Tian L, Dong Y, Zhu Q, Chen Y. Hepatol Res. 2013 Mar 4. doi: 10.1111/hepr.12105. [Epub ahead of print]


  587. Molecular virology of chronic hepatitis B and C: Parallels, contrasts and impact on drug development and treatment outcome
    Delaney WE 4th. Antiviral Res. 2013 Apr 18. pii: S0166-3542(13)00096-X. doi: 10.1016/j.antiviral.2013.04.010. [Epub ahead of print]


  588. Association of the rs3077 and rs9277535 polymorphisms in HLA-DP with hepatitis B virus infection and spontaneous clearance: A meta-analysis
    Zhang XL, Ni XC, Jia JH, Dong JH, Yu FX, Ma N, Liu XH, Li M, Liu DW. Scand J Gastroenterol. 2013 Apr 22. [Epub ahead of print]


  589. Guidelines for avoiding risks resulting from discontinuation of nucleoside/nucleotide analogs in patients with chronic hepatitis B
    Tanaka E, Matsumoto A. Hepatol Res. 2013 Mar 8. doi: 10.1111/hepr.12108. [Epub ahead of print]


  590. Diagnostic accuracy of hepatic venous pressure gradient measurement in the prediction of stage 1 compensated liver cirrhosis in patients with chronic hepatitis B
    Suk KT, Kim HC, Namkung S, Han SH, Choi KC, Park SH, Sung HT, Kim CH, Kim SH, Ham YL, Kang HM, Kim DJ. Eur J Gastroenterol Hepatol. 2013 Apr 18. [Epub ahead of print]


  591. Snapshot on drug-resistance rate and profiles in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice
    Salpini R, Alteri C, Cento V, Pollicita M, Micheli V, Gubertini G, De Sanctis GM, Visca M, Romano S, Sarrecchia C, Andreoni M, Angelico M, Parruti G, Svicher V, Perno CF. J Med Virol. 2013 Jun;85(6):996-1004. doi: 10.1002/jmv.23567.


  592. Reactivation of hepatitis B virus associated with chemotherapy and immunosuppressive agent
    Wijaya I, Hasan I. Acta Med Indones. 2013 Jan;45(1):61-6.


  593. Impact of peginterferon alpha-2b and entecavir hydrate combination therapy on persistent viral suppression in patients with chronic hepatitis B
    Hagiwara S, Kudo M, Osaki Y, Matsuo H, Inuzuka T, Matsumoto A, Tanaka E, Sakurai T, Ueshima K, Inoue T, Yada N, Nishida N. J Med Virol. 2013 Jun;85(6):987-95. doi: 10.1002/jmv.23564.


  594. Association between gene polymorphisms of IL-28 and response to lamivudine in Chinese rural patients with chronic hepatitis B
    Yu F, Wang Y, Yuan S, Ma J, Ma N, Zhang X, Liu X, Liu D. Scand J Gastroenterol. 2013 Apr 16. [Epub ahead of print]


  595. Does Guasha Offer Hepatoprotective Effect to Chronic Inactive Hepatitis B Carriers? A Built-in Design to Control Subject Expectation
    Chan ST, Yuen JW, Gohel MD, Wong HC, Chung CP, Sun Y, Ng JN, Lie R, Kwong KK. J Altern Complement Med. 2013 Apr 11. [Epub ahead of print]


  596. Hepatitis B and C infection in international travelers
    Johnson DF, Leder K, Torresi J. J Travel Med. 2013 May;20(3):194-202. doi: 10.1111/jtm.12026. Epub 2013 Apr 4.


  597. Peginterferon-2a combined with response-guided short-term lamivudine improves response rate in hepatitis B e antigen-positive hepatitis B patients: a pilot study
    Huang Z, Deng H, Zhao Q, Zheng Y, Peng L, Lin C, Zhao Z, Gao Z.


  598. Long-term therapy for chronic hepatitis B: HBV DNA suppression leading to cirrhosis reversal
    Marcellin P, Asselah T. J Gastroenterol Hepatol. 2013 Apr 11. doi: 10.1111/jgh.12213. [Epub ahead of print]


  599. Chronic hepatitis B treatment initiation and modification patterns in five European countries: a 2-year longitudinal, non-interventional study
    Marcellin P, Arama V, Leblebicioglu H, Zarski JP, Zeuzem S, Mauss S, Sieklucki J, Acalovschi M, Usluer G, Klauck I, Morais E, Bjork S, Lescrauwaet B, Kamar D, Simon K; the AI; Longitudinal Study Group. Antivir Ther. 2013 Apr 10. doi: 10.3851/IMP2573. [Epub ahead of print]


  600. Coinfection with Hepatitis B and D: Epidemiology, Prevalence and Disease in Patients in Northern California
    Gish RG, Yi DH, Kane S, Clark M, Mangahas M, Baqai S, Winters MA, Proudfoot J, Glenn JS. J Gastroenterol Hepatol. 2013 Apr 11. doi: 10.1111/jgh.12217. [Epub ahead of print]


  601. Update in the management of chronic hepatitis B
    Tujios SR, Lee WM. Curr Opin Gastroenterol. 2013 May;29(3):250-6. doi: 10.1097/MOG.0b013e32835ff1e9.


  602. Renal dysfunction and hypophosphatemia during long-term lamivudine plus adefovir dipivoxil therapy in patients with chronic hepatitis B
    Tanaka M, Suzuki F, Seko Y, Hara T, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H. J Gastroenterol. 2013 Mar 26. [Epub ahead of print]


  603. Liver transplantation in hepatitis B core negative recipients using livers from hepatitis B core positive donor: 13 years experience
    Bohorquez HE, Cohen AJ, Girgrah N, Bruce DS, Carmody IC, Joshi S, Reichman TW, Therapondos G, Mason AL, Loss GE. Liver Transpl. 2013 Mar 22. doi: 10.1002/lt.23644. [Epub ahead of print]


  604. Entecavir versus lamivudine for hepatitis B prophylaxis in patients with haematological disease
    Chen FW, Coyle L, Jones BE, Pattullo V. Liver Int. 2013 Mar 2. doi: 10.1111/liv.12154. [Epub ahead of print]


  605. Significance of anti-HBc only in blood donors: a serological and virological study after hepatitis B vaccination
    Gessoni G, Beggio S, Barin P, Favarato M, Galli C, Valverde S, Nata MB, Salvadego MM, Marchiori G. Blood Transfus. 2013 Feb 21:1-6. doi: 10.2450/2013.0227-12. [Epub ahead of print]


  606. Formal hepatitis C education enhances HCV care coordination, expedites HCV treatment and improves antiviral response
    Lubega S, Agbim U, Surjadi M, Mahoney M, Khalili M. Liver Int. 2013 Mar 7. doi: 10.1111/liv.12150. [Epub ahead of print]


  607. Prediction models of long-term cirrhosis and HCC risk in chronic hepatitis B patients: Risk scores integrating host and virus profiles
    Lee MH, Yang HI, Liu J, Batrla-Utermann R, Jen CL, Iloeje UH, Lu SN, You SL, Wang LY, Chen CJ; for the R.E.V.E.A.L.-HBV Study Group. Hepatology. 2013 Mar 15. doi: 10.1002/hep.26385. [Epub ahead of print]


  608. Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients
    Marcellin P, Bonino F, Yurdaydin C, Hadziyannis S, Moucari R, Kapprell HP, Rothe V, Popescu M, Brunetto MR. Hepatol Int. 2013 Mar;7(1):88-97. Epub 2012 Mar 23.


  609. Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients
    Marcellin P, Bonino F, Yurdaydin C, Hadziyannis S, Moucari R, Kapprell HP, Rothe V, Popescu M, Brunetto MR. Hepatol Int. 2013 Mar;7(1):88-97. Epub 2012 Mar 23.


  610. Occult hepatitis B virus infection as a cause of posttransfusion hepatitis in patients with cancers
    Sodhi JS, Wani N, Jeelani S, Geelani S, Akhtar F, Javid G, Yattoo GN, Shah A, Gulzar GM, Khan MA, Parveen S, Saif RU, Showkat A. Indian J Gastroenterol. 2013 Mar 20. [Epub ahead of print]


  611. Association Between Metabolic Syndrome and Its Individual Components With Viral Hepatitis B
    Jinjuvadia R, Liangpunsakul S. Am J Med Sci. 2013 Mar 19. [Epub ahead of print]


  612. Role of maternal viremia and placental infection in hepatitis B virus intrauterine transmission
    Chen Y, Wang L, Xu Y, Liu X, Li S, Qian Q, Hu B, Zhou A, Chen T, Zhao Y. Microbes Infect. 2013 Mar 14. pii: S1286-4579(13)00037-3. doi: 10.1016/j.micinf.2013.02.008. [Epub ahead of print]


  613. Immunoglobulin g4-associated de novo autoimmune hepatitis after liver transplantation for chronic hepatitis B- and C-related cirrhosis and hepatocellular carcinoma: a case report with literature review
    Zhao XY, Rakhda MI, Wang TI, Jia JD. Transplant Proc. 2013 Mar;45(2):824-7. doi: 10.1016/j.transproceed.2012.02.049.


  614. APRI, the FIB-4 score, and Forn's index have noninvasive diagnostic value for liver fibrosis in patients with chronic hepatitis B
    Ucar F, Sezer S, Ginis Z, Ozturk G, Albayrak A, Basar O, Ekiz F, Coban S, Yuksel O, Armutcu F, Akbal E. Eur J Gastroenterol Hepatol. 2013 Mar 18. [Epub ahead of print]


  615. The diagnostic value of non-invasive tests for the evaluation of liver fibrosis in chronic hepatitis B patients
    Erdogan S, Dogan HO, Sezer S, Uysal S, Ozhamam E, Kayacetin S, Koca Y. Scand J Clin Lab Invest. 2013 Mar 20. [Epub ahead of print]


  616. Quantitative hepatitis B surface antigen analysis in hepatitis B e antigen-positive, nucleoside-naive patients treated with entecavir
    Gish RG, Chang TT, Lai CL, de Man RA, Gadano A, Llamoso C, Tang H. Antivir Ther. 2013 Mar 19. doi: 10.3851/IMP2559. [Epub ahead of print]


  617. Connective tissue growth factor (CTGF/CCN2) in serum is an indicator of fibrogenic progression and malignant transformation in patients with chronic hepatitis B infection
    Gressner OA, Fang M, Li H, Lu LG, Gressner AM, Gao CF. Clin Chim Acta. 2013 Mar 15;421C:126-131. doi: 10.1016/j.cca.2013.02.029. [Epub ahead of print]


  618. Assessing Adherence to Accepted National Guidelines for Immigrant and Refugee Screening and Vaccines in an Urban Primary Care Practice: A Retrospective Chart Review
    Waldorf B, Gill C, Crosby SS. J Immigr Minor Health. 2013 Mar 20. [Epub ahead of print]


  619. Adefovir treatment for chronic hepatitis B in heart transplant recipients
    Durante-Mangoni E, Iossa D, Pinto D, Molaro R, Agrusta F, Amarelli C, Ragone E, Grimaldi M, Maiello C, Utili R. Clin Transplant. 2013 Mar 21. doi: 10.1111/ctr.12109. [Epub ahead of print]


  620. Telbivudine treatment in chronic hepatitis B: experience from China
    You H, Jia J. J Viral Hepat. 2013 Apr;20 Suppl 1:3-8. doi: 10.1111/jvh.12058.


  621. Efficacy of postoperative antiviral combined transcatheter arterial chemoembolization therapy in prevention of hepatitis B-related hepatocellular carcinoma recurrence
    Yan Q, Ni J, Zhang GL, Yao X, Yuan WB, Zhou L, Zheng SS. Chin Med J (Engl). 2013 Mar;126(5):855-9.


  622. Risk of occult hepatitis B virus infection reactivation in patients with solid tumours undergoing chemotherapy
    Saitta C, Musolino C, Marabello G, Martino D, Leonardi MS, Pollicino T, Altavilla G, Raimondo G. Dig Liver Dis. 2013 Mar 11. pii: S1590-8658(13)00042-X. doi: 10.1016/j.dld.2013.01.022. [Epub ahead of print]


  623. Prophylactic Effect of Antiretroviral Therapy on Hepatitis B Virus Infection
    Gatanaga H, Hayashida T, Tanuma J, Oka S. Clin Infect Dis. 2013 Mar 28. [Epub ahead of print]


  624. Ocular effects of pegylated interferon-? in patients with chronic hepatitis B
    Koktekir BE, Sumer S, Bakbak B, Gedik S, Gonul S, Ural O. Cutan Ocul Toxicol. 2013 Mar 12. [Epub ahead of print]


  625. Mother-to-Infant Transmission of Hepatitis B Virus Infection: Significance of Maternal Viral Load and Strategies for Intervention
    Wen WH, Chang MH, Zhao LL, Ni YH, Hsu HY, Wu JF, Chen PJ, Chen DS, Chen HL. J Hepatol. 2013 Feb 25. pii: S0168-8278(13)00137-2. doi: 10.1016/j.jhep.2013.02.015. [Epub ahead of print]


  626. Individualized treatment of HBeAg-negative CHB using peg-interferon alfa-2a as first-line and week 12 HBV-DNA\HBsAg stopping rule. A cost-effectiveness analysis
    Iannazzo S, Coco B, Brunetto MR, Rossetti F, Caputo A, Latour A, Espinos B, Bonino F.


  627. Telbivudine treatment is associated with high hepatitis B e antigen seroconversion and immune modulatory effects in chronic hepatitis B patients
    Wang GQ, Ding YP, Dong YH. J Viral Hepat. 2013 Apr;20 Suppl 1:9-17. doi: 10.1111/jvh.12059.


  628. Efficacy and safety of telbivudine plus adefovir dipivoxil combination therapy and entecavir monotherapy for HBeAg-positive chronic hepatitis B patients with resistance to adefovir dipivoxil
    Lu JJ, Liu K, Ma YJ, Wang J, Chen EQ, Tang H. J Viral Hepat. 2013 Apr;20 Suppl 1:40-5. doi: 10.1111/jvh.12062.


  629. Safety of telbivudine treatment for chronic hepatitis B for the entire pregnancy
    Liu M, Cai H, Yi W. J Viral Hepat. 2013 Apr;20 Suppl 1:65-70. doi: 10.1111/jvh.12066.


  630. Efficacy of telbivudine treatment for hepatitis B e antigen-positive chronic hepatitis B patients with poor response to adefovir dipivoxil
    Li Y, Zhang Y, Wang JP, Lian JQ, Bai XF. J Viral Hepat. 2013 Apr;20 Suppl 1:46-51. doi: 10.1111/jvh.12063.


  631. Efficacy of sequential use of telbivudine in hepatitis B e antigen-positive chronic hepatitis B patients with partial responses to pegylated interferon: a pilot study
    Huang Z, Zhao Z, Zheng Y, Peng L, Lin C, Deng H, Gao Z. J Viral Hepat. 2013 Apr;20 Suppl 1:52-7. doi: 10.1111/jvh.12064.


  632. Forty-eight-week retrospective study of telbivudine and lamivudine treatment in patients with hepatitis B-related cirrhosis
    Han Z, Shi Y, Zhu J, Chen Y, Yin F, Xia L, Luo G, Gao Z, Liu J, Jia G, Li C, Zhou X, Han Y. J Viral Hepat. 2013 Apr;20 Suppl 1:58-64. doi: 10.1111/jvh.12065.


  633. IL28B Polymorphism Correlates with Active Hepatitis in Patients with HBeAg-Negative Chronic Hepatitis B
    Lee IC, Lin CH, Huang YH, Huo TI, Su CW, Hou MC, Huang HC, Lee KC, Chan CC, Lin MW, Lin HC, Lee SD. PLoS One. 2013;8(2):e58071. doi: 10.1371/journal.pone.0058071. Epub 2013 Feb 28.


  634. Reduction of hepatitis B surface antigen levels and HBsAg seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy
    Seto WK, Wong DK, Fung J, Huang FY, Lai CL, Yuen MF. Hepatology. 2013 Mar 6. doi: 10.1002/hep.26376. [Epub ahead of print]


  635. Differential Plasma MicroRNA Profiles in HBeAg Positive and HBeAg Negative Children with Chronic Hepatitis B
    Winther TN, Bang-Berthelsen CH, Heiberg IL, Pociot F, Hogh B. PLoS One. 2013;8(3):e58236. doi: 10.1371/journal.pone.0058236. Epub 2013 Mar 4.


  636. Efficacy of Entecavir Treatment for up to 5 Years in Nucleos(t)ide-Naïve Chronic Hepatitis B Patients in Real Life
    Luo J, Li X, Wu Y, Lin G, Pang Y, Zhang X, Ao Y, Du Z, Zhao Z, Chong Y. Int J Med Sci. 2013;10(4):427-33. doi: 10.7150/ijms.5472. Epub 2013 Mar 1.


  637. Acute Hepatitis B in an Urban Tertiary Care Hospital in the United States: A Cohort Evaluation
    Sharif O, Krishnan PV, Thekdi AD, Gordon SC. J Clin Gastroenterol. 2013 Mar 6. [Epub ahead of print]


  638. Abnormal regional homogeneity of resting-state brain activity in patients with HBV-related cirrhosis without overt hepatic encephalopathy
    Lv XF, Qiu YW, Tian JZ, Xie CM, Han LJ, Su HH, Liu ZY, Peng JP, Lin CL, Wu MS, Jiang GH, Zhang XL. Liver Int. 2013 Mar;33(3):375-83. doi: 10.1111/liv.12096.


  639. Cost-minimization analysis of the U.S. Army accession screening and immunization program
    Tzeng J, Jankosky C, Hughes H. Mil Med. 2012 Dec;177(12):1508-12.


  640. Association of cytokine gene polymorphisms and serum concentrations with the outcome of chronic hepatitis B
    Conde SR, Feitosa RN, Freitas FB, Hermes RB, Demachki S, Araújo MT, Soares MC, Ishak R, Vallinoto AC. Cytokine. 2013 Feb 5. pii: S1043-4666(13)00034-3. doi: 10.1016/j.cyto.2013.01.004. [Epub ahead of print]


  641. Comparative assessment of liver fibrosis by computerized morphometry in naïve patients with chronic hepatitis B and C
    Sturm N, Marlu A, Arvers P, Zarski JP, Leroy V. Liver Int. 2013 Mar;33(3):428-38. doi: 10.1111/liv.12092.


  642. Chronic hepatitis B: What should be the goal for new therapies?
    Block TM, Gish R, Guo H, Mehta A, Cuconati A, Thomas London W, Guo JT. Antiviral Res. 2013 Feb 4. pii: S0166-3542(13)00021-1. doi: 10.1016/j.antiviral.2013.01.006. [Epub ahead of print]


  643. Hepatitis B surface antigen could contribute to the immunopathogenesis of hepatitis B virus infection
    Kondo Y, Ninomiya M, Kakazu E, Kimura O, Shimosegawa T. ISRN Gastroenterol. 2013;2013:935295. doi: 10.1155/2013/935295. Epub 2013 Jan 16.


  644. Does hepatitis B treatment reduce the incidence of hepatocellular carcinoma?
    Sherman M. Hepatology. 2013 Feb 11. doi: 10.1002/hep.26317. [Epub ahead of print]


  645. Serum HBV RNA and HBeAg are useful markers for the safe discontinuation of nucleotide analogue treatments in chronic hepatitis B patients
    Tsuge M, Murakami E, Imamura M, Abe H, Miki D, Hiraga N, Takahashi S, Ochi H, Nelson Hayes C, Ginba H, Matsuyama K, Kawakami H, Chayama K. J Gastroenterol. 2013 Feb 9. [Epub ahead of print]


  646. Effects of antiviral therapy on hepatitis B virus reactivation and liver function after resection or chemoembolization for hepatocellular carcinoma
    Lao XM, Luo G, Ye LT, Luo C, Shi M, Wang D, Guo R, Chen M, Li S, Lin X, Yuan Y. Liver Int. 2013 Jan 12. doi: 10.1111/liv.12112. [Epub ahead of print]


  647. Hepatitis B
    Tong MJ, Trieu J. J Dig Dis. 2013 Feb 21. doi: 10.1111/1751-2980.12051. [Epub ahead of print]


  648. Towards complete eradication of hepatitis B infection from perinatal transmission: review of the mechanisms of in utero infection and the use of antiviral treatment during pregnancy
    Cheung KW, Seto MT, Wong SF. Eur J Obstet Gynecol Reprod Biol. 2013 Mar 4. pii: S0301-2115(13)00087-0. doi: 10.1016/j.ejogrb.2013.02.001. [Epub ahead of print]


  649. Noninvasive fibrosis indices predict intrahepatic distant recurrence of hepatitis B-related hepatocellular carcinoma following radiofrequency ablation
    Seo JY, Kim W, Kwon JH, Jin EH, Yu SJ, Kim HY, Jung YJ, Kim D, Kim YJ, Yoon JH, Lee HS. Liver Int. 2013 Jan 30. doi: 10.1111/liv.12132. [Epub ahead of print]


  650. Granulocyte-colony stimulating factor therapy improves survival in patients with hepatitis B virus-associated acute-on-chronic liver failure
    Duan XZ, Liu FF, Tong JJ, Yang HZ, Chen J, Liu XY, Mao YL, Xin SJ, Hu JH. World J Gastroenterol. 2013 Feb 21;19(7):1104-10. doi: 10.3748/wjg.v19.i7.1104.


  651. Use of the International Classification of Diseases, 9th revision, coding in identifying chronic hepatitis B virus infection in health system data: implications for national surveillance
    Mahajan R, Moorman AC, Liu SJ, Rupp L, Klevens RM; for the Chronic Hepatitis Cohort Study (CHeCS) investigators*. J Am Med Inform Assoc. 2013 Mar 5. [Epub ahead of print]


  652. Expression of Interleukin-17 associated with disease progression and liver fibrosis with hepatitis B virus infection: IL-17 in HBV infection
    Du WJ, Zhen JH, Zeng ZQ, Zheng ZM, Xu Y, Qin LY, Chen SJ. Diagn Pathol. 2013 Feb 28;8:40. doi: 10.1186/1746-1596-8-40.


  653. A randomized trial of emtricitabine/tenofovir disoproxil fumarate after hepatitis B immunoglobulin withdrawal post-liver transplant
    Teperman LW, Poordad F, Bzowej N, Martin P, Pungpapong S, Schiano T, Flaherty J, Dinh P, Rossi S, Subramanian GM, Spivey J. Liver Transpl. 2013 Feb 27. doi: 10.1002/lt.23628. [Epub ahead of print]


  654. Longitudinal Change of HBsAg in HBeAg-negative Patients with Genotype B or C Infection
    Su TH, Liu CJ, Tseng TC, Liu CH, Yang HC, Chen CL, Chen PJ, Kao JH, Chen DS. PLoS One. 2013;8(2):e55916. doi: 10.1371/journal.pone.0055916. Epub 2013 Feb 20.


  655. Combination of lamivudine and adefovir without hepatitis B immune globulin is safe and effective prophylaxis against hepatitis B virus recurrence in hepatitis B surface antigen-positive liver transplant candidates
    Gane EJ, Patterson S, Strasser SI, McCaughan GW, Angus PW. Liver Transpl. 2013 Mar;19(3):268-74. doi: 10.1002/lt.23600.


  656. Prevention of mother-to-child transmission of hepatitis B virus (HBV) during pregnancy and the puerperium: Current standards of care
    Giles ML, Grace R, Tai A, Michalak K, Walker SP. Aust N Z J Obstet Gynaecol. 2013 Mar 4. doi: 10.1111/ajo.12061. [Epub ahead of print]


  657. NK cells: a double-edged sword in chronic hepatitis B virus infection
    Maini MK, Peppa D. Front Immunol. 2013;4:57. doi: 10.3389/fimmu.2013.00057. Epub 2013 Mar 1.


  658. Diagnostic difficulties, therapeutic strategies, and performance of scoring systems in patients with autoimmune hepatitis and concurrent hepatitis B/C
    Efe C, Wahlin S, Ozaslan E, Purnak T, Muratori L, Quarneti C, Tatar G, Simsek H, Muratori P, Schiano TD. Scand J Gastroenterol. 2013 Mar 1. [Epub ahead of print]


  659. Efficacy of entecavir switch therapy in chronic hepatitis B patients with incomplete virological response to telbivudine
    Lo AO, Wong VW, Wong GL, Chan HY, Cheung CM, Chan HL. Antivir Ther. 2013 Mar 5. doi: 10.3851/IMP2526. [Epub ahead of print]


  660. Which patients respond best to hepatitis B vaccination after a hepatitis B virus-related liver transplantation?
    Takaki A, Yagi T, Yasunaka T, Sadamori H, Shinoura S, Umeda Y, Yoshida R, Sato D, Nobuoka D, Utsumi M, Yasuda Y, Nakayama E, Miyake Y, Ikeda F, Shiraha H, Nouso K, Fujiwara T, Yamamoto K. J Gastroenterol. 2013 Feb 23. [Epub ahead of print]


  661. Hepatitis B surface antigen serum level is associated with fibrosis severity in treatment-naïve, e antigen-positive patients
    Martinot-Peignoux M, Carvalho-Filho R, Lapalus M, Netto-Cardoso AC, Lada O, Batrla R, Krause F, Asselah T, Marcellin P. J Hepatol. 2013 Jan 28. pii: S0168-8278(13)00075-5. doi: 10.1016/j.jhep.2013.01.028. [Epub ahead of print]


  662. Invasive fungal infections secondary to acute-on-chronic liver failure: a retrospective study
    Lin LN, Zhu Y, Che FB, Gu JL, Chen JH. Mycoses. 2013 Feb 1. doi: 10.1111/myc.12044. [Epub ahead of print]


  663. Infectivity of blood products from donors with occult hepatitis B virus infection
    Allain JP, Mihaljevic I, Gonzalez-Fraile MI, Gubbe K, Holm-Harritshøj L, Garcia JM, Brojer E, Erikstrup C, Saniewski M, Wernish L, Bianco L, Ullum H, Candotti D, Lelie N, Gerlich WH, Chudy M. Transfusion. 2013 Jan 30. doi: 10.1111/trf.12096. [Epub ahead of print]


  664. Evolving Frequency and Outcomes of Liver Transplantation Based on Etiology of Liver Disease
    Singal AK, Guturu P, Hmoud B, Kuo YF, Salameh H, Wiesner RH. Transplantation. 2013 Jan 30. [Epub ahead of print]


  665. Comparative Efficacy of Oral Nucleoside or Nucleotide Analog Monotherapy Used in Chronic Hepatitis B: A Mixed-Treatment Comparison Meta-analysis
    Wiens A, Lenzi L, Venson R, Correr CJ, Rotta I, Pedroso ML, Pontarolo R. Pharmacotherapy. 2013 Feb;33(2):144-51. doi: 10.1002/phar.1188. Epub 2013 Jan 28.


  666. Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis b with high baseline viral load (? 9 log10 copies/mL)
    Gordon SC, Krastev Z, Horban A, Petersen J, Sperl J, Dinh P, Martins EB, Yee LJ, Flaherty JF, Kitrinos KM, Rustgi VK, Marcellin P. Hepatology. 2013 Jan 30. doi: 10.1002/hep.26277. [Epub ahead of print]


  667. Efficacy of 3 years of adefovir monotherapy in chronic hepatitis B patients with lamivudine resistance
    Song MN, Hong MZ, Luo DQ, Huang WQ, Min F, Fan RH, Wu WB, Zhang L. World J Hepatol. 2012 Dec 27;4(12):389-93. doi: 10.4254/wjh.v4.i12.389.


  668. Interferon-alpha plus adefovir combination therapy versus interferon-alpha monotherapy for chronic hepatitis B treatment: A meta-analysis
    Huang R, Hao Y, Zhang J, Wu C. Hepatol Res. 2013 Jan 10. doi: 10.1111/hepr.12058. [Epub ahead of print]


  669. IL21 and IL21R polymorphisms and their interactive effects on serum IL-21 and IgE levels in patients with chronic hepatitis B virus infection
    Li N, Zhu Q, Li Z, Han Q, Chen J, Lv Y, Wang Y, Zeng X, Chen Y, Yang C, Liu Z. Hum Immunol. 2013 Jan 24. pii: S0198-8859(13)00016-5. doi: 10.1016/j.humimm.2013.01.005. [Epub ahead of print]


  670. The use of individual patient-level data (IPD) to quantify the impact of pretreatment predictors of response to treatment in chronic hepatitis B patients
    Ali S, Mealing S, Hawkins N, Lescrauwaet B, Bjork S, Mantovani L, Lampertico P. BMJ Open. 2013 Jan 24;3(1). pii: e001309. doi: 10.1136/bmjopen-2012-001309. Print 2013.


  671. Hepatitis B testing and access to care among racial and ethnic minorities in selected communities across the United States, 2009-2010
    Hu DJ, Xing J, Tohme RA, Liao Y, Pollack H, Ward JW, Holmberg SD. Hepatology. 2013 Jan 28. doi: 10.1002/hep.26286. [Epub ahead of print]


  672. Evaluation of seven noninvasive models in staging liver fibrosis in patients with chronic hepatitis B virus infection
    Ma J, Jiang Y, Gong G. Eur J Gastroenterol Hepatol. 2013 Jan 24. [Epub ahead of print]


  673. Serum bilirubin levels are inversely associated with nonalcoholic fatty liver disease
    Kwak MS, Kim D, Chung GE, Kang SJ, Park MJ, Kim YJ, Yoon JH, Lee HS. Clin Mol Hepatol. 2012 Dec;18(4):383-90. doi: 10.3350/cmh.2012.18.4.383. Epub 2012 Dec 21.


  674. Dramatic reduction of liver cancer incidence in young adults: 28 year follow-up of etiological interventions in an endemic area of China
    Sun Z, Chen T, Thorgeirsson SS, Zhan Q, Chen J, Park JH, Lu P, Hsia CC, Wang N, Xu L, Lu L, Huang F, Zhu Y, Lu J, Ni Z, Zhang Q, Wu Y, Liu G, Wu Z, Qu C, Gail MH. Carcinogenesis. 2013 Jan 14. [Epub ahead of print]


  675. Efficacy of pegylated interferon alpha2a in patients without HBeAg loss after the withdrawal of long-term lamivudine therapy
    Zhang XQ, Zhang HY, You JP, Mao Q. Virol J. 2013 Jan 15;10(1):21. [Epub ahead of print]


  676. Diagnostic and therapeutic progress of multi-drug resistance with anti-HBV nucleos(t)ide analogues
    Song ZL, Cui YJ, Zheng WP, Teng DH, Zheng H. World J Gastroenterol. 2012 Dec 28;18(48):7149-57. doi: 10.3748/wjg.v18.i48.7149.


  677. Can mean platelet volume determine the severity of liver fibrosis or inflammation in patients with chronic hepatitis B?
    Ceylan B, Fincanci M, Yardimci C, Eren G, Tözalgan U, Müderriso?lu C, Pa?ao?lu E. Eur J Gastroenterol Hepatol. 2013 Jan 15. [Epub ahead of print]


  678. Treatment strategies using adefovir dipivoxil for individuals with lamivudine-resistant chronic hepatitis B
    Yun TJ, Jung JY, Kim CH, Um SH, An H, Seo YS, Kim JD, Yim HJ, Keum B, Kim YS, Jeen YT, Lee HS, Chun HJ, Kim CD, Ryu HS. World J Gastroenterol. 2012 Dec 21;18(47):6987-95. doi: 10.3748/wjg.v18.i47.6987.


  679. Tenofovir rescue therapy for chronic hepatitis B patients after multiple treatment failures
    Kim YJ, Sinn DH, Gwak GY, Choi MS, Koh KC, Paik SW, Yoo BC, Lee JH. World J Gastroenterol. 2012 Dec 21;18(47):6996-7002. doi: 10.3748/wjg.v18.i47.6996.


  680. Hepatitis B in immunosuppressed cancer patients: Pathogenesis, incidence and prophylaxis
    Mandalà M, Fagiuoli S, Francisci D, Bruno R, Merelli B, Pasulo L, Tondini C, Labianca R, Roila F. Crit Rev Oncol Hematol. 2013 Jan 10. pii: S1040-8428(12)00250-8. doi: 10.1016/j.critrevonc.2012.12.004. [Epub ahead of print]


  681. Kinetics and prediction of HBsAg loss during therapy with analogues in patients affected by chronic hepatitis B HBeAg negative and genotype D
    Boglione L, D'Avolio A, Cariti G, Gregori G, Burdino E, Baietto L, Cusato J, Ghisetti V, De Rosa FG, Perri GD. Liver Int. 2012 Dec 12. doi: 10.1111/liv.12091. [Epub ahead of print]


  682. Knowledge and Behaviors Toward Hepatitis B and the Hepatitis B Vaccine in the Laotian Community in Minnesota
    Xiong M, Nguyen RH, Strayer L, Chanthanouvong S, Yuan JM. J Immigr Minor Health. 2013 Jan 11. [Epub ahead of print]


  683. HBV infection increases the risk of pancreatic cancer: a meta-analysis
    Luo G, Hao NB, Hu CJ, Yong X, Lü MH, Cheng BJ, Zhang Y, Yang SM. Cancer Causes Control. 2013 Jan 10. [Epub ahead of print]


  684. Telbivudine on-treatment HBsAg loss in naive HBeAg negative chronic hepatitis B: a case report and brief review of the literature
    Bertino G, Ardiri AM, Calvagno GS, Bertino N, Ruggeri MI, Malaguarnera M, Malaguarnera G, Toro A, Di Carlo I. Clin Ter. 2012 Nov;163(6):e429-34.


  685. Clin Dev Immunol. 2012;2012:843134. doi: 10.1155/2012/843134. Epub 2012 Dec 13. Rapid Immunization Scheme for Spouses of Individuals Estabilished as Hepatitis B Carriers during Premarital Tests.
    Tosun S, Yücetürk M, Dönmez AB, Gündüz T.


  686. Optimal management of chronic hepatitis B patients with treatment failure and antiviral drug resistance
    Zoulim F, Locarnini S. Liver Int. 2013 Feb;33 Suppl 1:116-24. doi: 10.1111/liv.12069.


  687. Impact of therapy on the outcome of chronic hepatitis B
    Liaw YF. Liver Int. 2013 Feb;33 Suppl 1:111-5. doi: 10.1111/liv.12057.


  688. Antiviral therapy for patients with chronic hepatitis B with multi-drug resistance to nucleoside analogues
    Ozeki I, Hige S, Karino Y, Kimura M, Arakawa T, Nakajima T, Kuwata Y, Ohmura T, Sato T, Toyota J. Nihon Shokakibyo Gakkai Zasshi. 2013;110(1):44-55.


  689. IL28B GENOTYPE IS NOT USEFUL FOR PREDICTING TREATMENT OUTCOME IN ASIAN CHRONIC HEPATITIS B PATIENTS TREATED WITH PEGYLATED-INTERFERON-α
    Holmes JA, Nguyen T, Ratnam D, Heerasing NM, Tehan JV, Bonanzinga S, Dev A, Bell S, Pianko S, Chen R, Visvanathan K, Hammond R, Iser D, Rusli F, Sievert W, Desmond PV, Bowden DS, Thompson AJ. J Gastroenterol Hepatol. 2013 Jan 9. doi: 10.1111/jgh.12110. [Epub ahead of print]


  690. The role of HBsAg quantification for monitoring natural history and treatment outcome
    Martinot-Peignoux M, Lapalus M, Asselah T, Marcellin P. Liver Int. 2013 Feb;33 Suppl 1:125-32. doi: 10.1111/liv.12075.


  691. Outbreak of hepatitis B virus infections associated with assisted monitoring of blood glucose in an assisted living facility-virginia, 2010
    Bender TJ, Wise ME, Utah O, Moorman AC, Sharapov U, Drobeniuc J, Khudyakov Y, Fricchione M, White-Comstock MB, Thompson ND, Patel PR. PLoS One. 2012;7(12):e50012. doi: 10.1371/journal.pone.0050012. Epub 2012 Dec 26.


  692. Trends in viral hepatitis cost-effectiveness studies
    Saab S, Choi Y, Rahal H, Li K, Tong M. Am J Manag Care. 2012 Dec;18(12):790-8.


  693. Association of chronic liver disease with depression: a population-based study
    Lee K, Otgonsuren M, Younoszai Z, Mir HM, Younossi ZM. Psychosomatics. 2013 Jan;54(1):52-9. doi: 10.1016/j.psym.2012.09.005.


  694. Lack of association between hepatitis B virus pre-S mutations and recurrence after surgical resection in hepatocellular carcinoma
    Heo NY, Lee HC, Park YK, Park JW, Lim YS, Kim KM, Shim JH, Lee YJ. J Med Virol. 2013 Jan 7. doi: 10.1002/jmv.23502. [Epub ahead of print]


  695. Combined effects of p53 and MDM2 polymorphisms on susceptibility and surgical prognosis in hepatitis B virus-related hepatocellular carcinoma
    Yim HJ, Seo YS, Yoon EL, Kim CW, Lee CD, Park SH, Lee MS, Park CK, Chae HB, Kim MY, Baik SK, Kim YS, Kim JH, Lee JI, Lee JW, Hong SP, Um SH. Liver Int. 2013 Feb;33(2):244-54. doi: 10.1111/liv.12036.


  696. Combined effects of p53 and MDM2 polymorphisms on susceptibility and surgical prognosis in hepatitis B virus-related hepatocellular carcinoma
    Yang Y, Xia T, Li N, Zhang J, Yang Y, Cong W, Deng Q, Lan K, Zhou W. Protein Cell. 2013 Jan;4(1):71-81. doi: 10.1007/s13238-012-2067-9. Epub 2012 Dec 22.


  697. Study on noninvasive laboratory tests for fibrosis in chronic HBV infection and their evaluation
    Chen J, Liu C, Chen H, Liu Q, Yang B, Ou Q. J Clin Lab Anal. 2013 Jan;27(1):5-11. doi: 10.1002/jcla.21554. Epub 2013 Jan 4.


  698. Early on-treatment change in liver stiffness predicts development of liver-related events in chronic hepatitis B patients receiving antiviral therapy
    Kim BK, Oh HJ, Park JY, Kim do Y, Ahn SH, Han KH, Park Y, J Yoo E, Park YN, Kim SU. Liver Int. 2013 Feb;33(2):180-9. doi: 10.1111/liv.12020.


  699. Identification of risk factors associated with immunoprophylaxis failure to prevent the vertical transmission of hepatitis B virus
    Yin Y, Wu L, Zhang J, Zhou J, Zhang P, Hou H. J Infect. 2012 Dec 31. pii: S0163-4453(12)00389-1. doi: 10.1016/j.jinf.2012.12.008. [Epub ahead of print]


  700. Hepatitis B Screening in US Travelers Seen at the Boston Area Travel Medicine Network
    Chen LH, Barnett ED, Wilson ME, Macleod W, Yanni EA, Ooi W, Karchmer AW, Kogelman L, Marano N, Hamer DH. J Travel Med. 2013 Jan;20(1):29-36. doi: 10.1111/jtm.12002.


  701. IL17A gene polymorphisms, serum IL-17A and IgE levels, and hepatocellular carcinoma risk in patients with chronic hepatitis B virus infection
    Li N, Zhu Q, Li Z, Han Q, Zhang G, Chen J, Lv Y, Xing F, Chen Y, Zeng X, Liu Z. Mol Carcinog. 2012 Dec 31. doi: 10.1002/mc.21992. [Epub ahead of print]


  702. Genetic variations of PD1 and TIM3 are differentially and interactively associated with the development of cirrhosis and HCC in patients with chronic HBV infection
    Li Z, Li N, Zhu Q, Zhang G, Han Q, Zhang P, Xun M, Wang Y, Zeng X, Yang C, Liu Z. Infect Genet Evol. 2013 Jan 2. pii: S1567-1348(12)00390-5. doi: 10.1016/j.meegid.2012.12.008. [Epub ahead of print]


  703. Trends in viral hepatitis cost-effectiveness studies
    Saab S, Choi Y, Rahal H, Li K, Tong M. Am J Manag Care. 2012 Dec;18(12):790-8.


  704. The Diversity and Management of Chronic Hepatitis B Virus Infections in the UK - A Wake up Call
    Tedder RS, Rodger AJ, Fries L, Ijaz S, Thursz M, Rosenberg W, Naoumov N, Banatvala J, Williams R, Dusheiko G, Chokshi S, Wong T, Rosenberg G, Moreea S, Bassendine M, Jacobs M, Mills PR, Mutimer D, Ryder S, Bathgate A, Hussaini H, Dillon J, Wright M, Bird G, Collier J, Anderson M, Johnson A; for the CUSHIB Study Group. Clin Infect Dis. 2012 Dec 7. [Epub ahead of print]


  705. Hepatitis B screening: who to target? A French Sexually Transmitted Infection Clinic Experience
    Spenatto N, Boulinguez S, Mularczyk M, Molinier L, Bureau C, Saune K, Viraben R. J Hepatol. 2012 Dec 5. pii: S0168-8278(12)00914-2. doi: 10.1016/j.jhep.2012.11.044. [Epub ahead of print]


  706. Heavy alcohol consumption increases the incidence of hepatocellular carcinoma in hepatitis B virus-related cirrhosis
    Lin CW, Lin CC, Mo LR, Chang CY, Perng DS, Hsu CC, Lo GH, Chen YS, Yen YC, Hu JT, Yu ML, Lee PH, Lin JT, Yang SS. J Hepatol. 2012 Dec 6. pii: S0168-8278(12)00916-6. doi: 10.1016/j.jhep.2012.11.045. [Epub ahead of print]


  707. Long-term Hepatitis B Surface Antigen (HBsAg) Kinetics during Nucleoside/Nucleotide Analogue Therapy: Finite Treatment Duration Unlikely
    Chevaliez S, Hézode C, Bahrami S, Grare M, Pawlotsky JM. J Hepatol. 2012 Dec 3. pii: S0168-8278(12)00909-9. doi: 10.1016/j.jhep.2012.11.039. [Epub ahead of print]


  708. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study
    Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, Washington MK, Germanidis G, Flaherty JF, Schall RA, Bornstein JD, Kitrinos KM, Subramanian GM, McHutchison JG, Heathcote EJ. Lancet. 2012 Dec 7. pii: S0140-6736(12)61425-1. doi: 10.1016/S0140-6736(12)61425-1. [Epub ahead of print]


  709. Genetic variants in STAT4 and HLA-DQ genes confer risk of hepatitis B virus-related hepatocellular carcinoma
    Jiang DK, Sun J, Cao G, Liu Y, Lin D, Gao YZ, Ren WH, Long XD, Zhang H, Ma XP, Wang Z, Jiang W, Chen TY, Gao Y, Sun LD, Long JR, Huang HX, Wang D, Yu H, Zhang P, Tang LS, Peng B, Cai H, Liu TT, Zhou P, Liu F, Lin X, Tao S, Wan B, Sai-Yin HX, Qin LX, Yin J, Liu L, Wu C, Pei Y, Zhou YF, Zhai Y, Lu PX, Tan A, Zuo XB, Fan J, Chang J, Gu X, Wang NJ, Li Y, Liu YK, Zhai K, Zhang H, Hu Z, Liu J, Yi Q, Xiang Y, Shi R, Ding Q, Zheng W, Shu XO, Mo Z, Shugart YY, Zhang XJ, Zhou G, Shen H, Zheng SL, Xu J, Yu L. Nat Genet. 2012 Dec 16;45(1):72-5. doi: 10.1038/ng.2483. Epub 2012 Dec 16.


  710. Cumulative viral evolutionary changes in chronic hepatitis B virus infection precedes hepatitis B e antigen seroconversion
    Cheng Y, Guindon S, Rodrigo A, Wee LY, Inoue M, Thompson AJ, Locarnini S, Lim SG. Gut. 2012 Dec 15. [Epub ahead of print]


  711. Influence of Information Sources on Hepatitis B Screening Behavior and Relevant Psychosocial Factors Among Asian Immigrants
    Tanaka M, Strong C, Lee S, Juon HS. J Immigr Minor Health. 2012 Dec 13. [Epub ahead of print]


  712. Safety of lamivudine treatment for chronic hepatitis B in early pregnancy
    Yi W, Liu M, Cai HD. World J Gastroenterol. 2012 Dec 7;18(45):6645-50. doi: 10.3748/wjg.v18.i45.6645.


  713. Considerations for the long-term treatment of chronic hepatitis B with nucleos(t)ide analogs
    Petersen J, Buti M. Expert Rev Gastroenterol Hepatol. 2012 Dec;6(6):683-94. doi: 10.1586/egh.12.52.


  714. A Predictive Scoring System for the Seroclearance of HBsAg in HBeAg-seronegative Chronic Hepatitis B Patients with Genotype B or C Infection
    Liu J, Lee MH, Batrla-Utermann R, Jen CL, Iloeje UH, Lu SN, Wang LY, You SL, Hsiao CK, Yang HI, Chen CJ. J Hepatol. 2012 Dec 12. pii: S0168-8278(12)00954-3. doi: 10.1016/j.jhep.2012.12.006. [Epub ahead of print]


  715. Hepatitis B and C in liver transplantation: new strategies to combat the enemies
    Beckebaum S, Kabar I, Cicinnati VR. Rev Med Virol. 2012 Dec 13. doi: 10.1002/rmv.1734. [Epub ahead of print]


  716. The survival benefit of liver transplantation for hepatocellular carcinoma patients with hepatitis B virus infection and cirrhosis
    Zhang Q, Chen X, Zang Y, Zhang L, Chen H, Wang L, Niu Y, Ren X, Shen Z, Shang L. PLoS One. 2012;7(12):e50919. doi: 10.1371/journal.pone.0050919. Epub 2012 Dec 7.


  717. Evaluation of Hepatitis B Viraemia Levels in Patients with HBeAg-negative Chronic Hepatitis B Virus Infection
    Atay AE, Seven G, Yalcin K, Pasa S, Degertekin H. J Int Med Res. 2012;40(5):1891-6.


  718. Antibody persistence and the effect of a booster dose given 5, 10 or 15years after vaccinating preadolescents with a recombinant hepatitis B vaccine
    Gilca V, De Serres G, Boulianne N, Murphy D, De Wals P, Ouakki M, Trudeau G, Massé R, Dionne M. Vaccine. 2012 Dec 1. pii: S0264-410X(12)01630-1. doi: 10.1016/j.vaccine.2012.11.037. [Epub ahead of print]


  719. Liver stiffness measurement in cirrhotic patient - Implications of disease activity and treatment efficacy
    Xu HW, Lu SN, Hung CH, Chang KC, Hu TH, Wang JH. Kaohsiung J Med Sci. 2012 Dec;28(12):641-8. doi: 10.1016/j.kjms.2012.04.032. Epub 2012 Aug 1.


  720. The Frequency of Adjusted Renal Dosing of Tenofovir DF and Its Effects on Patient Outcomes
    Langness JA, Hindman JT, Johnson SC, Kiser JJ. J Pharm Pract. 2012 Dec 2. [Epub ahead of print]


  721. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection
    Hosaka T, Suzuki F, Kobayashi M, Seko Y, Kawamura Y, Sezaki H, Akuta N, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H. Hepatology. 2012 Dec 5. doi: 10.1002/hep.26180. [Epub ahead of print]


  722. Atypical serological profiles in hepatitis B virus infection
    Pondé RA. Eur J Clin Microbiol Infect Dis. 2012 Nov 29. [Epub ahead of print]


  723. Hepatitis B-core Antibody Positive Donors in Liver Transplantation and Their Impact on Graft Survival: Evidence From The Liver Match Cohort Study
    Angelico M, Nardi A, Marianelli T, Caccamo L, Romagnoli R, Tisone G, Pinna AD, Avolio AW, Fagiuoli S, Burra P, Strazzabosco M, Costa AN. J Hepatol. 2012 Nov 27. pii: S0168-8278(12)00894-X. doi: 10.1016/j.jhep.2012.11.025. [Epub ahead of print]


  724. Treatment of lamivudine-resistant chronic hepatitis B infection: a multicenter retrospective study
    Lee SJ, Yim HJ, Hwang SG, Seo YS, Kim JH, Yoon EL, Lee JM, Kim BH, Park SJ, Park YM, Kim HS, Lee SH, Ahn SH, Lee JI, Lee JW, Kim IH, Kim HS, Hong SP. Scand J Gastroenterol. 2012 Nov 30. [Epub ahead of print]


  725. Reactivation of hepatitis viruses following immunomodulationg systemic chemotherapy
    Watanabe T, Tanaka Y. Hepatol Res. 2012 Oct 30. doi: 10.1111/hepr.12014. [Epub ahead of print]


  726. The Short-Term Efficacy of Entecavir in Lamivudine-Resistant Chronic Hepatitis B: Influence of Sequential Adefovir-Refractoriness
    Kim JH, Kim YS, Jung YK, Kim YS, Kwon OS, Ku YS, Choi DJ, Kim JH. Hepatogastroenterology. 2012 Nov 28;60(125). doi: 10.5754/hge12917. [Epub ahead of print]


  727. Reactivation of Hepatitis B Virus in Patients Receiving Chemotherapy
    Ikeda M. Jpn J Clin Oncol. 2012 Nov 25. [Epub ahead of print]


 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Live CME Meetings
Telewebs
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2015 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.